[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fYr-dQq3IIEtixIb2eSIT66BGBnYBDp0ka-GHM9LcO4w":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":84,"rows":91},"Hanmi Pharmaceutical Company Limited",[4],187,false,14,36,52995,18,6,[14,17,20,23,25,28,31,33],{"name":15,"count":16},"Healthy",51,{"name":18,"count":19},"Hypertension",22,{"name":21,"count":22},"Diabetes Mellitus",8,{"name":24,"count":12},"Obesity",{"name":26,"count":27},"Erectile Dysfunction",5,{"name":29,"count":30},"Non Small Cell Lung Cancer",4,{"name":32,"count":30},"Hyperlipidemia",{"name":34,"count":30},"Type 2 Diabetes Mellitus",[36,41,46,51,56,61,66,71,76,80],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06174779","A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus","2025-12-31","HM11260C",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07297693","A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers","2026-03-25","HIP2503",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT04505436","Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects","2026-06-27","HM15211",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT04732416","HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)","2026-07","HM15136",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06174766","A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients","2026-12-31","HGP2102-1",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07205900","Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus","2027-01","HM15275",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT07219589","A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants","2027-03","HM17321",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06234397","Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors","2027-08","BH3120",{"nctId":77,"briefTitle":78,"date":79,"intervention":65},"NCT07527650","Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus","2027-09",{"nctId":81,"briefTitle":82,"date":83,"intervention":40},"NCT07379333","A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin","2027-11",[85,86,87,88,89,90],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[92,184,208,226,244,262,301,345,377,404,422,447,491,555,573,597,617,635,653,726,767,794,812,839,864,882,907,932,950,968,986,1004,1022,1049,1067,1091,1109,1172,1231,1270,1311,1352,1392,1451,1481,1527,1558,1584,1632,1665,1687,1725,1761,1800,1822,1858,1885,1907,1938,1960,1982,2010,2047,2069,2091,2113,2141,2159,2177,2195,2213,2231,2257,2275,2293,2311,2335,2353,2371,2389,2407,2425,2443,2470,2488,2506,2524,2542,2565,2583,2601,2619,2644,2662,2680,2705,2723,2741,2759,2777,2795,2823,2841,2859,2877,2895,2913,2931,2949,2967,2993,3023,3041,3059,3077,3095,3113,3131,3149,3167,3185,3208,3255,3296,3323,3354,3387,3409,3427,3445,3463,3487,3511,3536,3554,3572,3590,3608,3632,3650,3673,3691,3709,3758,3801,3845,3871,3907,3948,3974,4007,4039,4069,4097,4119,4141,4163,4185,4218,4240,4262,4289,4315,4346,4380,4405,4423,4444,4465,4486,4504,4522,4546,4570,4588,4606,4633,4651,4669,4687,4705,4728,4746,4768,4786,4804,4822,4840,4858,4883,4901,4919,4940,4958,4976,4999,5022,5040,5062,5080,5102,5127,5145,5163,5186,5204,5230,5248,5266,5284,5302,5320,5343,5367,5385,5403,5427,5445,5470,5488,5506,5524,5542,5564,5582,5609,5627,5645,5663,5681,5699,5717,5735,5757,5784,5802,5830,5848,5866,5884,5902,5925,5943,5961,5985,6003,6026,6050,6068,6086,6104,6127,6145,6168,6186,6204,6222,6246,6264,6289,6314,6339,6363],{"intervention":40,"totalTrials":22,"cells":93},{"EARLY_PHASE1":94,"PHASE1":97,"PHASE2":121,"PHASE3":161,"PHASE4":180,"NA":182},{"trials":95,"activeCount":96},[],0,{"trials":98,"activeCount":96},[99,111],{"nctId":100,"briefTitle":101,"status":102,"phases":103,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":108,"interventions":109},"NCT02059564","A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus","UNKNOWN",[86],"2014-10","2014-12","2013-12",44,[21],[40,110],"Victoza",{"nctId":112,"briefTitle":113,"status":114,"phases":115,"primaryCompletion":116,"completion":116,"start":117,"enrollment":118,"conditions":119,"interventions":120},"NCT01093729","A Study of HM11260C in Healthy Male Subject","COMPLETED",[86],"2010-10","2010-02",41,[15],[40,40,40,40,40],{"trials":122,"activeCount":96},[123,133,143,152],{"nctId":124,"briefTitle":125,"status":114,"phases":126,"primaryCompletion":127,"completion":128,"start":129,"enrollment":130,"conditions":131,"interventions":132},"NCT02075281","Effect of LAPS-Exendin on Body Weight in Obese Population",[87],"2015-01","2015-02","2014-02",297,[24],[40],{"nctId":134,"briefTitle":135,"status":114,"phases":136,"primaryCompletion":104,"completion":105,"start":137,"enrollment":138,"conditions":139,"interventions":141},"NCT02057172","Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes",[87],"2014-01",254,[140],"Type 2 Diabetes",[40,142],"liraglutide",{"nctId":144,"briefTitle":145,"status":114,"phases":146,"primaryCompletion":147,"completion":148,"start":129,"enrollment":149,"conditions":150,"interventions":151},"NCT02081118","Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes",[87],"2015-03","2015-04",209,[140],[40],{"nctId":153,"briefTitle":154,"status":114,"phases":155,"primaryCompletion":156,"start":157,"enrollment":158,"conditions":159,"interventions":160},"NCT01452451","Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus",[87],"2013-06","2011-12",72,[21],[40],{"trials":162,"activeCount":179,"soonestReadout":39},[163,171],{"nctId":81,"briefTitle":82,"status":164,"phases":165,"primaryCompletion":83,"completion":166,"start":167,"enrollment":168,"conditions":169,"interventions":170},"RECRUITING",[88],"2028-01","2026-04-13",118,[140],[40],{"nctId":37,"briefTitle":38,"status":172,"phases":173,"primaryCompletion":39,"completion":174,"start":175,"enrollment":176,"conditions":177,"interventions":178},"ACTIVE_NOT_RECRUITING",[88],"2026-07-31","2024-01-03",420,[24],[40],2,{"trials":181,"activeCount":96},[],{"trials":183,"activeCount":96},[],{"intervention":60,"totalTrials":185,"cells":186},1,{"EARLY_PHASE1":187,"PHASE1":189,"PHASE2":191,"PHASE3":193,"PHASE4":204,"NA":206},{"trials":188,"activeCount":96},[],{"trials":190,"activeCount":96},[],{"trials":192,"activeCount":96},[],{"trials":194,"activeCount":185,"soonestReadout":59},[195],{"nctId":57,"briefTitle":58,"status":164,"phases":196,"primaryCompletion":59,"completion":59,"start":197,"enrollment":198,"conditions":199,"interventions":200},[88],"2024-05-10",324,[18],[60,201,202,203],"HGP2102-2","RLD2209-1","RLD2209-2",{"trials":205,"activeCount":96},[],{"trials":207,"activeCount":96},[],{"intervention":201,"totalTrials":185,"cells":209},{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":222,"NA":224},{"trials":211,"activeCount":96},[],{"trials":213,"activeCount":96},[],{"trials":215,"activeCount":96},[],{"trials":217,"activeCount":185,"soonestReadout":59},[218],{"nctId":57,"briefTitle":58,"status":164,"phases":219,"primaryCompletion":59,"completion":59,"start":197,"enrollment":198,"conditions":220,"interventions":221},[88],[18],[60,201,202,203],{"trials":223,"activeCount":96},[],{"trials":225,"activeCount":96},[],{"intervention":202,"totalTrials":185,"cells":227},{"EARLY_PHASE1":228,"PHASE1":230,"PHASE2":232,"PHASE3":234,"PHASE4":240,"NA":242},{"trials":229,"activeCount":96},[],{"trials":231,"activeCount":96},[],{"trials":233,"activeCount":96},[],{"trials":235,"activeCount":185,"soonestReadout":59},[236],{"nctId":57,"briefTitle":58,"status":164,"phases":237,"primaryCompletion":59,"completion":59,"start":197,"enrollment":198,"conditions":238,"interventions":239},[88],[18],[60,201,202,203],{"trials":241,"activeCount":96},[],{"trials":243,"activeCount":96},[],{"intervention":203,"totalTrials":185,"cells":245},{"EARLY_PHASE1":246,"PHASE1":248,"PHASE2":250,"PHASE3":252,"PHASE4":258,"NA":260},{"trials":247,"activeCount":96},[],{"trials":249,"activeCount":96},[],{"trials":251,"activeCount":96},[],{"trials":253,"activeCount":185,"soonestReadout":59},[254],{"nctId":57,"briefTitle":58,"status":164,"phases":255,"primaryCompletion":59,"completion":59,"start":197,"enrollment":198,"conditions":256,"interventions":257},[88],[18],[60,201,202,203],{"trials":259,"activeCount":96},[],{"trials":261,"activeCount":96},[],{"intervention":65,"totalTrials":263,"cells":264},3,{"EARLY_PHASE1":265,"PHASE1":267,"PHASE2":278,"PHASE3":295,"PHASE4":297,"NA":299},{"trials":266,"activeCount":96},[],{"trials":268,"activeCount":96},[269],{"nctId":270,"briefTitle":271,"status":114,"phases":272,"primaryCompletion":273,"completion":273,"start":274,"enrollment":275,"conditions":276,"interventions":277},"NCT06481098","A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.",[86],"2025-05-02","2024-05-28",74,[24],[65],{"trials":279,"activeCount":179,"soonestReadout":64},[280,287],{"nctId":62,"briefTitle":63,"status":172,"phases":281,"primaryCompletion":64,"completion":64,"start":282,"enrollment":283,"conditions":284,"interventions":286},[87],"2025-12-02",267,[285,24],"Obese",[65],{"nctId":77,"briefTitle":78,"status":164,"phases":288,"primaryCompletion":79,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":294},[87],"2027-10","2026-06",180,[34,293],"T2DM",[65],{"trials":296,"activeCount":96},[],{"trials":298,"activeCount":96},[],{"trials":300,"activeCount":96},[],{"intervention":55,"totalTrials":263,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":329,"PHASE3":339,"PHASE4":341,"NA":343},{"trials":304,"activeCount":96},[],{"trials":306,"activeCount":96},[307,319],{"nctId":308,"briefTitle":309,"status":114,"phases":310,"primaryCompletion":311,"completion":311,"start":312,"enrollment":313,"conditions":314,"interventions":318},"NCT04167553","Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities",[86],"2020-12-09","2019-08-30",52,[315,316,317],"Obese With Comorbidities","Overweight With Comorbidities","Type2 Diabetes",[55],{"nctId":320,"briefTitle":321,"status":114,"phases":322,"primaryCompletion":323,"completion":323,"start":324,"enrollment":325,"conditions":326,"interventions":328},"NCT04032782","A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy Subjects",[86],"2019-08-29","2018-10-02",40,[327],"Pharmacology",[55],{"trials":330,"activeCount":185,"soonestReadout":54},[331],{"nctId":52,"briefTitle":53,"status":172,"phases":332,"primaryCompletion":54,"completion":333,"start":334,"enrollment":335,"conditions":336,"interventions":338},[87],"2027-05","2022-05-05",16,[337],"Congenital Hyperinsulinism",[55],{"trials":340,"activeCount":96},[],{"trials":342,"activeCount":96},[],{"trials":344,"activeCount":96},[],{"intervention":50,"totalTrials":179,"cells":346},{"EARLY_PHASE1":347,"PHASE1":349,"PHASE2":361,"PHASE3":371,"PHASE4":373,"NA":375},{"trials":348,"activeCount":96},[],{"trials":350,"activeCount":96},[351],{"nctId":352,"briefTitle":353,"status":114,"phases":354,"primaryCompletion":355,"completion":355,"start":356,"enrollment":357,"conditions":358,"interventions":360},"NCT03744182","A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD",[86],"2020-03-18","2018-11-01",66,[359],"NAFLD",[50],{"trials":362,"activeCount":185,"soonestReadout":49},[363],{"nctId":47,"briefTitle":48,"status":172,"phases":364,"primaryCompletion":49,"completion":365,"start":366,"enrollment":367,"conditions":368,"interventions":370},[87],"2026-07-27","2020-07-31",215,[369],"NASH - Nonalcoholic Steatohepatitis",[50],{"trials":372,"activeCount":96},[],{"trials":374,"activeCount":96},[],{"trials":376,"activeCount":96},[],{"intervention":378,"totalTrials":185,"cells":379},"Belvarafenib",{"EARLY_PHASE1":380,"PHASE1":382,"PHASE2":384,"PHASE3":398,"PHASE4":400,"NA":402},{"trials":381,"activeCount":96},[],{"trials":383,"activeCount":96},[],{"trials":385,"activeCount":185,"soonestReadout":390},[386],{"nctId":387,"briefTitle":388,"status":164,"phases":389,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":394,"interventions":396},"NCT07449754","Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma",[87],"2029-09","2030-03","2026-02-12",45,[395],"Advanced or Metastatic Melanoma",[378,397],"Cobimetinib",{"trials":399,"activeCount":96},[],{"trials":401,"activeCount":96},[],{"trials":403,"activeCount":96},[],{"intervention":397,"totalTrials":185,"cells":405},{"EARLY_PHASE1":406,"PHASE1":408,"PHASE2":410,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":407,"activeCount":96},[],{"trials":409,"activeCount":96},[],{"trials":411,"activeCount":185,"soonestReadout":390},[412],{"nctId":387,"briefTitle":388,"status":164,"phases":413,"primaryCompletion":390,"completion":391,"start":392,"enrollment":393,"conditions":414,"interventions":415},[87],[395],[378,397],{"trials":417,"activeCount":96},[],{"trials":419,"activeCount":96},[],{"trials":421,"activeCount":96},[],{"intervention":423,"totalTrials":185,"cells":424},"HM15912 Active",{"EARLY_PHASE1":425,"PHASE1":427,"PHASE2":429,"PHASE3":441,"PHASE4":443,"NA":445},{"trials":426,"activeCount":96},[],{"trials":428,"activeCount":96},[],{"trials":430,"activeCount":185,"soonestReadout":435},[431],{"nctId":432,"briefTitle":433,"status":164,"phases":434,"primaryCompletion":435,"completion":436,"start":437,"enrollment":11,"conditions":438,"interventions":440},"NCT04775706","Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects",[87],"2027-12","2028-05","2022-03-03",[439],"Short Bowel Syndrome",[423],{"trials":442,"activeCount":96},[],{"trials":444,"activeCount":96},[],{"trials":446,"activeCount":96},[],{"intervention":448,"totalTrials":263,"cells":449},"pembrolizumab",{"EARLY_PHASE1":450,"PHASE1":452,"PHASE2":471,"PHASE3":485,"PHASE4":487,"NA":489},{"trials":451,"activeCount":96},[],{"trials":453,"activeCount":179,"soonestReadout":74},[454,465],{"nctId":455,"briefTitle":456,"status":164,"phases":457,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":461,"interventions":463},"NCT06724016","Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors",[86],"2031-07","2024-12-11",292,[462],"Advanced or Metastatic Solid Tumors",[464,448],"HM16390",{"nctId":72,"briefTitle":73,"status":164,"phases":466,"primaryCompletion":74,"completion":166,"start":467,"enrollment":468,"conditions":469,"interventions":470},[86],"2023-12-28",245,[462],[75,448],{"trials":472,"activeCount":96},[473],{"nctId":474,"briefTitle":475,"status":114,"phases":476,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":482},"NCT04768686","FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer",[87],"2024-08-12","2021-05-18",20,[481],"Gastric Cancer",[483,484],"FLX475","Pembrolizumab",{"trials":486,"activeCount":96},[],{"trials":488,"activeCount":96},[],{"trials":490,"activeCount":96},[],{"intervention":492,"totalTrials":27,"cells":493},"HCP1306",{"EARLY_PHASE1":494,"PHASE1":496,"PHASE2":547,"PHASE3":549,"PHASE4":551,"NA":553},{"trials":495,"activeCount":96},[],{"trials":497,"activeCount":185,"soonestReadout":44},[498,509,520,527,537],{"nctId":499,"briefTitle":500,"status":114,"phases":501,"primaryCompletion":105,"completion":127,"start":502,"enrollment":503,"conditions":504,"interventions":506},"NCT02941848","Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers",[86],"2014-11",60,[505],"Primary Hypercholesterolemia",[507,508,492],"HGP0816","HGP1404",{"nctId":510,"briefTitle":511,"status":114,"phases":512,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":516,"interventions":517},"NCT04081844","A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.",[86],"2018-06-28","2018-05-03",31,[15],[492,518,519],"HGP0904","HGP0608",{"nctId":42,"briefTitle":43,"status":521,"phases":522,"primaryCompletion":44,"completion":523,"start":524,"enrollment":503,"conditions":525,"interventions":526},"NOT_YET_RECRUITING",[86],"2026-04-10","2025-12-19",[15],[45,492],{"nctId":528,"briefTitle":529,"status":114,"phases":530,"primaryCompletion":531,"completion":531,"start":532,"enrollment":357,"conditions":533,"interventions":534},"NCT06518122","A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers",[86],"2025-01-03","2024-09-01",[15],[492,535,536],"RLD2302","RLD2102",{"nctId":538,"briefTitle":539,"status":114,"phases":540,"primaryCompletion":541,"completion":541,"start":542,"enrollment":543,"conditions":544,"interventions":545},"NCT04322266","A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.",[86],"2019-02-13","2018-12-21",61,[15],[546,492,518,519],"HCP1701",{"trials":548,"activeCount":96},[],{"trials":550,"activeCount":96},[],{"trials":552,"activeCount":96},[],{"trials":554,"activeCount":96},[],{"intervention":464,"totalTrials":185,"cells":556},{"EARLY_PHASE1":557,"PHASE1":559,"PHASE2":565,"PHASE3":567,"PHASE4":569,"NA":571},{"trials":558,"activeCount":96},[],{"trials":560,"activeCount":185,"soonestReadout":458},[561],{"nctId":455,"briefTitle":456,"status":164,"phases":562,"primaryCompletion":458,"completion":458,"start":459,"enrollment":460,"conditions":563,"interventions":564},[86],[462],[464,448],{"trials":566,"activeCount":96},[],{"trials":568,"activeCount":96},[],{"trials":570,"activeCount":96},[],{"trials":572,"activeCount":96},[],{"intervention":574,"totalTrials":185,"cells":575},"HM97662",{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":589,"PHASE3":591,"PHASE4":593,"NA":595},{"trials":577,"activeCount":96},[],{"trials":579,"activeCount":185,"soonestReadout":166},[580],{"nctId":581,"briefTitle":582,"status":164,"phases":583,"primaryCompletion":166,"completion":584,"start":585,"enrollment":586,"conditions":587,"interventions":588},"NCT05598151","Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors",[86],"2028-06","2023-01-11",170,[462],[574],{"trials":590,"activeCount":96},[],{"trials":592,"activeCount":96},[],{"trials":594,"activeCount":96},[],{"trials":596,"activeCount":96},[],{"intervention":70,"totalTrials":185,"cells":598},{"EARLY_PHASE1":599,"PHASE1":601,"PHASE2":609,"PHASE3":611,"PHASE4":613,"NA":615},{"trials":600,"activeCount":96},[],{"trials":602,"activeCount":185,"soonestReadout":69},[603],{"nctId":67,"briefTitle":68,"status":164,"phases":604,"primaryCompletion":69,"completion":69,"start":605,"enrollment":606,"conditions":607,"interventions":608},[86],"2025-11-06",90,[24,285],[70],{"trials":610,"activeCount":96},[],{"trials":612,"activeCount":96},[],{"trials":614,"activeCount":96},[],{"trials":616,"activeCount":96},[],{"intervention":45,"totalTrials":185,"cells":618},{"EARLY_PHASE1":619,"PHASE1":621,"PHASE2":627,"PHASE3":629,"PHASE4":631,"NA":633},{"trials":620,"activeCount":96},[],{"trials":622,"activeCount":185,"soonestReadout":44},[623],{"nctId":42,"briefTitle":43,"status":521,"phases":624,"primaryCompletion":44,"completion":523,"start":524,"enrollment":503,"conditions":625,"interventions":626},[86],[15],[45,492],{"trials":628,"activeCount":96},[],{"trials":630,"activeCount":96},[],{"trials":632,"activeCount":96},[],{"trials":634,"activeCount":96},[],{"intervention":75,"totalTrials":185,"cells":636},{"EARLY_PHASE1":637,"PHASE1":639,"PHASE2":645,"PHASE3":647,"PHASE4":649,"NA":651},{"trials":638,"activeCount":96},[],{"trials":640,"activeCount":185,"soonestReadout":74},[641],{"nctId":72,"briefTitle":73,"status":164,"phases":642,"primaryCompletion":74,"completion":166,"start":467,"enrollment":468,"conditions":643,"interventions":644},[86],[462],[75,448],{"trials":646,"activeCount":96},[],{"trials":648,"activeCount":96},[],{"trials":650,"activeCount":96},[],{"trials":652,"activeCount":96},[],{"intervention":654,"totalTrials":27,"cells":655},"Losartan",{"EARLY_PHASE1":656,"PHASE1":658,"PHASE2":660,"PHASE3":683,"PHASE4":705,"NA":724},{"trials":657,"activeCount":96},[],{"trials":659,"activeCount":96},[],{"trials":661,"activeCount":96},[662,673],{"nctId":663,"briefTitle":664,"status":114,"phases":665,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":669,"interventions":670},"NCT00942344","Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension",[87],"2007-12","2007-05",320,[18],[671,672,654],"Amlodipine plus Losartan","Amlodipine",{"nctId":674,"briefTitle":675,"status":114,"phases":676,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":680,"interventions":681},"NCT03897868","A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension",[87],"2020-02-26","2019-03-21",248,[18],[682,672,654],"HCP1803",{"trials":684,"activeCount":96},[685,694],{"nctId":686,"briefTitle":687,"status":114,"phases":688,"primaryCompletion":689,"completion":689,"start":690,"enrollment":691,"conditions":692,"interventions":693},"NCT00940680","Efficacy\u002FSafety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension",[88],"2008-11","2008-04",142,[18],[671,654],{"nctId":695,"briefTitle":696,"status":114,"phases":697,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":701,"interventions":703},"NCT04074551","A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia",[88],"2020-03-17","2019-07-16",145,[18,702],"Dyslipidemias",[546,654,672,704],"Rosuvastatin and Ezetimibe",{"trials":706,"activeCount":96},[707],{"nctId":708,"briefTitle":709,"status":114,"phases":710,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":714,"interventions":719},"NCT03666351","Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease",[89],"2022-07-25","2018-10-18",128,[715,716,18,717,718],"Aortic Stenosis","Aortic Regurgitation","LVM","Left Ventricular Hypertrophy",[720,654,721,722,723],"Amlodipine 5mg","Losartan and Amlodipine","Amlodipine\u002FLosartan\u002FChlorthalidone","current treatment",{"trials":725,"activeCount":96},[],{"intervention":727,"totalTrials":263,"cells":728},"Amlodipine, Losartan",{"EARLY_PHASE1":729,"PHASE1":731,"PHASE2":748,"PHASE3":750,"PHASE4":752,"NA":765},{"trials":730,"activeCount":96},[],{"trials":732,"activeCount":96},[733,741],{"nctId":734,"briefTitle":735,"status":114,"phases":736,"primaryCompletion":116,"completion":737,"start":738,"enrollment":158,"conditions":739,"interventions":740},"NCT01197001","A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan",[86],"2010-11","2010-08",[15],[671,727],{"nctId":742,"briefTitle":735,"status":114,"phases":743,"primaryCompletion":737,"completion":744,"start":745,"enrollment":158,"conditions":746,"interventions":747},"NCT01197014",[86],"2010-12","2010-09",[15],[671,727],{"trials":749,"activeCount":96},[],{"trials":751,"activeCount":96},[],{"trials":753,"activeCount":96},[754],{"nctId":755,"briefTitle":756,"status":114,"phases":757,"primaryCompletion":758,"completion":759,"start":760,"enrollment":761,"conditions":762,"interventions":764},"NCT01830517","Diurnal Variation in Hypertensive Stroke Patients",[89],"2011-06","2012-02","2007-08",84,[18,763],"Stroke",[727],{"trials":766,"activeCount":96},[],{"intervention":768,"totalTrials":185,"cells":769},"Clopidogrel",{"EARLY_PHASE1":770,"PHASE1":772,"PHASE2":774,"PHASE3":776,"PHASE4":778,"NA":792},{"trials":771,"activeCount":96},[],{"trials":773,"activeCount":96},[],{"trials":775,"activeCount":96},[],{"trials":777,"activeCount":96},[],{"trials":779,"activeCount":96},[780],{"nctId":781,"briefTitle":782,"status":114,"phases":783,"primaryCompletion":784,"completion":785,"start":786,"enrollment":787,"conditions":788,"interventions":790},"NCT01830491","Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients",[89],"2009-08","2009-12","2009-03",162,[789],"Coronary Artery Disease (CAD)",[768,791],"aspirin 100mg",{"trials":793,"activeCount":96},[],{"intervention":791,"totalTrials":185,"cells":795},{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":810},{"trials":797,"activeCount":96},[],{"trials":799,"activeCount":96},[],{"trials":801,"activeCount":96},[],{"trials":803,"activeCount":96},[],{"trials":805,"activeCount":96},[806],{"nctId":781,"briefTitle":782,"status":114,"phases":807,"primaryCompletion":784,"completion":785,"start":786,"enrollment":787,"conditions":808,"interventions":809},[89],[789],[768,791],{"trials":811,"activeCount":96},[],{"intervention":813,"totalTrials":185,"cells":814},"MUCOLASE",{"EARLY_PHASE1":815,"PHASE1":817,"PHASE2":819,"PHASE3":821,"PHASE4":823,"NA":837},{"trials":816,"activeCount":96},[],{"trials":818,"activeCount":96},[],{"trials":820,"activeCount":96},[],{"trials":822,"activeCount":96},[],{"trials":824,"activeCount":96},[825],{"nctId":826,"briefTitle":827,"status":102,"phases":828,"primaryCompletion":829,"completion":830,"start":831,"enrollment":832,"conditions":833,"interventions":836},"NCT04252963","Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)",[89],"2021-02","2021-05","2018-11-02",346,[834,835],"Acute Upper Respiratory Infection","Acute Bronchitis",[813],{"trials":838,"activeCount":96},[],{"intervention":840,"totalTrials":185,"cells":841},"Simvast CR",{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":848,"PHASE4":850,"NA":862},{"trials":843,"activeCount":96},[],{"trials":845,"activeCount":96},[],{"trials":847,"activeCount":96},[],{"trials":849,"activeCount":96},[],{"trials":851,"activeCount":96},[852],{"nctId":853,"briefTitle":854,"status":102,"phases":855,"primaryCompletion":856,"completion":856,"start":744,"enrollment":857,"conditions":858,"interventions":860},"NCT01564875","Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia",[89],"2012-05",122,[859,32],"Chronic Kidney Disease",[840,861],"Zocor",{"trials":863,"activeCount":96},[],{"intervention":861,"totalTrials":185,"cells":865},{"EARLY_PHASE1":866,"PHASE1":868,"PHASE2":870,"PHASE3":872,"PHASE4":874,"NA":880},{"trials":867,"activeCount":96},[],{"trials":869,"activeCount":96},[],{"trials":871,"activeCount":96},[],{"trials":873,"activeCount":96},[],{"trials":875,"activeCount":96},[876],{"nctId":853,"briefTitle":854,"status":102,"phases":877,"primaryCompletion":856,"completion":856,"start":744,"enrollment":857,"conditions":878,"interventions":879},[89],[859,32],[840,861],{"trials":881,"activeCount":96},[],{"intervention":883,"totalTrials":185,"cells":884},"Acetyl-L-carnitine hydrochloride 500mg",{"EARLY_PHASE1":885,"PHASE1":887,"PHASE2":889,"PHASE3":891,"PHASE4":893,"NA":905},{"trials":886,"activeCount":96},[],{"trials":888,"activeCount":96},[],{"trials":890,"activeCount":96},[],{"trials":892,"activeCount":96},[],{"trials":894,"activeCount":96},[895],{"nctId":896,"briefTitle":897,"status":102,"phases":898,"primaryCompletion":899,"completion":899,"start":900,"enrollment":901,"conditions":902,"interventions":904},"NCT04346862","Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease",[89],"2020-06-30","2016-01-26",636,[903],"Mild Cognitive Impairment",[883],{"trials":906,"activeCount":96},[],{"intervention":908,"totalTrials":185,"cells":909},"Cavir",{"EARLY_PHASE1":910,"PHASE1":912,"PHASE2":914,"PHASE3":916,"PHASE4":918,"NA":930},{"trials":911,"activeCount":96},[],{"trials":913,"activeCount":96},[],{"trials":915,"activeCount":96},[],{"trials":917,"activeCount":96},[],{"trials":919,"activeCount":96},[920],{"nctId":921,"briefTitle":922,"status":102,"phases":923,"primaryCompletion":924,"completion":924,"start":127,"enrollment":925,"conditions":926,"interventions":928},"NCT02523547","Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude",[89],"2017-02",134,[927],"Chronic Hepatitis B",[908,929],"Baraclude",{"trials":931,"activeCount":96},[],{"intervention":929,"totalTrials":185,"cells":933},{"EARLY_PHASE1":934,"PHASE1":936,"PHASE2":938,"PHASE3":940,"PHASE4":942,"NA":948},{"trials":935,"activeCount":96},[],{"trials":937,"activeCount":96},[],{"trials":939,"activeCount":96},[],{"trials":941,"activeCount":96},[],{"trials":943,"activeCount":96},[944],{"nctId":921,"briefTitle":922,"status":102,"phases":945,"primaryCompletion":924,"completion":924,"start":127,"enrollment":925,"conditions":946,"interventions":947},[89],[927],[908,929],{"trials":949,"activeCount":96},[],{"intervention":720,"totalTrials":185,"cells":951},{"EARLY_PHASE1":952,"PHASE1":954,"PHASE2":956,"PHASE3":958,"PHASE4":960,"NA":966},{"trials":953,"activeCount":96},[],{"trials":955,"activeCount":96},[],{"trials":957,"activeCount":96},[],{"trials":959,"activeCount":96},[],{"trials":961,"activeCount":96},[962],{"nctId":708,"briefTitle":709,"status":114,"phases":963,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":964,"interventions":965},[89],[715,716,18,717,718],[720,654,721,722,723],{"trials":967,"activeCount":96},[],{"intervention":721,"totalTrials":185,"cells":969},{"EARLY_PHASE1":970,"PHASE1":972,"PHASE2":974,"PHASE3":976,"PHASE4":978,"NA":984},{"trials":971,"activeCount":96},[],{"trials":973,"activeCount":96},[],{"trials":975,"activeCount":96},[],{"trials":977,"activeCount":96},[],{"trials":979,"activeCount":96},[980],{"nctId":708,"briefTitle":709,"status":114,"phases":981,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":982,"interventions":983},[89],[715,716,18,717,718],[720,654,721,722,723],{"trials":985,"activeCount":96},[],{"intervention":722,"totalTrials":185,"cells":987},{"EARLY_PHASE1":988,"PHASE1":990,"PHASE2":992,"PHASE3":994,"PHASE4":996,"NA":1002},{"trials":989,"activeCount":96},[],{"trials":991,"activeCount":96},[],{"trials":993,"activeCount":96},[],{"trials":995,"activeCount":96},[],{"trials":997,"activeCount":96},[998],{"nctId":708,"briefTitle":709,"status":114,"phases":999,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":1000,"interventions":1001},[89],[715,716,18,717,718],[720,654,721,722,723],{"trials":1003,"activeCount":96},[],{"intervention":723,"totalTrials":185,"cells":1005},{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1012,"PHASE4":1014,"NA":1020},{"trials":1007,"activeCount":96},[],{"trials":1009,"activeCount":96},[],{"trials":1011,"activeCount":96},[],{"trials":1013,"activeCount":96},[],{"trials":1015,"activeCount":96},[1016],{"nctId":708,"briefTitle":709,"status":114,"phases":1017,"primaryCompletion":711,"completion":711,"start":712,"enrollment":713,"conditions":1018,"interventions":1019},[89],[715,716,18,717,718],[720,654,721,722,723],{"trials":1021,"activeCount":96},[],{"intervention":1023,"totalTrials":185,"cells":1024},"one-way education",{"EARLY_PHASE1":1025,"PHASE1":1027,"PHASE2":1029,"PHASE3":1031,"PHASE4":1033,"NA":1047},{"trials":1026,"activeCount":96},[],{"trials":1028,"activeCount":96},[],{"trials":1030,"activeCount":96},[],{"trials":1032,"activeCount":96},[],{"trials":1034,"activeCount":96},[1035],{"nctId":1036,"briefTitle":1037,"status":114,"phases":1038,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":1043,"interventions":1045},"NCT03110874","Clinical Trial on Education Method of Fluterol® Inhalation Inhaler for Asthma Control",[89],"2016-09-01","2017-05-10","2015-10-08",184,[1044],"Asthma",[1023,1046],"two-way education",{"trials":1048,"activeCount":96},[],{"intervention":1046,"totalTrials":185,"cells":1050},{"EARLY_PHASE1":1051,"PHASE1":1053,"PHASE2":1055,"PHASE3":1057,"PHASE4":1059,"NA":1065},{"trials":1052,"activeCount":96},[],{"trials":1054,"activeCount":96},[],{"trials":1056,"activeCount":96},[],{"trials":1058,"activeCount":96},[],{"trials":1060,"activeCount":96},[1061],{"nctId":1036,"briefTitle":1037,"status":114,"phases":1062,"primaryCompletion":1039,"completion":1040,"start":1041,"enrollment":1042,"conditions":1063,"interventions":1064},[89],[1044],[1023,1046],{"trials":1066,"activeCount":96},[],{"intervention":1068,"totalTrials":185,"cells":1069},"Amosartan® tab",{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1076,"PHASE4":1078,"NA":1089},{"trials":1071,"activeCount":96},[],{"trials":1073,"activeCount":96},[],{"trials":1075,"activeCount":96},[],{"trials":1077,"activeCount":96},[],{"trials":1079,"activeCount":96},[1080],{"nctId":1081,"briefTitle":1082,"status":114,"phases":1083,"primaryCompletion":1084,"completion":1084,"start":738,"enrollment":1085,"conditions":1086,"interventions":1087},"NCT01828359","The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.",[89],"2013-01",199,[18],[1068,1088],"Cozaar® plus pro tab",{"trials":1090,"activeCount":96},[],{"intervention":1088,"totalTrials":185,"cells":1092},{"EARLY_PHASE1":1093,"PHASE1":1095,"PHASE2":1097,"PHASE3":1099,"PHASE4":1101,"NA":1107},{"trials":1094,"activeCount":96},[],{"trials":1096,"activeCount":96},[],{"trials":1098,"activeCount":96},[],{"trials":1100,"activeCount":96},[],{"trials":1102,"activeCount":96},[1103],{"nctId":1081,"briefTitle":1082,"status":114,"phases":1104,"primaryCompletion":1084,"completion":1084,"start":738,"enrollment":1085,"conditions":1105,"interventions":1106},[89],[18],[1068,1088],{"trials":1108,"activeCount":96},[],{"intervention":518,"totalTrials":12,"cells":1110},{"EARLY_PHASE1":1111,"PHASE1":1113,"PHASE2":1143,"PHASE3":1145,"PHASE4":1168,"NA":1170},{"trials":1112,"activeCount":96},[],{"trials":1114,"activeCount":96},[1115,1125,1135,1139],{"nctId":1116,"briefTitle":1117,"status":114,"phases":1118,"primaryCompletion":105,"completion":105,"start":1119,"enrollment":1120,"conditions":1121,"interventions":1122},"NCT02243319","Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904",[86],"2014-09",24,[15],[1123,518,1124],"HGP1201","HGP0904 and HGP1201 co-administraion",{"nctId":1126,"briefTitle":1127,"status":114,"phases":1128,"primaryCompletion":104,"completion":104,"start":1129,"enrollment":1130,"conditions":1131,"interventions":1133},"NCT02387554","Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405",[86],"2014-08",33,[1132],"Hypertension(HTN)",[518,519,1134],"HGP1405",{"nctId":510,"briefTitle":511,"status":114,"phases":1136,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":1137,"interventions":1138},[86],[15],[492,518,519],{"nctId":538,"briefTitle":539,"status":114,"phases":1140,"primaryCompletion":541,"completion":541,"start":542,"enrollment":543,"conditions":1141,"interventions":1142},[86],[15],[546,492,518,519],{"trials":1144,"activeCount":96},[],{"trials":1146,"activeCount":96},[1147,1157],{"nctId":1148,"briefTitle":1149,"status":114,"phases":1150,"primaryCompletion":1151,"completion":1152,"start":1119,"enrollment":1153,"conditions":1154,"interventions":1155},"NCT02587988","Trial to Evaluate the Efficacy and Safety of HCP1302",[88],"2015-05","2015-08",232,[26,18],[1156,518],"HCP1302",{"nctId":1158,"briefTitle":1159,"status":114,"phases":1160,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":1164,"interventions":1165},"NCT02899455","Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia",[88],"2016-06","2014-07",146,[18,32],[518,519,507,1166,1167],"HGP0904 Placebo","HGP0816 Placebo",{"trials":1169,"activeCount":96},[],{"trials":1171,"activeCount":96},[],{"intervention":1173,"totalTrials":27,"cells":1174},"HIP1402",{"EARLY_PHASE1":1175,"PHASE1":1177,"PHASE2":1215,"PHASE3":1217,"PHASE4":1227,"NA":1229},{"trials":1176,"activeCount":96},[],{"trials":1178,"activeCount":96},[1179,1189,1199,1208],{"nctId":1180,"briefTitle":1181,"status":114,"phases":1182,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":9,"conditions":1185,"interventions":1187},"NCT02715401","PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers",[86],"2015-11","2015-10",[26,1186],"Prostatic Hyperplasia",[1188,1123,1173],"HCP1303",{"nctId":1190,"briefTitle":1191,"status":114,"phases":1192,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":543,"conditions":1196,"interventions":1197},"NCT04084197","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.",[86],"2018-12-31","2019-01-04","2018-12-19",[15],[1173,1198],"HIP1801",{"nctId":1200,"briefTitle":1201,"status":114,"phases":1202,"primaryCompletion":1152,"completion":1203,"start":1204,"enrollment":1205,"conditions":1206,"interventions":1207},"NCT02712411","Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers",[86],"2015-09","2015-07",30,[26,1186],[1188,1123,1173],{"nctId":1209,"briefTitle":1210,"status":114,"phases":1211,"primaryCompletion":1184,"completion":1184,"start":1203,"enrollment":1120,"conditions":1212,"interventions":1213},"NCT02529800","Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers",[86],[15],[1173,1214],"HGP0412",{"trials":1216,"activeCount":96},[],{"trials":1218,"activeCount":96},[1219],{"nctId":1220,"briefTitle":1221,"status":114,"phases":1222,"primaryCompletion":1151,"completion":1204,"start":104,"enrollment":1223,"conditions":1224,"interventions":1226},"NCT02390882","A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH",[88],494,[1225],"Benign Prostate Hyperplasia",[1214,1173],{"trials":1228,"activeCount":96},[],{"trials":1230,"activeCount":96},[],{"intervention":671,"totalTrials":27,"cells":1232},{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1245,"PHASE3":1251,"PHASE4":1266,"NA":1268},{"trials":1234,"activeCount":96},[],{"trials":1236,"activeCount":96},[1237,1241],{"nctId":734,"briefTitle":735,"status":114,"phases":1238,"primaryCompletion":116,"completion":737,"start":738,"enrollment":158,"conditions":1239,"interventions":1240},[86],[15],[671,727],{"nctId":742,"briefTitle":735,"status":114,"phases":1242,"primaryCompletion":737,"completion":744,"start":745,"enrollment":158,"conditions":1243,"interventions":1244},[86],[15],[671,727],{"trials":1246,"activeCount":96},[1247],{"nctId":663,"briefTitle":664,"status":114,"phases":1248,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":1249,"interventions":1250},[87],[18],[671,672,654],{"trials":1252,"activeCount":96},[1253,1262],{"nctId":1254,"briefTitle":1255,"status":114,"phases":1256,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":1259,"conditions":1260,"interventions":1261},"NCT00940667","Efficacy\u002FSafety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension",[88],"2008-12","2008-05",185,[18],[671,672],{"nctId":686,"briefTitle":687,"status":114,"phases":1263,"primaryCompletion":689,"completion":689,"start":690,"enrollment":691,"conditions":1264,"interventions":1265},[88],[18],[671,654],{"trials":1267,"activeCount":96},[],{"trials":1269,"activeCount":96},[],{"intervention":672,"totalTrials":27,"cells":1271},{"EARLY_PHASE1":1272,"PHASE1":1274,"PHASE2":1276,"PHASE3":1286,"PHASE4":1307,"NA":1309},{"trials":1273,"activeCount":96},[],{"trials":1275,"activeCount":96},[],{"trials":1277,"activeCount":96},[1278,1282],{"nctId":663,"briefTitle":664,"status":114,"phases":1279,"primaryCompletion":666,"completion":666,"start":667,"enrollment":668,"conditions":1280,"interventions":1281},[87],[18],[671,672,654],{"nctId":674,"briefTitle":675,"status":114,"phases":1283,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":1284,"interventions":1285},[87],[18],[682,672,654],{"trials":1287,"activeCount":96},[1288,1292,1303],{"nctId":1254,"briefTitle":1255,"status":114,"phases":1289,"primaryCompletion":1257,"completion":1257,"start":1258,"enrollment":1259,"conditions":1290,"interventions":1291},[88],[18],[671,672],{"nctId":1293,"briefTitle":1294,"status":114,"phases":1295,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":1299,"interventions":1300},"NCT01127217","Efficacy\u002FSafety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension",[88],"2010-03","2009-05",149,[18],[1301,1302],"amlodipine\u002Flosartan","amlodipine",{"nctId":695,"briefTitle":696,"status":114,"phases":1304,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":1305,"interventions":1306},[88],[18,702],[546,654,672,704],{"trials":1308,"activeCount":96},[],{"trials":1310,"activeCount":96},[],{"intervention":507,"totalTrials":30,"cells":1312},{"EARLY_PHASE1":1313,"PHASE1":1315,"PHASE2":1329,"PHASE3":1331,"PHASE4":1348,"NA":1350},{"trials":1314,"activeCount":96},[],{"trials":1316,"activeCount":96},[1317,1321],{"nctId":499,"briefTitle":500,"status":114,"phases":1318,"primaryCompletion":105,"completion":127,"start":502,"enrollment":503,"conditions":1319,"interventions":1320},[86],[505],[507,508,492],{"nctId":1322,"briefTitle":1323,"status":114,"phases":1324,"primaryCompletion":1152,"completion":1152,"start":1204,"enrollment":9,"conditions":1325,"interventions":1326},"NCT02554136","Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816",[86],[15],[1327,507,1328],"HGP0918","HGP0918 + HGP0816",{"trials":1330,"activeCount":96},[],{"trials":1332,"activeCount":96},[1333,1337],{"nctId":1158,"briefTitle":1159,"status":114,"phases":1334,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":1335,"interventions":1336},[88],[18,32],[518,519,507,1166,1167],{"nctId":1338,"briefTitle":1339,"status":102,"phases":1340,"primaryCompletion":1341,"completion":1342,"start":104,"enrollment":1343,"conditions":1344,"interventions":1346},"NCT02551172","Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD",[88],"2016-01","2016-02",270,[1345],"Hyperlipidemias",[1347,507],"HCP1105",{"trials":1349,"activeCount":96},[],{"trials":1351,"activeCount":96},[],{"intervention":1123,"totalTrials":30,"cells":1353},{"EARLY_PHASE1":1354,"PHASE1":1356,"PHASE2":1370,"PHASE3":1372,"PHASE4":1388,"NA":1390},{"trials":1355,"activeCount":96},[],{"trials":1357,"activeCount":96},[1358,1362,1366],{"nctId":1180,"briefTitle":1181,"status":114,"phases":1359,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":9,"conditions":1360,"interventions":1361},[86],[26,1186],[1188,1123,1173],{"nctId":1116,"briefTitle":1117,"status":114,"phases":1363,"primaryCompletion":105,"completion":105,"start":1119,"enrollment":1120,"conditions":1364,"interventions":1365},[86],[15],[1123,518,1124],{"nctId":1200,"briefTitle":1201,"status":114,"phases":1367,"primaryCompletion":1152,"completion":1203,"start":1204,"enrollment":1205,"conditions":1368,"interventions":1369},[86],[26,1186],[1188,1123,1173],{"trials":1371,"activeCount":96},[],{"trials":1373,"activeCount":96},[1374],{"nctId":1375,"briefTitle":1376,"status":114,"phases":1377,"primaryCompletion":1341,"completion":1378,"start":147,"enrollment":1379,"conditions":1380,"interventions":1382},"NCT02667938","A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules",[88],"2016-05",510,[1381],"Benign Prostatic Hyperplasia",[1383,1384,1123,1385,1386,1387],"HCP1303 capsule 5\u002F0.2mg","HCP1303 capsule 5\u002F0.4mg","HCP1303 capsule 5\u002F0.2mg placebo","HCP1303 capsule 5\u002F0.4mg placebo","HGP1201 placebo",{"trials":1389,"activeCount":96},[],{"trials":1391,"activeCount":96},[],{"intervention":1393,"totalTrials":30,"cells":1394},"HCP1803-3",{"EARLY_PHASE1":1395,"PHASE1":1397,"PHASE2":1409,"PHASE3":1424,"PHASE4":1447,"NA":1449},{"trials":1396,"activeCount":96},[],{"trials":1398,"activeCount":96},[1399],{"nctId":1400,"briefTitle":1401,"status":114,"phases":1402,"primaryCompletion":1403,"completion":1403,"start":1404,"enrollment":479,"conditions":1405,"interventions":1406},"NCT05723549","A Study to Evaluate the PK, Safety and Tolerability of HCP1803.",[86],"2023-03-20","2023-02-02",[15],[1393,1407,1408],"RLD2002","HCP1904-1",{"trials":1410,"activeCount":96},[1411],{"nctId":1412,"briefTitle":1413,"status":114,"phases":1414,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":468,"conditions":1417,"interventions":1418},"NCT04959305","A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension",[87],"2022-02-28","2021-04-22",[18],[1393,1419,1420,1421,1422,1423],"RLD2003","RLD2004","RLD2005","HPP2003-3","HPP2005",{"trials":1425,"activeCount":96},[1426,1437],{"nctId":1427,"briefTitle":1428,"status":114,"phases":1429,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1432,"conditions":1433,"interventions":1434},"NCT06438172","A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension",[88],"2024-12-02","2024-03-25",249,[18],[1393,1435,1422,1436],"RLD2001-1","HPP2002-1",{"nctId":1438,"briefTitle":1439,"status":114,"phases":1440,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":1443,"conditions":1444,"interventions":1445},"NCT05362110","A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension",[88],"2023-06-05","2022-05-16",361,[18],[1393,1407,1422,1446],"HPP2004",{"trials":1448,"activeCount":96},[],{"trials":1450,"activeCount":96},[],{"intervention":519,"totalTrials":30,"cells":1452},{"EARLY_PHASE1":1453,"PHASE1":1455,"PHASE2":1469,"PHASE3":1471,"PHASE4":1477,"NA":1479},{"trials":1454,"activeCount":96},[],{"trials":1456,"activeCount":96},[1457,1461,1465],{"nctId":1126,"briefTitle":1127,"status":114,"phases":1458,"primaryCompletion":104,"completion":104,"start":1129,"enrollment":1130,"conditions":1459,"interventions":1460},[86],[1132],[518,519,1134],{"nctId":510,"briefTitle":511,"status":114,"phases":1462,"primaryCompletion":513,"completion":513,"start":514,"enrollment":515,"conditions":1463,"interventions":1464},[86],[15],[492,518,519],{"nctId":538,"briefTitle":539,"status":114,"phases":1466,"primaryCompletion":541,"completion":541,"start":542,"enrollment":543,"conditions":1467,"interventions":1468},[86],[15],[546,492,518,519],{"trials":1470,"activeCount":96},[],{"trials":1472,"activeCount":96},[1473],{"nctId":1158,"briefTitle":1159,"status":114,"phases":1474,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":1475,"interventions":1476},[88],[18,32],[518,519,507,1166,1167],{"trials":1478,"activeCount":96},[],{"trials":1480,"activeCount":96},[],{"intervention":1408,"totalTrials":30,"cells":1482},{"EARLY_PHASE1":1483,"PHASE1":1485,"PHASE2":1510,"PHASE3":1512,"PHASE4":1523,"NA":1525},{"trials":1484,"activeCount":96},[],{"trials":1486,"activeCount":96},[1487,1495,1499],{"nctId":1488,"briefTitle":1489,"status":114,"phases":1490,"primaryCompletion":711,"completion":711,"start":1491,"enrollment":335,"conditions":1492,"interventions":1493},"NCT05407220","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.",[86],"2022-06-29",[15],[1408,1494],"HCP1904-3",{"nctId":1400,"briefTitle":1401,"status":114,"phases":1496,"primaryCompletion":1403,"completion":1403,"start":1404,"enrollment":479,"conditions":1497,"interventions":1498},[86],[15],[1393,1407,1408],{"nctId":1500,"briefTitle":1501,"status":114,"phases":1502,"primaryCompletion":1503,"completion":1503,"start":1504,"enrollment":1505,"conditions":1506,"interventions":1507},"NCT05191563","A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.",[86],"2021-09-12","2021-07-31",56,[15],[1408,1508,1509],"RLD2006","RLD2001-2",{"trials":1511,"activeCount":96},[],{"trials":1513,"activeCount":96},[1514],{"nctId":1515,"briefTitle":1516,"status":114,"phases":1517,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":1520,"conditions":1521,"interventions":1522},"NCT04820907","Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients",[88],"2021-09-30","2020-10-27",123,[18],[1408,1435],{"trials":1524,"activeCount":96},[],{"trials":1526,"activeCount":96},[],{"intervention":1435,"totalTrials":263,"cells":1528},{"EARLY_PHASE1":1529,"PHASE1":1531,"PHASE2":1533,"PHASE3":1535,"PHASE4":1554,"NA":1556},{"trials":1530,"activeCount":96},[],{"trials":1532,"activeCount":96},[],{"trials":1534,"activeCount":96},[],{"trials":1536,"activeCount":96},[1537,1546,1550],{"nctId":1538,"briefTitle":1539,"status":114,"phases":1540,"primaryCompletion":1541,"completion":1541,"start":1542,"enrollment":1543,"conditions":1544,"interventions":1545},"NCT05199129","Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients",[88],"2022-09-14","2021-11-17",166,[18],[1494,1435],{"nctId":1427,"briefTitle":1428,"status":114,"phases":1547,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1432,"conditions":1548,"interventions":1549},[88],[18],[1393,1435,1422,1436],{"nctId":1515,"briefTitle":1516,"status":114,"phases":1551,"primaryCompletion":1518,"completion":1518,"start":1519,"enrollment":1520,"conditions":1552,"interventions":1553},[88],[18],[1408,1435],{"trials":1555,"activeCount":96},[],{"trials":1557,"activeCount":96},[],{"intervention":1422,"totalTrials":263,"cells":1559},{"EARLY_PHASE1":1560,"PHASE1":1562,"PHASE2":1564,"PHASE3":1570,"PHASE4":1580,"NA":1582},{"trials":1561,"activeCount":96},[],{"trials":1563,"activeCount":96},[],{"trials":1565,"activeCount":96},[1566],{"nctId":1412,"briefTitle":1413,"status":114,"phases":1567,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":468,"conditions":1568,"interventions":1569},[87],[18],[1393,1419,1420,1421,1422,1423],{"trials":1571,"activeCount":96},[1572,1576],{"nctId":1427,"briefTitle":1428,"status":114,"phases":1573,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1432,"conditions":1574,"interventions":1575},[88],[18],[1393,1435,1422,1436],{"nctId":1438,"briefTitle":1439,"status":114,"phases":1577,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":1443,"conditions":1578,"interventions":1579},[88],[18],[1393,1407,1422,1446],{"trials":1581,"activeCount":96},[],{"trials":1583,"activeCount":96},[],{"intervention":1585,"totalTrials":263,"cells":1586},"HIP1601",{"EARLY_PHASE1":1587,"PHASE1":1589,"PHASE2":1601,"PHASE3":1603,"PHASE4":1628,"NA":1630},{"trials":1588,"activeCount":96},[],{"trials":1590,"activeCount":96},[1591],{"nctId":1592,"briefTitle":1593,"status":102,"phases":1594,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT03372850","Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations",[86],"2018-06-15","2018-02-15",96,[15],[1585,1600],"HGP1705",{"trials":1602,"activeCount":96},[],{"trials":1604,"activeCount":96},[1605,1617],{"nctId":1606,"briefTitle":1607,"status":114,"phases":1608,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":1612,"interventions":1614},"NCT04080726","Efficacy and Safety of HIP1601 Capsule",[88],"2019-12-03","2018-10-25",213,[1613],"Erosive Gastroesophageal Reflux Disease",[1585,1600,1615,1616],"HIP1601 Placebo","HGP1705 Placebo",{"nctId":1618,"briefTitle":1619,"status":114,"phases":1620,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":1624,"interventions":1626},"NCT04325620","Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease",[88],"2020-08-03","2019-06-10",208,[1625],"Non-erosive Gastroesphageal Reflux Disease",[1585,1627],"HGP1805",{"trials":1629,"activeCount":96},[],{"trials":1631,"activeCount":96},[],{"intervention":1600,"totalTrials":263,"cells":1633},{"EARLY_PHASE1":1634,"PHASE1":1636,"PHASE2":1653,"PHASE3":1655,"PHASE4":1661,"NA":1663},{"trials":1635,"activeCount":96},[],{"trials":1637,"activeCount":96},[1638,1642],{"nctId":1592,"briefTitle":1593,"status":102,"phases":1639,"primaryCompletion":1595,"completion":1595,"start":1596,"enrollment":1597,"conditions":1640,"interventions":1641},[86],[15],[1585,1600],{"nctId":1643,"briefTitle":1644,"status":114,"phases":1645,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":1648,"conditions":1649,"interventions":1651},"NCT04324905","Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers",[86],"2020-10-30","2020-04-29",49,[1650],"Healthy Volunteer",[1652,1600],"HIP1802",{"trials":1654,"activeCount":96},[],{"trials":1656,"activeCount":96},[1657],{"nctId":1606,"briefTitle":1607,"status":114,"phases":1658,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":1659,"interventions":1660},[88],[1613],[1585,1600,1615,1616],{"trials":1662,"activeCount":96},[],{"trials":1664,"activeCount":96},[],{"intervention":1494,"totalTrials":179,"cells":1666},{"EARLY_PHASE1":1667,"PHASE1":1669,"PHASE2":1675,"PHASE3":1677,"PHASE4":1683,"NA":1685},{"trials":1668,"activeCount":96},[],{"trials":1670,"activeCount":96},[1671],{"nctId":1488,"briefTitle":1489,"status":114,"phases":1672,"primaryCompletion":711,"completion":711,"start":1491,"enrollment":335,"conditions":1673,"interventions":1674},[86],[15],[1408,1494],{"trials":1676,"activeCount":96},[],{"trials":1678,"activeCount":96},[1679],{"nctId":1538,"briefTitle":1539,"status":114,"phases":1680,"primaryCompletion":1541,"completion":1541,"start":1542,"enrollment":1543,"conditions":1681,"interventions":1682},[88],[18],[1494,1435],{"trials":1684,"activeCount":96},[],{"trials":1686,"activeCount":96},[],{"intervention":1688,"totalTrials":179,"cells":1689},"HCP1102",{"EARLY_PHASE1":1690,"PHASE1":1692,"PHASE2":1706,"PHASE3":1708,"PHASE4":1721,"NA":1723},{"trials":1691,"activeCount":96},[],{"trials":1693,"activeCount":96},[1694],{"nctId":1695,"briefTitle":1696,"status":114,"phases":1697,"primaryCompletion":1698,"completion":1699,"start":1700,"enrollment":1701,"conditions":1702,"interventions":1704},"NCT01651481","Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination",[86],"2012-09","2012-12","2012-07",28,[1703],"Rhinitis",[1688,1705],"Singulair and Xyzal",{"trials":1707,"activeCount":96},[],{"trials":1709,"activeCount":96},[1710],{"nctId":1711,"briefTitle":1712,"status":114,"phases":1713,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":1716,"conditions":1717,"interventions":1719},"NCT04324918","Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis",[88],"2019-06-24","2018-10-23",174,[1718],"Perennial Allergic Rhinitis",[1688,1720],"HGP1408",{"trials":1722,"activeCount":96},[],{"trials":1724,"activeCount":96},[],{"intervention":1726,"totalTrials":179,"cells":1727},"Levocetirizine",{"EARLY_PHASE1":1728,"PHASE1":1730,"PHASE2":1742,"PHASE3":1744,"PHASE4":1757,"NA":1759},{"trials":1729,"activeCount":96},[],{"trials":1731,"activeCount":96},[1732],{"nctId":1733,"briefTitle":1734,"status":114,"phases":1735,"primaryCompletion":1736,"completion":1736,"start":1737,"enrollment":1205,"conditions":1738,"interventions":1739},"NCT01491503","A Drug Interaction Study of Montelukast and Levocetirizine",[86],"2012-01","2011-11",[15],[1726,1740,1741],"montelukast sodium","Montelukast & levocetirizine",{"trials":1743,"activeCount":96},[],{"trials":1745,"activeCount":96},[1746],{"nctId":1747,"briefTitle":1748,"status":114,"phases":1749,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":1753,"interventions":1754},"NCT01640535","Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients",[88],"2013-02","2012-06",283,[1718],[1755,1726,1756],"Montelukast + Levocetirizine","Montelukast",{"trials":1758,"activeCount":96},[],{"trials":1760,"activeCount":96},[],{"intervention":1762,"totalTrials":179,"cells":1763},"HIP2101",{"EARLY_PHASE1":1764,"PHASE1":1766,"PHASE2":1780,"PHASE3":1782,"PHASE4":1796,"NA":1798},{"trials":1765,"activeCount":96},[],{"trials":1767,"activeCount":96},[1768],{"nctId":1769,"briefTitle":1770,"status":114,"phases":1771,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":1775,"conditions":1776,"interventions":1778},"NCT04967014","Study to Evaluate the Safety and Pharmacodynamic\u002FPharmacokinetic Characteristics of HIP2101 in Healthy Volunteers",[86],"2021-06-01","2021-06-18","2021-05-06",32,[1777],"Healthy Adult Volunteer",[1762,1779],"RLD2101",{"trials":1781,"activeCount":96},[],{"trials":1783,"activeCount":96},[1784],{"nctId":1785,"briefTitle":1786,"status":114,"phases":1787,"primaryCompletion":1788,"completion":1788,"start":1789,"enrollment":1790,"conditions":1791,"interventions":1793},"NCT05024721","Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis",[88],"2022-03-07","2021-08-09",326,[1792],"Gastritis",[1762,1779,1794,1795],"HPP2101","HPP2102",{"trials":1797,"activeCount":96},[],{"trials":1799,"activeCount":96},[],{"intervention":1779,"totalTrials":179,"cells":1801},{"EARLY_PHASE1":1802,"PHASE1":1804,"PHASE2":1810,"PHASE3":1812,"PHASE4":1818,"NA":1820},{"trials":1803,"activeCount":96},[],{"trials":1805,"activeCount":96},[1806],{"nctId":1769,"briefTitle":1770,"status":114,"phases":1807,"primaryCompletion":1772,"completion":1773,"start":1774,"enrollment":1775,"conditions":1808,"interventions":1809},[86],[1777],[1762,1779],{"trials":1811,"activeCount":96},[],{"trials":1813,"activeCount":96},[1814],{"nctId":1785,"briefTitle":1786,"status":114,"phases":1815,"primaryCompletion":1788,"completion":1788,"start":1789,"enrollment":1790,"conditions":1816,"interventions":1817},[88],[1792],[1762,1779,1794,1795],{"trials":1819,"activeCount":96},[],{"trials":1821,"activeCount":96},[],{"intervention":1823,"totalTrials":179,"cells":1824},"HCP0910",{"EARLY_PHASE1":1825,"PHASE1":1827,"PHASE2":1837,"PHASE3":1839,"PHASE4":1854,"NA":1856},{"trials":1826,"activeCount":96},[],{"trials":1828,"activeCount":96},[1829],{"nctId":1830,"briefTitle":1831,"status":114,"phases":1832,"primaryCompletion":156,"completion":1833,"start":759,"enrollment":1505,"conditions":1834,"interventions":1835},"NCT01521455","Therapeutic Equivalence Study of HCP0910 250\u002F50 Mcg to Seretide 250 Diskus in Asthmatic Patients",[86],"2013-07",[1044],[1823,1836],"Seretide Diskus",{"trials":1838,"activeCount":96},[],{"trials":1840,"activeCount":96},[1841],{"nctId":1842,"briefTitle":1843,"status":102,"phases":1844,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":1848,"conditions":1849,"interventions":1851},"NCT02941679","Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients",[88],"2018-02","2018-04","2016-10",252,[1850],"Chronic Obstructive Pulmonary Disease",[1852,1853,1823],"HCP1202","HGP1011",{"trials":1855,"activeCount":96},[],{"trials":1857,"activeCount":96},[],{"intervention":1509,"totalTrials":179,"cells":1859},{"EARLY_PHASE1":1860,"PHASE1":1862,"PHASE2":1868,"PHASE3":1870,"PHASE4":1881,"NA":1883},{"trials":1861,"activeCount":96},[],{"trials":1863,"activeCount":96},[1864],{"nctId":1500,"briefTitle":1501,"status":114,"phases":1865,"primaryCompletion":1503,"completion":1503,"start":1504,"enrollment":1505,"conditions":1866,"interventions":1867},[86],[15],[1408,1508,1509],{"trials":1869,"activeCount":96},[],{"trials":1871,"activeCount":96},[1872],{"nctId":1873,"briefTitle":1874,"status":114,"phases":1875,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":857,"conditions":1878,"interventions":1879},"NCT04830449","Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients",[88],"2021-08-24","2020-10-29",[18],[1880,1509],"HCP1904-2",{"trials":1882,"activeCount":96},[],{"trials":1884,"activeCount":96},[],{"intervention":1214,"totalTrials":179,"cells":1886},{"EARLY_PHASE1":1887,"PHASE1":1889,"PHASE2":1895,"PHASE3":1897,"PHASE4":1903,"NA":1905},{"trials":1888,"activeCount":96},[],{"trials":1890,"activeCount":96},[1891],{"nctId":1209,"briefTitle":1210,"status":114,"phases":1892,"primaryCompletion":1184,"completion":1184,"start":1203,"enrollment":1120,"conditions":1893,"interventions":1894},[86],[15],[1173,1214],{"trials":1896,"activeCount":96},[],{"trials":1898,"activeCount":96},[1899],{"nctId":1220,"briefTitle":1221,"status":114,"phases":1900,"primaryCompletion":1151,"completion":1204,"start":104,"enrollment":1223,"conditions":1901,"interventions":1902},[88],[1225],[1214,1173],{"trials":1904,"activeCount":96},[],{"trials":1906,"activeCount":96},[],{"intervention":1908,"totalTrials":179,"cells":1909},"HCP1401",{"EARLY_PHASE1":1910,"PHASE1":1912,"PHASE2":1922,"PHASE3":1924,"PHASE4":1934,"NA":1936},{"trials":1911,"activeCount":96},[],{"trials":1913,"activeCount":96},[1914],{"nctId":1915,"briefTitle":1916,"status":114,"phases":1917,"primaryCompletion":1183,"completion":1183,"start":1152,"enrollment":1918,"conditions":1919,"interventions":1920},"NCT04252872","Pharmacokinetics of HCP1401 and Co-administration of HCP0605, HGP1405 in Healthy Male Volunteers",[86],64,[15],[1921,1134,1908],"HCP0605",{"trials":1923,"activeCount":96},[],{"trials":1925,"activeCount":96},[1926],{"nctId":1927,"briefTitle":1928,"status":114,"phases":1929,"primaryCompletion":1930,"completion":1930,"start":148,"enrollment":1931,"conditions":1932,"interventions":1933},"NCT02916602","A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605",[88],"2016-09",340,[18],[1908,1921],{"trials":1935,"activeCount":96},[],{"trials":1937,"activeCount":96},[],{"intervention":1921,"totalTrials":179,"cells":1939},{"EARLY_PHASE1":1940,"PHASE1":1942,"PHASE2":1948,"PHASE3":1950,"PHASE4":1956,"NA":1958},{"trials":1941,"activeCount":96},[],{"trials":1943,"activeCount":96},[1944],{"nctId":1915,"briefTitle":1916,"status":114,"phases":1945,"primaryCompletion":1183,"completion":1183,"start":1152,"enrollment":1918,"conditions":1946,"interventions":1947},[86],[15],[1921,1134,1908],{"trials":1949,"activeCount":96},[],{"trials":1951,"activeCount":96},[1952],{"nctId":1927,"briefTitle":1928,"status":114,"phases":1953,"primaryCompletion":1930,"completion":1930,"start":148,"enrollment":1931,"conditions":1954,"interventions":1955},[88],[18],[1908,1921],{"trials":1957,"activeCount":96},[],{"trials":1959,"activeCount":96},[],{"intervention":1407,"totalTrials":179,"cells":1961},{"EARLY_PHASE1":1962,"PHASE1":1964,"PHASE2":1970,"PHASE3":1972,"PHASE4":1978,"NA":1980},{"trials":1963,"activeCount":96},[],{"trials":1965,"activeCount":96},[1966],{"nctId":1400,"briefTitle":1401,"status":114,"phases":1967,"primaryCompletion":1403,"completion":1403,"start":1404,"enrollment":479,"conditions":1968,"interventions":1969},[86],[15],[1393,1407,1408],{"trials":1971,"activeCount":96},[],{"trials":1973,"activeCount":96},[1974],{"nctId":1438,"briefTitle":1439,"status":114,"phases":1975,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":1443,"conditions":1976,"interventions":1977},[88],[18],[1393,1407,1422,1446],{"trials":1979,"activeCount":96},[],{"trials":1981,"activeCount":96},[],{"intervention":1347,"totalTrials":179,"cells":1983},{"EARLY_PHASE1":1984,"PHASE1":1986,"PHASE2":1998,"PHASE3":2000,"PHASE4":2006,"NA":2008},{"trials":1985,"activeCount":96},[],{"trials":1987,"activeCount":96},[1988],{"nctId":1989,"briefTitle":1990,"status":114,"phases":1991,"primaryCompletion":1992,"completion":1847,"start":1161,"enrollment":1993,"conditions":1994,"interventions":1995},"NCT02941796","Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers",[86],"2016-07",68,[1345],[1347,1996,1997],"HCP0918","HCP0816",{"trials":1999,"activeCount":96},[],{"trials":2001,"activeCount":96},[2002],{"nctId":1338,"briefTitle":1339,"status":102,"phases":2003,"primaryCompletion":1341,"completion":1342,"start":104,"enrollment":1343,"conditions":2004,"interventions":2005},[88],[1345],[1347,507],{"trials":2007,"activeCount":96},[],{"trials":2009,"activeCount":96},[],{"intervention":2011,"totalTrials":179,"cells":2012},"HGP1910",{"EARLY_PHASE1":2013,"PHASE1":2015,"PHASE2":2028,"PHASE3":2030,"PHASE4":2043,"NA":2045},{"trials":2014,"activeCount":96},[],{"trials":2016,"activeCount":96},[2017],{"nctId":2018,"briefTitle":2019,"status":114,"phases":2020,"primaryCompletion":2021,"completion":2021,"start":2022,"enrollment":2023,"conditions":2024,"interventions":2025},"NCT04762407","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903",[86],"2021-02-24","2020-11-20",57,[15],[2011,2026,2027],"HGP1909","HCP1903",{"trials":2029,"activeCount":96},[],{"trials":2031,"activeCount":96},[2032],{"nctId":2033,"briefTitle":2034,"status":114,"phases":2035,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":2039,"conditions":2040,"interventions":2041},"NCT04652349","Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia",[88],"2020-12-17","2021-01-14","2020-07-06",279,[505],[2011,2027,2026,2042],"HGP1911",{"trials":2044,"activeCount":96},[],{"trials":2046,"activeCount":96},[],{"intervention":2026,"totalTrials":179,"cells":2048},{"EARLY_PHASE1":2049,"PHASE1":2051,"PHASE2":2057,"PHASE3":2059,"PHASE4":2065,"NA":2067},{"trials":2050,"activeCount":96},[],{"trials":2052,"activeCount":96},[2053],{"nctId":2018,"briefTitle":2019,"status":114,"phases":2054,"primaryCompletion":2021,"completion":2021,"start":2022,"enrollment":2023,"conditions":2055,"interventions":2056},[86],[15],[2011,2026,2027],{"trials":2058,"activeCount":96},[],{"trials":2060,"activeCount":96},[2061],{"nctId":2033,"briefTitle":2034,"status":114,"phases":2062,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":2039,"conditions":2063,"interventions":2064},[88],[505],[2011,2027,2026,2042],{"trials":2066,"activeCount":96},[],{"trials":2068,"activeCount":96},[],{"intervention":2027,"totalTrials":179,"cells":2070},{"EARLY_PHASE1":2071,"PHASE1":2073,"PHASE2":2079,"PHASE3":2081,"PHASE4":2087,"NA":2089},{"trials":2072,"activeCount":96},[],{"trials":2074,"activeCount":96},[2075],{"nctId":2018,"briefTitle":2019,"status":114,"phases":2076,"primaryCompletion":2021,"completion":2021,"start":2022,"enrollment":2023,"conditions":2077,"interventions":2078},[86],[15],[2011,2026,2027],{"trials":2080,"activeCount":96},[],{"trials":2082,"activeCount":96},[2083],{"nctId":2033,"briefTitle":2034,"status":114,"phases":2084,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":2039,"conditions":2085,"interventions":2086},[88],[505],[2011,2027,2026,2042],{"trials":2088,"activeCount":96},[],{"trials":2090,"activeCount":96},[],{"intervention":546,"totalTrials":179,"cells":2092},{"EARLY_PHASE1":2093,"PHASE1":2095,"PHASE2":2101,"PHASE3":2103,"PHASE4":2109,"NA":2111},{"trials":2094,"activeCount":96},[],{"trials":2096,"activeCount":96},[2097],{"nctId":538,"briefTitle":539,"status":114,"phases":2098,"primaryCompletion":541,"completion":541,"start":542,"enrollment":543,"conditions":2099,"interventions":2100},[86],[15],[546,492,518,519],{"trials":2102,"activeCount":96},[],{"trials":2104,"activeCount":96},[2105],{"nctId":695,"briefTitle":696,"status":114,"phases":2106,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":2107,"interventions":2108},[88],[18,702],[546,654,672,704],{"trials":2110,"activeCount":96},[],{"trials":2112,"activeCount":96},[],{"intervention":2114,"totalTrials":185,"cells":2115},"HGP0816 5mg",{"EARLY_PHASE1":2116,"PHASE1":2118,"PHASE2":2120,"PHASE3":2122,"PHASE4":2137,"NA":2139},{"trials":2117,"activeCount":96},[],{"trials":2119,"activeCount":96},[],{"trials":2121,"activeCount":96},[],{"trials":2123,"activeCount":96},[2124],{"nctId":2125,"briefTitle":2126,"status":114,"phases":2127,"primaryCompletion":128,"completion":148,"start":2128,"enrollment":2129,"conditions":2130,"interventions":2131},"NCT02205606","Efficacy\u002FSafety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia",[88],"2014-06",412,[505],[2114,2132,2133,2134,2135,2136],"HGP0816 10mg","HGP0816 20mg","HCP1306 5\u002F10mg","HCP1306 10\u002F10mg","HCP1306 20\u002F10mg",{"trials":2138,"activeCount":96},[],{"trials":2140,"activeCount":96},[],{"intervention":2132,"totalTrials":185,"cells":2142},{"EARLY_PHASE1":2143,"PHASE1":2145,"PHASE2":2147,"PHASE3":2149,"PHASE4":2155,"NA":2157},{"trials":2144,"activeCount":96},[],{"trials":2146,"activeCount":96},[],{"trials":2148,"activeCount":96},[],{"trials":2150,"activeCount":96},[2151],{"nctId":2125,"briefTitle":2126,"status":114,"phases":2152,"primaryCompletion":128,"completion":148,"start":2128,"enrollment":2129,"conditions":2153,"interventions":2154},[88],[505],[2114,2132,2133,2134,2135,2136],{"trials":2156,"activeCount":96},[],{"trials":2158,"activeCount":96},[],{"intervention":2133,"totalTrials":185,"cells":2160},{"EARLY_PHASE1":2161,"PHASE1":2163,"PHASE2":2165,"PHASE3":2167,"PHASE4":2173,"NA":2175},{"trials":2162,"activeCount":96},[],{"trials":2164,"activeCount":96},[],{"trials":2166,"activeCount":96},[],{"trials":2168,"activeCount":96},[2169],{"nctId":2125,"briefTitle":2126,"status":114,"phases":2170,"primaryCompletion":128,"completion":148,"start":2128,"enrollment":2129,"conditions":2171,"interventions":2172},[88],[505],[2114,2132,2133,2134,2135,2136],{"trials":2174,"activeCount":96},[],{"trials":2176,"activeCount":96},[],{"intervention":2134,"totalTrials":185,"cells":2178},{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2185,"PHASE4":2191,"NA":2193},{"trials":2180,"activeCount":96},[],{"trials":2182,"activeCount":96},[],{"trials":2184,"activeCount":96},[],{"trials":2186,"activeCount":96},[2187],{"nctId":2125,"briefTitle":2126,"status":114,"phases":2188,"primaryCompletion":128,"completion":148,"start":2128,"enrollment":2129,"conditions":2189,"interventions":2190},[88],[505],[2114,2132,2133,2134,2135,2136],{"trials":2192,"activeCount":96},[],{"trials":2194,"activeCount":96},[],{"intervention":2135,"totalTrials":185,"cells":2196},{"EARLY_PHASE1":2197,"PHASE1":2199,"PHASE2":2201,"PHASE3":2203,"PHASE4":2209,"NA":2211},{"trials":2198,"activeCount":96},[],{"trials":2200,"activeCount":96},[],{"trials":2202,"activeCount":96},[],{"trials":2204,"activeCount":96},[2205],{"nctId":2125,"briefTitle":2126,"status":114,"phases":2206,"primaryCompletion":128,"completion":148,"start":2128,"enrollment":2129,"conditions":2207,"interventions":2208},[88],[505],[2114,2132,2133,2134,2135,2136],{"trials":2210,"activeCount":96},[],{"trials":2212,"activeCount":96},[],{"intervention":2136,"totalTrials":185,"cells":2214},{"EARLY_PHASE1":2215,"PHASE1":2217,"PHASE2":2219,"PHASE3":2221,"PHASE4":2227,"NA":2229},{"trials":2216,"activeCount":96},[],{"trials":2218,"activeCount":96},[],{"trials":2220,"activeCount":96},[],{"trials":2222,"activeCount":96},[2223],{"nctId":2125,"briefTitle":2126,"status":114,"phases":2224,"primaryCompletion":128,"completion":148,"start":2128,"enrollment":2129,"conditions":2225,"interventions":2226},[88],[505],[2114,2132,2133,2134,2135,2136],{"trials":2228,"activeCount":96},[],{"trials":2230,"activeCount":96},[],{"intervention":2232,"totalTrials":185,"cells":2233},"HCP1004",{"EARLY_PHASE1":2234,"PHASE1":2236,"PHASE2":2238,"PHASE3":2240,"PHASE4":2253,"NA":2255},{"trials":2235,"activeCount":96},[],{"trials":2237,"activeCount":96},[],{"trials":2239,"activeCount":96},[],{"trials":2241,"activeCount":96},[2242],{"nctId":2243,"briefTitle":2244,"status":114,"phases":2245,"primaryCompletion":2246,"completion":2246,"start":2247,"enrollment":2248,"conditions":2249,"interventions":2251},"NCT06595004","A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients",[88],"2025-06-18","2024-11-22",310,[2250],"Chronic Low-back Pain",[2232,2252],"RLD2401",{"trials":2254,"activeCount":96},[],{"trials":2256,"activeCount":96},[],{"intervention":2252,"totalTrials":185,"cells":2258},{"EARLY_PHASE1":2259,"PHASE1":2261,"PHASE2":2263,"PHASE3":2265,"PHASE4":2271,"NA":2273},{"trials":2260,"activeCount":96},[],{"trials":2262,"activeCount":96},[],{"trials":2264,"activeCount":96},[],{"trials":2266,"activeCount":96},[2267],{"nctId":2243,"briefTitle":2244,"status":114,"phases":2268,"primaryCompletion":2246,"completion":2246,"start":2247,"enrollment":2248,"conditions":2269,"interventions":2270},[88],[2250],[2232,2252],{"trials":2272,"activeCount":96},[],{"trials":2274,"activeCount":96},[],{"intervention":1720,"totalTrials":185,"cells":2276},{"EARLY_PHASE1":2277,"PHASE1":2279,"PHASE2":2281,"PHASE3":2283,"PHASE4":2289,"NA":2291},{"trials":2278,"activeCount":96},[],{"trials":2280,"activeCount":96},[],{"trials":2282,"activeCount":96},[],{"trials":2284,"activeCount":96},[2285],{"nctId":1711,"briefTitle":1712,"status":114,"phases":2286,"primaryCompletion":1714,"completion":1714,"start":1715,"enrollment":1716,"conditions":2287,"interventions":2288},[88],[1718],[1688,1720],{"trials":2290,"activeCount":96},[],{"trials":2292,"activeCount":96},[],{"intervention":1436,"totalTrials":185,"cells":2294},{"EARLY_PHASE1":2295,"PHASE1":2297,"PHASE2":2299,"PHASE3":2301,"PHASE4":2307,"NA":2309},{"trials":2296,"activeCount":96},[],{"trials":2298,"activeCount":96},[],{"trials":2300,"activeCount":96},[],{"trials":2302,"activeCount":96},[2303],{"nctId":1427,"briefTitle":1428,"status":114,"phases":2304,"primaryCompletion":1430,"completion":1430,"start":1431,"enrollment":1432,"conditions":2305,"interventions":2306},[88],[18],[1393,1435,1422,1436],{"trials":2308,"activeCount":96},[],{"trials":2310,"activeCount":96},[],{"intervention":2312,"totalTrials":185,"cells":2313},"HCP1102+HGP0711Placebo",{"EARLY_PHASE1":2314,"PHASE1":2316,"PHASE2":2318,"PHASE3":2320,"PHASE4":2331,"NA":2333},{"trials":2315,"activeCount":96},[],{"trials":2317,"activeCount":96},[],{"trials":2319,"activeCount":96},[],{"trials":2321,"activeCount":96},[2322],{"nctId":2323,"briefTitle":2324,"status":114,"phases":2325,"primaryCompletion":1204,"completion":1204,"start":1119,"enrollment":2326,"conditions":2327,"interventions":2329},"NCT02552667","Efficacy and Safety of HCP1102 Capsule",[88],228,[2328],"Asthma With Allergic Rhinitis",[2312,2330],"HCP1102Placebo+HGP0711",{"trials":2332,"activeCount":96},[],{"trials":2334,"activeCount":96},[],{"intervention":2330,"totalTrials":185,"cells":2336},{"EARLY_PHASE1":2337,"PHASE1":2339,"PHASE2":2341,"PHASE3":2343,"PHASE4":2349,"NA":2351},{"trials":2338,"activeCount":96},[],{"trials":2340,"activeCount":96},[],{"trials":2342,"activeCount":96},[],{"trials":2344,"activeCount":96},[2345],{"nctId":2323,"briefTitle":2324,"status":114,"phases":2346,"primaryCompletion":1204,"completion":1204,"start":1119,"enrollment":2326,"conditions":2347,"interventions":2348},[88],[2328],[2312,2330],{"trials":2350,"activeCount":96},[],{"trials":2352,"activeCount":96},[],{"intervention":1383,"totalTrials":185,"cells":2354},{"EARLY_PHASE1":2355,"PHASE1":2357,"PHASE2":2359,"PHASE3":2361,"PHASE4":2367,"NA":2369},{"trials":2356,"activeCount":96},[],{"trials":2358,"activeCount":96},[],{"trials":2360,"activeCount":96},[],{"trials":2362,"activeCount":96},[2363],{"nctId":1375,"briefTitle":1376,"status":114,"phases":2364,"primaryCompletion":1341,"completion":1378,"start":147,"enrollment":1379,"conditions":2365,"interventions":2366},[88],[1381],[1383,1384,1123,1385,1386,1387],{"trials":2368,"activeCount":96},[],{"trials":2370,"activeCount":96},[],{"intervention":1384,"totalTrials":185,"cells":2372},{"EARLY_PHASE1":2373,"PHASE1":2375,"PHASE2":2377,"PHASE3":2379,"PHASE4":2385,"NA":2387},{"trials":2374,"activeCount":96},[],{"trials":2376,"activeCount":96},[],{"trials":2378,"activeCount":96},[],{"trials":2380,"activeCount":96},[2381],{"nctId":1375,"briefTitle":1376,"status":114,"phases":2382,"primaryCompletion":1341,"completion":1378,"start":147,"enrollment":1379,"conditions":2383,"interventions":2384},[88],[1381],[1383,1384,1123,1385,1386,1387],{"trials":2386,"activeCount":96},[],{"trials":2388,"activeCount":96},[],{"intervention":1385,"totalTrials":185,"cells":2390},{"EARLY_PHASE1":2391,"PHASE1":2393,"PHASE2":2395,"PHASE3":2397,"PHASE4":2403,"NA":2405},{"trials":2392,"activeCount":96},[],{"trials":2394,"activeCount":96},[],{"trials":2396,"activeCount":96},[],{"trials":2398,"activeCount":96},[2399],{"nctId":1375,"briefTitle":1376,"status":114,"phases":2400,"primaryCompletion":1341,"completion":1378,"start":147,"enrollment":1379,"conditions":2401,"interventions":2402},[88],[1381],[1383,1384,1123,1385,1386,1387],{"trials":2404,"activeCount":96},[],{"trials":2406,"activeCount":96},[],{"intervention":1386,"totalTrials":185,"cells":2408},{"EARLY_PHASE1":2409,"PHASE1":2411,"PHASE2":2413,"PHASE3":2415,"PHASE4":2421,"NA":2423},{"trials":2410,"activeCount":96},[],{"trials":2412,"activeCount":96},[],{"trials":2414,"activeCount":96},[],{"trials":2416,"activeCount":96},[2417],{"nctId":1375,"briefTitle":1376,"status":114,"phases":2418,"primaryCompletion":1341,"completion":1378,"start":147,"enrollment":1379,"conditions":2419,"interventions":2420},[88],[1381],[1383,1384,1123,1385,1386,1387],{"trials":2422,"activeCount":96},[],{"trials":2424,"activeCount":96},[],{"intervention":1387,"totalTrials":185,"cells":2426},{"EARLY_PHASE1":2427,"PHASE1":2429,"PHASE2":2431,"PHASE3":2433,"PHASE4":2439,"NA":2441},{"trials":2428,"activeCount":96},[],{"trials":2430,"activeCount":96},[],{"trials":2432,"activeCount":96},[],{"trials":2434,"activeCount":96},[2435],{"nctId":1375,"briefTitle":1376,"status":114,"phases":2436,"primaryCompletion":1341,"completion":1378,"start":147,"enrollment":1379,"conditions":2437,"interventions":2438},[88],[1381],[1383,1384,1123,1385,1386,1387],{"trials":2440,"activeCount":96},[],{"trials":2442,"activeCount":96},[],{"intervention":2444,"totalTrials":185,"cells":2445},"HIP0612",{"EARLY_PHASE1":2446,"PHASE1":2448,"PHASE2":2450,"PHASE3":2452,"PHASE4":2466,"NA":2468},{"trials":2447,"activeCount":96},[],{"trials":2449,"activeCount":96},[],{"trials":2451,"activeCount":96},[],{"trials":2453,"activeCount":96},[2454],{"nctId":2455,"briefTitle":2456,"status":114,"phases":2457,"primaryCompletion":2458,"completion":2458,"start":2459,"enrollment":1085,"conditions":2460,"interventions":2462},"NCT05656092","A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer",[88],"2024-12-19","2023-03-06",[2461],"Gastric Ulcer",[2444,2463,2464,2465],"HPP2202","RLD2204","HPP2201",{"trials":2467,"activeCount":96},[],{"trials":2469,"activeCount":96},[],{"intervention":2463,"totalTrials":185,"cells":2471},{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2484,"NA":2486},{"trials":2473,"activeCount":96},[],{"trials":2475,"activeCount":96},[],{"trials":2477,"activeCount":96},[],{"trials":2479,"activeCount":96},[2480],{"nctId":2455,"briefTitle":2456,"status":114,"phases":2481,"primaryCompletion":2458,"completion":2458,"start":2459,"enrollment":1085,"conditions":2482,"interventions":2483},[88],[2461],[2444,2463,2464,2465],{"trials":2485,"activeCount":96},[],{"trials":2487,"activeCount":96},[],{"intervention":2464,"totalTrials":185,"cells":2489},{"EARLY_PHASE1":2490,"PHASE1":2492,"PHASE2":2494,"PHASE3":2496,"PHASE4":2502,"NA":2504},{"trials":2491,"activeCount":96},[],{"trials":2493,"activeCount":96},[],{"trials":2495,"activeCount":96},[],{"trials":2497,"activeCount":96},[2498],{"nctId":2455,"briefTitle":2456,"status":114,"phases":2499,"primaryCompletion":2458,"completion":2458,"start":2459,"enrollment":1085,"conditions":2500,"interventions":2501},[88],[2461],[2444,2463,2464,2465],{"trials":2503,"activeCount":96},[],{"trials":2505,"activeCount":96},[],{"intervention":2465,"totalTrials":185,"cells":2507},{"EARLY_PHASE1":2508,"PHASE1":2510,"PHASE2":2512,"PHASE3":2514,"PHASE4":2520,"NA":2522},{"trials":2509,"activeCount":96},[],{"trials":2511,"activeCount":96},[],{"trials":2513,"activeCount":96},[],{"trials":2515,"activeCount":96},[2516],{"nctId":2455,"briefTitle":2456,"status":114,"phases":2517,"primaryCompletion":2458,"completion":2458,"start":2459,"enrollment":1085,"conditions":2518,"interventions":2519},[88],[2461],[2444,2463,2464,2465],{"trials":2521,"activeCount":96},[],{"trials":2523,"activeCount":96},[],{"intervention":1156,"totalTrials":185,"cells":2525},{"EARLY_PHASE1":2526,"PHASE1":2528,"PHASE2":2530,"PHASE3":2532,"PHASE4":2538,"NA":2540},{"trials":2527,"activeCount":96},[],{"trials":2529,"activeCount":96},[],{"trials":2531,"activeCount":96},[],{"trials":2533,"activeCount":96},[2534],{"nctId":1148,"briefTitle":1149,"status":114,"phases":2535,"primaryCompletion":1151,"completion":1152,"start":1119,"enrollment":1153,"conditions":2536,"interventions":2537},[88],[26,18],[1156,518],{"trials":2539,"activeCount":96},[],{"trials":2541,"activeCount":96},[],{"intervention":2543,"totalTrials":185,"cells":2544},"Simvastatin CR",{"EARLY_PHASE1":2545,"PHASE1":2547,"PHASE2":2549,"PHASE3":2551,"PHASE4":2561,"NA":2563},{"trials":2546,"activeCount":96},[],{"trials":2548,"activeCount":96},[],{"trials":2550,"activeCount":96},[],{"trials":2552,"activeCount":96},[2553],{"nctId":2554,"briefTitle":2555,"status":114,"phases":2556,"primaryCompletion":784,"completion":784,"start":2557,"enrollment":2558,"conditions":2559,"interventions":2560},"NCT00973115","Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia",[88],"2007-11",132,[32],[2543],{"trials":2562,"activeCount":96},[],{"trials":2564,"activeCount":96},[],{"intervention":1880,"totalTrials":185,"cells":2566},{"EARLY_PHASE1":2567,"PHASE1":2569,"PHASE2":2571,"PHASE3":2573,"PHASE4":2579,"NA":2581},{"trials":2568,"activeCount":96},[],{"trials":2570,"activeCount":96},[],{"trials":2572,"activeCount":96},[],{"trials":2574,"activeCount":96},[2575],{"nctId":1873,"briefTitle":1874,"status":114,"phases":2576,"primaryCompletion":1876,"completion":1876,"start":1877,"enrollment":857,"conditions":2577,"interventions":2578},[88],[18],[1880,1509],{"trials":2580,"activeCount":96},[],{"trials":2582,"activeCount":96},[],{"intervention":1166,"totalTrials":185,"cells":2584},{"EARLY_PHASE1":2585,"PHASE1":2587,"PHASE2":2589,"PHASE3":2591,"PHASE4":2597,"NA":2599},{"trials":2586,"activeCount":96},[],{"trials":2588,"activeCount":96},[],{"trials":2590,"activeCount":96},[],{"trials":2592,"activeCount":96},[2593],{"nctId":1158,"briefTitle":1159,"status":114,"phases":2594,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":2595,"interventions":2596},[88],[18,32],[518,519,507,1166,1167],{"trials":2598,"activeCount":96},[],{"trials":2600,"activeCount":96},[],{"intervention":1167,"totalTrials":185,"cells":2602},{"EARLY_PHASE1":2603,"PHASE1":2605,"PHASE2":2607,"PHASE3":2609,"PHASE4":2615,"NA":2617},{"trials":2604,"activeCount":96},[],{"trials":2606,"activeCount":96},[],{"trials":2608,"activeCount":96},[],{"trials":2610,"activeCount":96},[2611],{"nctId":1158,"briefTitle":1159,"status":114,"phases":2612,"primaryCompletion":1161,"completion":1161,"start":1162,"enrollment":1163,"conditions":2613,"interventions":2614},[88],[18,32],[518,519,507,1166,1167],{"trials":2616,"activeCount":96},[],{"trials":2618,"activeCount":96},[],{"intervention":2620,"totalTrials":185,"cells":2621},"efpeglenatide",{"EARLY_PHASE1":2622,"PHASE1":2624,"PHASE2":2626,"PHASE3":2628,"PHASE4":2640,"NA":2642},{"trials":2623,"activeCount":96},[],{"trials":2625,"activeCount":96},[],{"trials":2627,"activeCount":96},[],{"trials":2629,"activeCount":96},[2630],{"nctId":2631,"briefTitle":2632,"status":114,"phases":2633,"primaryCompletion":2634,"completion":2635,"start":2636,"enrollment":2637,"conditions":2638,"interventions":2639},"NCT03353350","Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise",[88],"2020-01-29","2020-09-07","2017-12-05",406,[34],[2620],{"trials":2641,"activeCount":96},[],{"trials":2643,"activeCount":96},[],{"intervention":1755,"totalTrials":185,"cells":2645},{"EARLY_PHASE1":2646,"PHASE1":2648,"PHASE2":2650,"PHASE3":2652,"PHASE4":2658,"NA":2660},{"trials":2647,"activeCount":96},[],{"trials":2649,"activeCount":96},[],{"trials":2651,"activeCount":96},[],{"trials":2653,"activeCount":96},[2654],{"nctId":1747,"briefTitle":1748,"status":114,"phases":2655,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":2656,"interventions":2657},[88],[1718],[1755,1726,1756],{"trials":2659,"activeCount":96},[],{"trials":2661,"activeCount":96},[],{"intervention":1756,"totalTrials":185,"cells":2663},{"EARLY_PHASE1":2664,"PHASE1":2666,"PHASE2":2668,"PHASE3":2670,"PHASE4":2676,"NA":2678},{"trials":2665,"activeCount":96},[],{"trials":2667,"activeCount":96},[],{"trials":2669,"activeCount":96},[],{"trials":2671,"activeCount":96},[2672],{"nctId":1747,"briefTitle":1748,"status":114,"phases":2673,"primaryCompletion":1750,"completion":1750,"start":1751,"enrollment":1752,"conditions":2674,"interventions":2675},[88],[1718],[1755,1726,1756],{"trials":2677,"activeCount":96},[],{"trials":2679,"activeCount":96},[],{"intervention":2681,"totalTrials":185,"cells":2682},"ALS-L1023",{"EARLY_PHASE1":2683,"PHASE1":2685,"PHASE2":2687,"PHASE3":2689,"PHASE4":2701,"NA":2703},{"trials":2684,"activeCount":96},[],{"trials":2686,"activeCount":96},[],{"trials":2688,"activeCount":96},[],{"trials":2690,"activeCount":96},[2691],{"nctId":2692,"briefTitle":2693,"status":2694,"phases":2695,"primaryCompletion":127,"completion":127,"start":2696,"enrollment":2697,"conditions":2698,"interventions":2700},"NCT01872182","Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome","TERMINATED",[88],"2013-05",200,[2699],"Abdominal Obesity Metabolic Syndrome",[2681],{"trials":2702,"activeCount":96},[],{"trials":2704,"activeCount":96},[],{"intervention":1794,"totalTrials":185,"cells":2706},{"EARLY_PHASE1":2707,"PHASE1":2709,"PHASE2":2711,"PHASE3":2713,"PHASE4":2719,"NA":2721},{"trials":2708,"activeCount":96},[],{"trials":2710,"activeCount":96},[],{"trials":2712,"activeCount":96},[],{"trials":2714,"activeCount":96},[2715],{"nctId":1785,"briefTitle":1786,"status":114,"phases":2716,"primaryCompletion":1788,"completion":1788,"start":1789,"enrollment":1790,"conditions":2717,"interventions":2718},[88],[1792],[1762,1779,1794,1795],{"trials":2720,"activeCount":96},[],{"trials":2722,"activeCount":96},[],{"intervention":1795,"totalTrials":185,"cells":2724},{"EARLY_PHASE1":2725,"PHASE1":2727,"PHASE2":2729,"PHASE3":2731,"PHASE4":2737,"NA":2739},{"trials":2726,"activeCount":96},[],{"trials":2728,"activeCount":96},[],{"trials":2730,"activeCount":96},[],{"trials":2732,"activeCount":96},[2733],{"nctId":1785,"briefTitle":1786,"status":114,"phases":2734,"primaryCompletion":1788,"completion":1788,"start":1789,"enrollment":1790,"conditions":2735,"interventions":2736},[88],[1792],[1762,1779,1794,1795],{"trials":2738,"activeCount":96},[],{"trials":2740,"activeCount":96},[],{"intervention":1615,"totalTrials":185,"cells":2742},{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2747,"PHASE3":2749,"PHASE4":2755,"NA":2757},{"trials":2744,"activeCount":96},[],{"trials":2746,"activeCount":96},[],{"trials":2748,"activeCount":96},[],{"trials":2750,"activeCount":96},[2751],{"nctId":1606,"briefTitle":1607,"status":114,"phases":2752,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":2753,"interventions":2754},[88],[1613],[1585,1600,1615,1616],{"trials":2756,"activeCount":96},[],{"trials":2758,"activeCount":96},[],{"intervention":1616,"totalTrials":185,"cells":2760},{"EARLY_PHASE1":2761,"PHASE1":2763,"PHASE2":2765,"PHASE3":2767,"PHASE4":2773,"NA":2775},{"trials":2762,"activeCount":96},[],{"trials":2764,"activeCount":96},[],{"trials":2766,"activeCount":96},[],{"trials":2768,"activeCount":96},[2769],{"nctId":1606,"briefTitle":1607,"status":114,"phases":2770,"primaryCompletion":1609,"completion":1609,"start":1610,"enrollment":1611,"conditions":2771,"interventions":2772},[88],[1613],[1585,1600,1615,1616],{"trials":2774,"activeCount":96},[],{"trials":2776,"activeCount":96},[],{"intervention":1627,"totalTrials":185,"cells":2778},{"EARLY_PHASE1":2779,"PHASE1":2781,"PHASE2":2783,"PHASE3":2785,"PHASE4":2791,"NA":2793},{"trials":2780,"activeCount":96},[],{"trials":2782,"activeCount":96},[],{"trials":2784,"activeCount":96},[],{"trials":2786,"activeCount":96},[2787],{"nctId":1618,"briefTitle":1619,"status":114,"phases":2788,"primaryCompletion":1621,"completion":1621,"start":1622,"enrollment":1623,"conditions":2789,"interventions":2790},[88],[1625],[1585,1627],{"trials":2792,"activeCount":96},[],{"trials":2794,"activeCount":96},[],{"intervention":2796,"totalTrials":185,"cells":2797},"Irbesartan\u002FAtorvastatin A",{"EARLY_PHASE1":2798,"PHASE1":2800,"PHASE2":2802,"PHASE3":2804,"PHASE4":2819,"NA":2821},{"trials":2799,"activeCount":96},[],{"trials":2801,"activeCount":96},[],{"trials":2803,"activeCount":96},[],{"trials":2805,"activeCount":96},[2806],{"nctId":2807,"briefTitle":2808,"status":114,"phases":2809,"primaryCompletion":2810,"completion":2696,"start":2811,"enrollment":2812,"conditions":2813,"interventions":2814},"NCT01442987","Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia",[88],"2013-04","2011-05",230,[18,32],[2796,2815,2816,2817,2818],"Irbesartan","Atorvastatin A","Irbesartan\u002FAtorvastatin B","Atorvastatin B",{"trials":2820,"activeCount":96},[],{"trials":2822,"activeCount":96},[],{"intervention":2815,"totalTrials":185,"cells":2824},{"EARLY_PHASE1":2825,"PHASE1":2827,"PHASE2":2829,"PHASE3":2831,"PHASE4":2837,"NA":2839},{"trials":2826,"activeCount":96},[],{"trials":2828,"activeCount":96},[],{"trials":2830,"activeCount":96},[],{"trials":2832,"activeCount":96},[2833],{"nctId":2807,"briefTitle":2808,"status":114,"phases":2834,"primaryCompletion":2810,"completion":2696,"start":2811,"enrollment":2812,"conditions":2835,"interventions":2836},[88],[18,32],[2796,2815,2816,2817,2818],{"trials":2838,"activeCount":96},[],{"trials":2840,"activeCount":96},[],{"intervention":2816,"totalTrials":185,"cells":2842},{"EARLY_PHASE1":2843,"PHASE1":2845,"PHASE2":2847,"PHASE3":2849,"PHASE4":2855,"NA":2857},{"trials":2844,"activeCount":96},[],{"trials":2846,"activeCount":96},[],{"trials":2848,"activeCount":96},[],{"trials":2850,"activeCount":96},[2851],{"nctId":2807,"briefTitle":2808,"status":114,"phases":2852,"primaryCompletion":2810,"completion":2696,"start":2811,"enrollment":2812,"conditions":2853,"interventions":2854},[88],[18,32],[2796,2815,2816,2817,2818],{"trials":2856,"activeCount":96},[],{"trials":2858,"activeCount":96},[],{"intervention":2817,"totalTrials":185,"cells":2860},{"EARLY_PHASE1":2861,"PHASE1":2863,"PHASE2":2865,"PHASE3":2867,"PHASE4":2873,"NA":2875},{"trials":2862,"activeCount":96},[],{"trials":2864,"activeCount":96},[],{"trials":2866,"activeCount":96},[],{"trials":2868,"activeCount":96},[2869],{"nctId":2807,"briefTitle":2808,"status":114,"phases":2870,"primaryCompletion":2810,"completion":2696,"start":2811,"enrollment":2812,"conditions":2871,"interventions":2872},[88],[18,32],[2796,2815,2816,2817,2818],{"trials":2874,"activeCount":96},[],{"trials":2876,"activeCount":96},[],{"intervention":2818,"totalTrials":185,"cells":2878},{"EARLY_PHASE1":2879,"PHASE1":2881,"PHASE2":2883,"PHASE3":2885,"PHASE4":2891,"NA":2893},{"trials":2880,"activeCount":96},[],{"trials":2882,"activeCount":96},[],{"trials":2884,"activeCount":96},[],{"trials":2886,"activeCount":96},[2887],{"nctId":2807,"briefTitle":2808,"status":114,"phases":2888,"primaryCompletion":2810,"completion":2696,"start":2811,"enrollment":2812,"conditions":2889,"interventions":2890},[88],[18,32],[2796,2815,2816,2817,2818],{"trials":2892,"activeCount":96},[],{"trials":2894,"activeCount":96},[],{"intervention":1301,"totalTrials":185,"cells":2896},{"EARLY_PHASE1":2897,"PHASE1":2899,"PHASE2":2901,"PHASE3":2903,"PHASE4":2909,"NA":2911},{"trials":2898,"activeCount":96},[],{"trials":2900,"activeCount":96},[],{"trials":2902,"activeCount":96},[],{"trials":2904,"activeCount":96},[2905],{"nctId":1293,"briefTitle":1294,"status":114,"phases":2906,"primaryCompletion":1296,"completion":1296,"start":1297,"enrollment":1298,"conditions":2907,"interventions":2908},[88],[18],[1301,1302],{"trials":2910,"activeCount":96},[],{"trials":2912,"activeCount":96},[],{"intervention":704,"totalTrials":185,"cells":2914},{"EARLY_PHASE1":2915,"PHASE1":2917,"PHASE2":2919,"PHASE3":2921,"PHASE4":2927,"NA":2929},{"trials":2916,"activeCount":96},[],{"trials":2918,"activeCount":96},[],{"trials":2920,"activeCount":96},[],{"trials":2922,"activeCount":96},[2923],{"nctId":695,"briefTitle":696,"status":114,"phases":2924,"primaryCompletion":698,"completion":698,"start":699,"enrollment":700,"conditions":2925,"interventions":2926},[88],[18,702],[546,654,672,704],{"trials":2928,"activeCount":96},[],{"trials":2930,"activeCount":96},[],{"intervention":2042,"totalTrials":185,"cells":2932},{"EARLY_PHASE1":2933,"PHASE1":2935,"PHASE2":2937,"PHASE3":2939,"PHASE4":2945,"NA":2947},{"trials":2934,"activeCount":96},[],{"trials":2936,"activeCount":96},[],{"trials":2938,"activeCount":96},[],{"trials":2940,"activeCount":96},[2941],{"nctId":2033,"briefTitle":2034,"status":114,"phases":2942,"primaryCompletion":2036,"completion":2037,"start":2038,"enrollment":2039,"conditions":2943,"interventions":2944},[88],[505],[2011,2027,2026,2042],{"trials":2946,"activeCount":96},[],{"trials":2948,"activeCount":96},[],{"intervention":1446,"totalTrials":185,"cells":2950},{"EARLY_PHASE1":2951,"PHASE1":2953,"PHASE2":2955,"PHASE3":2957,"PHASE4":2963,"NA":2965},{"trials":2952,"activeCount":96},[],{"trials":2954,"activeCount":96},[],{"trials":2956,"activeCount":96},[],{"trials":2958,"activeCount":96},[2959],{"nctId":1438,"briefTitle":1439,"status":114,"phases":2960,"primaryCompletion":1441,"completion":1441,"start":1442,"enrollment":1443,"conditions":2961,"interventions":2962},[88],[18],[1393,1407,1422,1446],{"trials":2964,"activeCount":96},[],{"trials":2966,"activeCount":96},[],{"intervention":2968,"totalTrials":185,"cells":2969},"Sildenafil",{"EARLY_PHASE1":2970,"PHASE1":2972,"PHASE2":2974,"PHASE3":2976,"PHASE4":2989,"NA":2991},{"trials":2971,"activeCount":96},[],{"trials":2973,"activeCount":96},[],{"trials":2975,"activeCount":96},[],{"trials":2977,"activeCount":96},[2978],{"nctId":2979,"briefTitle":2980,"status":102,"phases":2981,"primaryCompletion":2982,"completion":2982,"start":2983,"enrollment":2984,"conditions":2985,"interventions":2988},"NCT01913847","Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension",[88],"2018-12","2013-09",144,[2986,2987],"Pulmonary Hypertension","Systolic Dysfunction",[2968],{"trials":2990,"activeCount":96},[],{"trials":2992,"activeCount":96},[],{"intervention":2994,"totalTrials":185,"cells":2995},"HCP2102-1",{"EARLY_PHASE1":2996,"PHASE1":2998,"PHASE2":3000,"PHASE3":3002,"PHASE4":3019,"NA":3021},{"trials":2997,"activeCount":96},[],{"trials":2999,"activeCount":96},[],{"trials":3001,"activeCount":96},[],{"trials":3003,"activeCount":96},[3004],{"nctId":3005,"briefTitle":3006,"status":114,"phases":3007,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1432,"conditions":3010,"interventions":3011},"NCT05450601","A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients",[88],"2023-12-11","2022-09-01",[18],[2994,3012,3013,3014,3015,3016,3017,3018],"HPP2104-1","HCP2102-2","HPP2104-2","RLD2106-1","HPP2103-1","RLD2106-2","HPP2103-2",{"trials":3020,"activeCount":96},[],{"trials":3022,"activeCount":96},[],{"intervention":3012,"totalTrials":185,"cells":3024},{"EARLY_PHASE1":3025,"PHASE1":3027,"PHASE2":3029,"PHASE3":3031,"PHASE4":3037,"NA":3039},{"trials":3026,"activeCount":96},[],{"trials":3028,"activeCount":96},[],{"trials":3030,"activeCount":96},[],{"trials":3032,"activeCount":96},[3033],{"nctId":3005,"briefTitle":3006,"status":114,"phases":3034,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1432,"conditions":3035,"interventions":3036},[88],[18],[2994,3012,3013,3014,3015,3016,3017,3018],{"trials":3038,"activeCount":96},[],{"trials":3040,"activeCount":96},[],{"intervention":3013,"totalTrials":185,"cells":3042},{"EARLY_PHASE1":3043,"PHASE1":3045,"PHASE2":3047,"PHASE3":3049,"PHASE4":3055,"NA":3057},{"trials":3044,"activeCount":96},[],{"trials":3046,"activeCount":96},[],{"trials":3048,"activeCount":96},[],{"trials":3050,"activeCount":96},[3051],{"nctId":3005,"briefTitle":3006,"status":114,"phases":3052,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1432,"conditions":3053,"interventions":3054},[88],[18],[2994,3012,3013,3014,3015,3016,3017,3018],{"trials":3056,"activeCount":96},[],{"trials":3058,"activeCount":96},[],{"intervention":3014,"totalTrials":185,"cells":3060},{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3065,"PHASE3":3067,"PHASE4":3073,"NA":3075},{"trials":3062,"activeCount":96},[],{"trials":3064,"activeCount":96},[],{"trials":3066,"activeCount":96},[],{"trials":3068,"activeCount":96},[3069],{"nctId":3005,"briefTitle":3006,"status":114,"phases":3070,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1432,"conditions":3071,"interventions":3072},[88],[18],[2994,3012,3013,3014,3015,3016,3017,3018],{"trials":3074,"activeCount":96},[],{"trials":3076,"activeCount":96},[],{"intervention":3015,"totalTrials":185,"cells":3078},{"EARLY_PHASE1":3079,"PHASE1":3081,"PHASE2":3083,"PHASE3":3085,"PHASE4":3091,"NA":3093},{"trials":3080,"activeCount":96},[],{"trials":3082,"activeCount":96},[],{"trials":3084,"activeCount":96},[],{"trials":3086,"activeCount":96},[3087],{"nctId":3005,"briefTitle":3006,"status":114,"phases":3088,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1432,"conditions":3089,"interventions":3090},[88],[18],[2994,3012,3013,3014,3015,3016,3017,3018],{"trials":3092,"activeCount":96},[],{"trials":3094,"activeCount":96},[],{"intervention":3016,"totalTrials":185,"cells":3096},{"EARLY_PHASE1":3097,"PHASE1":3099,"PHASE2":3101,"PHASE3":3103,"PHASE4":3109,"NA":3111},{"trials":3098,"activeCount":96},[],{"trials":3100,"activeCount":96},[],{"trials":3102,"activeCount":96},[],{"trials":3104,"activeCount":96},[3105],{"nctId":3005,"briefTitle":3006,"status":114,"phases":3106,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1432,"conditions":3107,"interventions":3108},[88],[18],[2994,3012,3013,3014,3015,3016,3017,3018],{"trials":3110,"activeCount":96},[],{"trials":3112,"activeCount":96},[],{"intervention":3017,"totalTrials":185,"cells":3114},{"EARLY_PHASE1":3115,"PHASE1":3117,"PHASE2":3119,"PHASE3":3121,"PHASE4":3127,"NA":3129},{"trials":3116,"activeCount":96},[],{"trials":3118,"activeCount":96},[],{"trials":3120,"activeCount":96},[],{"trials":3122,"activeCount":96},[3123],{"nctId":3005,"briefTitle":3006,"status":114,"phases":3124,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1432,"conditions":3125,"interventions":3126},[88],[18],[2994,3012,3013,3014,3015,3016,3017,3018],{"trials":3128,"activeCount":96},[],{"trials":3130,"activeCount":96},[],{"intervention":3018,"totalTrials":185,"cells":3132},{"EARLY_PHASE1":3133,"PHASE1":3135,"PHASE2":3137,"PHASE3":3139,"PHASE4":3145,"NA":3147},{"trials":3134,"activeCount":96},[],{"trials":3136,"activeCount":96},[],{"trials":3138,"activeCount":96},[],{"trials":3140,"activeCount":96},[3141],{"nctId":3005,"briefTitle":3006,"status":114,"phases":3142,"primaryCompletion":3008,"completion":3008,"start":3009,"enrollment":1432,"conditions":3143,"interventions":3144},[88],[18],[2994,3012,3013,3014,3015,3016,3017,3018],{"trials":3146,"activeCount":96},[],{"trials":3148,"activeCount":96},[],{"intervention":1852,"totalTrials":185,"cells":3150},{"EARLY_PHASE1":3151,"PHASE1":3153,"PHASE2":3155,"PHASE3":3157,"PHASE4":3163,"NA":3165},{"trials":3152,"activeCount":96},[],{"trials":3154,"activeCount":96},[],{"trials":3156,"activeCount":96},[],{"trials":3158,"activeCount":96},[3159],{"nctId":1842,"briefTitle":1843,"status":102,"phases":3160,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":1848,"conditions":3161,"interventions":3162},[88],[1850],[1852,1853,1823],{"trials":3164,"activeCount":96},[],{"trials":3166,"activeCount":96},[],{"intervention":1853,"totalTrials":185,"cells":3168},{"EARLY_PHASE1":3169,"PHASE1":3171,"PHASE2":3173,"PHASE3":3175,"PHASE4":3181,"NA":3183},{"trials":3170,"activeCount":96},[],{"trials":3172,"activeCount":96},[],{"trials":3174,"activeCount":96},[],{"trials":3176,"activeCount":96},[3177],{"nctId":1842,"briefTitle":1843,"status":102,"phases":3178,"primaryCompletion":1845,"completion":1846,"start":1847,"enrollment":1848,"conditions":3179,"interventions":3180},[88],[1850],[1852,1853,1823],{"trials":3182,"activeCount":96},[],{"trials":3184,"activeCount":96},[],{"intervention":3186,"totalTrials":185,"cells":3187},"Pseudoephedrine \u002F Levocetirizine",{"EARLY_PHASE1":3188,"PHASE1":3190,"PHASE2":3192,"PHASE3":3194,"PHASE4":3204,"NA":3206},{"trials":3189,"activeCount":96},[],{"trials":3191,"activeCount":96},[],{"trials":3193,"activeCount":96},[],{"trials":3195,"activeCount":96},[3196],{"nctId":3197,"briefTitle":3198,"status":114,"phases":3199,"primaryCompletion":2810,"completion":2810,"start":2811,"enrollment":3200,"conditions":3201,"interventions":3203},"NCT01509209","Efficacy\u002FSafety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis",[88],137,[3202],"Vasomotor Rhinitis",[3186],{"trials":3205,"activeCount":96},[],{"trials":3207,"activeCount":96},[],{"intervention":3209,"totalTrials":30,"cells":3210},"HM61713",{"EARLY_PHASE1":3211,"PHASE1":3213,"PHASE2":3224,"PHASE3":3249,"PHASE4":3251,"NA":3253},{"trials":3212,"activeCount":96},[],{"trials":3214,"activeCount":96},[3215],{"nctId":3216,"briefTitle":3217,"status":114,"phases":3218,"primaryCompletion":3219,"completion":3219,"start":2983,"enrollment":3220,"conditions":3221,"interventions":3223},"NCT01894399","Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects",[86],"2013-11",59,[3222],"Healthy Volunteers",[3209],{"trials":3225,"activeCount":96},[3226,3235,3241],{"nctId":3227,"briefTitle":3228,"status":114,"phases":3229,"primaryCompletion":3230,"completion":3230,"start":3231,"enrollment":3232,"conditions":3233,"interventions":3234},"NCT01588145","Phase I\u002FII Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients",[86,87],"2017-08","2012-03",273,[29],[3209],{"nctId":3236,"briefTitle":3237,"status":114,"phases":3238,"primaryCompletion":3230,"completion":3230,"start":147,"enrollment":1130,"conditions":3239,"interventions":3240},"NCT02444819","Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy",[87],[29],[3209],{"nctId":3242,"briefTitle":3243,"status":2694,"phases":3244,"primaryCompletion":3245,"completion":3245,"start":3246,"enrollment":787,"conditions":3247,"interventions":3248},"NCT02485652","Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung",[87],"2020-12-08","2015-08-31",[29],[3209],{"trials":3250,"activeCount":96},[],{"trials":3252,"activeCount":96},[],{"trials":3254,"activeCount":96},[],{"intervention":3256,"totalTrials":263,"cells":3257},"HM781-36B",{"EARLY_PHASE1":3258,"PHASE1":3260,"PHASE2":3278,"PHASE3":3290,"PHASE4":3292,"NA":3294},{"trials":3259,"activeCount":96},[],{"trials":3261,"activeCount":96},[3262,3269],{"nctId":3263,"briefTitle":3264,"status":114,"phases":3265,"primaryCompletion":2696,"completion":2696,"start":758,"enrollment":479,"conditions":3266,"interventions":3268},"NCT01455584","Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors",[86],[3267],"Advanced Solid Malignancies",[3256],{"nctId":3270,"briefTitle":3271,"status":114,"phases":3272,"primaryCompletion":1084,"completion":1084,"start":3273,"enrollment":3274,"conditions":3275,"interventions":3277},"NCT01455571","Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors",[86],"2009-11",55,[3276],"Advanced Solid Tumor",[3256],{"trials":3279,"activeCount":96},[3280],{"nctId":3281,"briefTitle":3282,"status":114,"phases":3283,"primaryCompletion":1152,"completion":1152,"start":3284,"enrollment":107,"conditions":3285,"interventions":3287},"NCT01746771","A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer",[86,87],"2012-11",[3286],"HER-2 Positive Advanced Gastric Cancer",[3256,3288,3289],"Paclitaxel","Trastuzumab",{"trials":3291,"activeCount":96},[],{"trials":3293,"activeCount":96},[],{"trials":3295,"activeCount":96},[],{"intervention":3288,"totalTrials":179,"cells":3297},{"EARLY_PHASE1":3298,"PHASE1":3300,"PHASE2":3302,"PHASE3":3317,"PHASE4":3319,"NA":3321},{"trials":3299,"activeCount":96},[],{"trials":3301,"activeCount":96},[],{"trials":3303,"activeCount":96},[3304,3308],{"nctId":3281,"briefTitle":3282,"status":114,"phases":3305,"primaryCompletion":1152,"completion":1152,"start":3284,"enrollment":107,"conditions":3306,"interventions":3307},[86,87],[3286],[3256,3288,3289],{"nctId":3309,"briefTitle":3310,"status":102,"phases":3311,"primaryCompletion":3231,"completion":1699,"start":1297,"enrollment":3312,"conditions":3313,"interventions":3316},"NCT01491217","A Study of Oraxol® in Gastric Cancer Patients",[86,87],53,[3314,3315],"Advanced Metastatic Gastric Cancer","Recurrent Gastric Cancer",[3288],{"trials":3318,"activeCount":96},[],{"trials":3320,"activeCount":96},[],{"trials":3322,"activeCount":96},[],{"intervention":3324,"totalTrials":179,"cells":3325},"HM10560A",{"EARLY_PHASE1":3326,"PHASE1":3328,"PHASE2":3336,"PHASE3":3348,"PHASE4":3350,"NA":3352},{"trials":3327,"activeCount":96},[],{"trials":3329,"activeCount":96},[3330],{"nctId":3331,"briefTitle":3332,"status":114,"phases":3333,"primaryCompletion":738,"completion":738,"start":1296,"enrollment":1775,"conditions":3334,"interventions":3335},"NCT01093742","A Study of HM10560A in Healthy Male Subject",[86],[15],[3324],{"trials":3337,"activeCount":96},[3338],{"nctId":3339,"briefTitle":3340,"status":114,"phases":3341,"primaryCompletion":3342,"completion":1342,"start":3343,"enrollment":158,"conditions":3344,"interventions":3346},"NCT01822340","Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients",[87],"2015-06","2011-10",[3345],"Adult Growth Hormone Deficiency",[3324,3347],"Genotropin",{"trials":3349,"activeCount":96},[],{"trials":3351,"activeCount":96},[],{"trials":3353,"activeCount":96},[],{"intervention":3355,"totalTrials":179,"cells":3356},"HM10660A",{"EARLY_PHASE1":3357,"PHASE1":3359,"PHASE2":3372,"PHASE3":3381,"PHASE4":3383,"NA":3385},{"trials":3358,"activeCount":96},[],{"trials":3360,"activeCount":96},[3361],{"nctId":3362,"briefTitle":3363,"status":114,"phases":3364,"primaryCompletion":3365,"start":3366,"enrollment":3367,"conditions":3368,"interventions":3369},"NCT01504581","Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects",[86],"2011-09","2011-03",48,[15],[3355,3370,3371],"HM10660A placebo","Pegasys",{"trials":3373,"activeCount":96},[3374],{"nctId":3375,"briefTitle":3376,"status":102,"phases":3377,"primaryCompletion":1129,"start":1833,"enrollment":1918,"conditions":3378,"interventions":3380},"NCT02057887","Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)",[86,87],[3379],"Chronic Hepatitis C Virus Genotype I",[3355,3371],{"trials":3382,"activeCount":96},[],{"trials":3384,"activeCount":96},[],{"trials":3386,"activeCount":96},[],{"intervention":3371,"totalTrials":179,"cells":3388},{"EARLY_PHASE1":3389,"PHASE1":3391,"PHASE2":3397,"PHASE3":3403,"PHASE4":3405,"NA":3407},{"trials":3390,"activeCount":96},[],{"trials":3392,"activeCount":96},[3393],{"nctId":3362,"briefTitle":3363,"status":114,"phases":3394,"primaryCompletion":3365,"start":3366,"enrollment":3367,"conditions":3395,"interventions":3396},[86],[15],[3355,3370,3371],{"trials":3398,"activeCount":96},[3399],{"nctId":3375,"briefTitle":3376,"status":102,"phases":3400,"primaryCompletion":1129,"start":1833,"enrollment":1918,"conditions":3401,"interventions":3402},[86,87],[3379],[3355,3371],{"trials":3404,"activeCount":96},[],{"trials":3406,"activeCount":96},[],{"trials":3408,"activeCount":96},[],{"intervention":3289,"totalTrials":185,"cells":3410},{"EARLY_PHASE1":3411,"PHASE1":3413,"PHASE2":3415,"PHASE3":3421,"PHASE4":3423,"NA":3425},{"trials":3412,"activeCount":96},[],{"trials":3414,"activeCount":96},[],{"trials":3416,"activeCount":96},[3417],{"nctId":3281,"briefTitle":3282,"status":114,"phases":3418,"primaryCompletion":1152,"completion":1152,"start":3284,"enrollment":107,"conditions":3419,"interventions":3420},[86,87],[3286],[3256,3288,3289],{"trials":3422,"activeCount":96},[],{"trials":3424,"activeCount":96},[],{"trials":3426,"activeCount":96},[],{"intervention":142,"totalTrials":185,"cells":3428},{"EARLY_PHASE1":3429,"PHASE1":3431,"PHASE2":3433,"PHASE3":3439,"PHASE4":3441,"NA":3443},{"trials":3430,"activeCount":96},[],{"trials":3432,"activeCount":96},[],{"trials":3434,"activeCount":96},[3435],{"nctId":134,"briefTitle":135,"status":114,"phases":3436,"primaryCompletion":104,"completion":105,"start":137,"enrollment":138,"conditions":3437,"interventions":3438},[87],[140],[40,142],{"trials":3440,"activeCount":96},[],{"trials":3442,"activeCount":96},[],{"trials":3444,"activeCount":96},[],{"intervention":3347,"totalTrials":185,"cells":3446},{"EARLY_PHASE1":3447,"PHASE1":3449,"PHASE2":3451,"PHASE3":3457,"PHASE4":3459,"NA":3461},{"trials":3448,"activeCount":96},[],{"trials":3450,"activeCount":96},[],{"trials":3452,"activeCount":96},[3453],{"nctId":3339,"briefTitle":3340,"status":114,"phases":3454,"primaryCompletion":3342,"completion":1342,"start":3343,"enrollment":158,"conditions":3455,"interventions":3456},[87],[3345],[3324,3347],{"trials":3458,"activeCount":96},[],{"trials":3460,"activeCount":96},[],{"trials":3462,"activeCount":96},[],{"intervention":3464,"totalTrials":185,"cells":3465},"KX2-391 and Paclitaxel",{"EARLY_PHASE1":3466,"PHASE1":3468,"PHASE2":3470,"PHASE3":3481,"PHASE4":3483,"NA":3485},{"trials":3467,"activeCount":96},[],{"trials":3469,"activeCount":96},[],{"trials":3471,"activeCount":96},[3472],{"nctId":3473,"briefTitle":3474,"status":102,"phases":3475,"primaryCompletion":3476,"completion":1378,"start":1699,"enrollment":503,"conditions":3477,"interventions":3480},"NCT01764087","A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors",[86,87],"2015-12",[3478,481,3479],"Unspecified Adult Solid Tumor, Protocol Specific","Breast Cancer",[3464],{"trials":3482,"activeCount":96},[],{"trials":3484,"activeCount":96},[],{"trials":3486,"activeCount":96},[],{"intervention":3488,"totalTrials":185,"cells":3489},"Poziotinib",{"EARLY_PHASE1":3490,"PHASE1":3492,"PHASE2":3494,"PHASE3":3505,"PHASE4":3507,"NA":3509},{"trials":3491,"activeCount":96},[],{"trials":3493,"activeCount":96},[],{"trials":3495,"activeCount":96},[3496],{"nctId":3497,"briefTitle":3498,"status":2694,"phases":3499,"primaryCompletion":3500,"completion":3500,"start":3501,"enrollment":27,"conditions":3502,"interventions":3504},"NCT04044170","Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation",[87],"2020-04-13","2019-07-30",[3503],"NSCLC",[3488],{"trials":3506,"activeCount":96},[],{"trials":3508,"activeCount":96},[],{"trials":3510,"activeCount":96},[],{"intervention":3512,"totalTrials":185,"cells":3513},"NOV120101",{"EARLY_PHASE1":3514,"PHASE1":3516,"PHASE2":3518,"PHASE3":3530,"PHASE4":3532,"NA":3534},{"trials":3515,"activeCount":96},[],{"trials":3517,"activeCount":96},[],{"trials":3519,"activeCount":96},[3520],{"nctId":3521,"briefTitle":3522,"status":114,"phases":3523,"primaryCompletion":3524,"completion":3525,"start":148,"enrollment":3526,"conditions":3527,"interventions":3529},"NCT02418689","Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens",[87],"2017-06","2021-04",106,[3528],"Metastatic Breast Cancer",[3512],{"trials":3531,"activeCount":96},[],{"trials":3533,"activeCount":96},[],{"trials":3535,"activeCount":96},[],{"intervention":1419,"totalTrials":185,"cells":3537},{"EARLY_PHASE1":3538,"PHASE1":3540,"PHASE2":3542,"PHASE3":3548,"PHASE4":3550,"NA":3552},{"trials":3539,"activeCount":96},[],{"trials":3541,"activeCount":96},[],{"trials":3543,"activeCount":96},[3544],{"nctId":1412,"briefTitle":1413,"status":114,"phases":3545,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":468,"conditions":3546,"interventions":3547},[87],[18],[1393,1419,1420,1421,1422,1423],{"trials":3549,"activeCount":96},[],{"trials":3551,"activeCount":96},[],{"trials":3553,"activeCount":96},[],{"intervention":1420,"totalTrials":185,"cells":3555},{"EARLY_PHASE1":3556,"PHASE1":3558,"PHASE2":3560,"PHASE3":3566,"PHASE4":3568,"NA":3570},{"trials":3557,"activeCount":96},[],{"trials":3559,"activeCount":96},[],{"trials":3561,"activeCount":96},[3562],{"nctId":1412,"briefTitle":1413,"status":114,"phases":3563,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":468,"conditions":3564,"interventions":3565},[87],[18],[1393,1419,1420,1421,1422,1423],{"trials":3567,"activeCount":96},[],{"trials":3569,"activeCount":96},[],{"trials":3571,"activeCount":96},[],{"intervention":1421,"totalTrials":185,"cells":3573},{"EARLY_PHASE1":3574,"PHASE1":3576,"PHASE2":3578,"PHASE3":3584,"PHASE4":3586,"NA":3588},{"trials":3575,"activeCount":96},[],{"trials":3577,"activeCount":96},[],{"trials":3579,"activeCount":96},[3580],{"nctId":1412,"briefTitle":1413,"status":114,"phases":3581,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":468,"conditions":3582,"interventions":3583},[87],[18],[1393,1419,1420,1421,1422,1423],{"trials":3585,"activeCount":96},[],{"trials":3587,"activeCount":96},[],{"trials":3589,"activeCount":96},[],{"intervention":1423,"totalTrials":185,"cells":3591},{"EARLY_PHASE1":3592,"PHASE1":3594,"PHASE2":3596,"PHASE3":3602,"PHASE4":3604,"NA":3606},{"trials":3593,"activeCount":96},[],{"trials":3595,"activeCount":96},[],{"trials":3597,"activeCount":96},[3598],{"nctId":1412,"briefTitle":1413,"status":114,"phases":3599,"primaryCompletion":1415,"completion":1415,"start":1416,"enrollment":468,"conditions":3600,"interventions":3601},[87],[18],[1393,1419,1420,1421,1422,1423],{"trials":3603,"activeCount":96},[],{"trials":3605,"activeCount":96},[],{"trials":3607,"activeCount":96},[],{"intervention":3609,"totalTrials":185,"cells":3610},"Probiotics",{"EARLY_PHASE1":3611,"PHASE1":3613,"PHASE2":3615,"PHASE3":3626,"PHASE4":3628,"NA":3630},{"trials":3612,"activeCount":96},[],{"trials":3614,"activeCount":96},[],{"trials":3616,"activeCount":96},[3617],{"nctId":3618,"briefTitle":3619,"status":114,"phases":3620,"primaryCompletion":1751,"completion":1751,"start":2811,"enrollment":3621,"conditions":3622,"interventions":3624},"NCT01505777","Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea",[87],280,[3623],"Irritable Bowel Syndrome Without Diarrhea",[3609,3609,3609,3609,3625],"Probiotics (Medirac) placebo\u002Fmosapride placebo",{"trials":3627,"activeCount":96},[],{"trials":3629,"activeCount":96},[],{"trials":3631,"activeCount":96},[],{"intervention":3625,"totalTrials":185,"cells":3633},{"EARLY_PHASE1":3634,"PHASE1":3636,"PHASE2":3638,"PHASE3":3644,"PHASE4":3646,"NA":3648},{"trials":3635,"activeCount":96},[],{"trials":3637,"activeCount":96},[],{"trials":3639,"activeCount":96},[3640],{"nctId":3618,"briefTitle":3619,"status":114,"phases":3641,"primaryCompletion":1751,"completion":1751,"start":2811,"enrollment":3621,"conditions":3642,"interventions":3643},[87],[3623],[3609,3609,3609,3609,3625],{"trials":3645,"activeCount":96},[],{"trials":3647,"activeCount":96},[],{"trials":3649,"activeCount":96},[],{"intervention":3651,"totalTrials":185,"cells":3652},"Epirisone 50mg or placebo TID",{"EARLY_PHASE1":3653,"PHASE1":3655,"PHASE2":3657,"PHASE3":3667,"PHASE4":3669,"NA":3671},{"trials":3654,"activeCount":96},[],{"trials":3656,"activeCount":96},[],{"trials":3658,"activeCount":96},[3659],{"nctId":3660,"briefTitle":3661,"status":114,"phases":3662,"primaryCompletion":1833,"completion":1833,"start":1750,"enrollment":3663,"conditions":3664,"interventions":3666},"NCT01806818","Comparing Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients",[87],98,[3665],"Low Back Pain",[3651],{"trials":3668,"activeCount":96},[],{"trials":3670,"activeCount":96},[],{"trials":3672,"activeCount":96},[],{"intervention":483,"totalTrials":185,"cells":3674},{"EARLY_PHASE1":3675,"PHASE1":3677,"PHASE2":3679,"PHASE3":3685,"PHASE4":3687,"NA":3689},{"trials":3676,"activeCount":96},[],{"trials":3678,"activeCount":96},[],{"trials":3680,"activeCount":96},[3681],{"nctId":474,"briefTitle":475,"status":114,"phases":3682,"primaryCompletion":477,"completion":477,"start":478,"enrollment":479,"conditions":3683,"interventions":3684},[87],[481],[483,484],{"trials":3686,"activeCount":96},[],{"trials":3688,"activeCount":96},[],{"trials":3690,"activeCount":96},[],{"intervention":682,"totalTrials":185,"cells":3692},{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3703,"PHASE4":3705,"NA":3707},{"trials":3694,"activeCount":96},[],{"trials":3696,"activeCount":96},[],{"trials":3698,"activeCount":96},[3699],{"nctId":674,"briefTitle":675,"status":114,"phases":3700,"primaryCompletion":677,"completion":677,"start":678,"enrollment":679,"conditions":3701,"interventions":3702},[87],[18],[682,672,654],{"trials":3704,"activeCount":96},[],{"trials":3706,"activeCount":96},[],{"trials":3708,"activeCount":96},[],{"intervention":536,"totalTrials":30,"cells":3710},{"EARLY_PHASE1":3711,"PHASE1":3713,"PHASE2":3750,"PHASE3":3752,"PHASE4":3754,"NA":3756},{"trials":3712,"activeCount":96},[],{"trials":3714,"activeCount":96},[3715,3725,3737,3746],{"nctId":3716,"briefTitle":3717,"status":114,"phases":3718,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":3721,"conditions":3722,"interventions":3723},"NCT06346184","A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers",[86],"2024-06-10","2024-05-02",37,[15],[3724,535,536],"HCP2303",{"nctId":3726,"briefTitle":3727,"status":114,"phases":3728,"primaryCompletion":3729,"completion":3729,"start":3730,"enrollment":3731,"conditions":3732,"interventions":3733},"NCT05155995","A Study to Evaluate the Pharmacokinetics and Safety Between HCP2001 and Co-administration of Each Component in Healthy Volunteers",[86],"2022-11-27","2021-09-28",71,[15],[3734,3735,3736,536],"HCP2001","RLD2007","RLD2008",{"nctId":3738,"briefTitle":3739,"status":114,"phases":3740,"primaryCompletion":3741,"completion":3741,"start":3742,"enrollment":3743,"conditions":3744,"interventions":3745},"NCT06357910","A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions",[86],"2024-07-01","2024-05-17",34,[15],[3724,535,536],{"nctId":528,"briefTitle":529,"status":114,"phases":3747,"primaryCompletion":531,"completion":531,"start":532,"enrollment":357,"conditions":3748,"interventions":3749},[86],[15],[492,535,536],{"trials":3751,"activeCount":96},[],{"trials":3753,"activeCount":96},[],{"trials":3755,"activeCount":96},[],{"trials":3757,"activeCount":96},[],{"intervention":3759,"totalTrials":263,"cells":3760},"HM12470",{"EARLY_PHASE1":3761,"PHASE1":3763,"PHASE2":3793,"PHASE3":3795,"PHASE4":3797,"NA":3799},{"trials":3762,"activeCount":96},[],{"trials":3764,"activeCount":96},[3765,3775,3784],{"nctId":3766,"briefTitle":3767,"status":102,"phases":3768,"primaryCompletion":3769,"completion":3769,"start":3770,"enrollment":503,"conditions":3771,"interventions":3774},"NCT03332849","Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus",[86],"2018-04-30","2015-07-28",[3772,3773],"Type1 Diabetes Mellitus","Type2 Diabetes Mellitus",[3759],{"nctId":3776,"briefTitle":3777,"status":114,"phases":3778,"primaryCompletion":3779,"completion":3779,"start":127,"enrollment":3780,"conditions":3781,"interventions":3782},"NCT02302443","A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470",[86],"2017-05",100,[21],[3759,3783],"Active comparator",{"nctId":3785,"briefTitle":3786,"status":114,"phases":3787,"primaryCompletion":3788,"completion":3788,"start":3789,"enrollment":1505,"conditions":3790,"interventions":3792},"NCT03330327","Molar Potency Study of HM12470 in Healthy Subjects",[86],"2017-08-17","2015-03-30",[3791],"Healthy Subjects",[3759],{"trials":3794,"activeCount":96},[],{"trials":3796,"activeCount":96},[],{"trials":3798,"activeCount":96},[],{"trials":3800,"activeCount":96},[],{"intervention":3802,"totalTrials":263,"cells":3803},"HM12460A",{"EARLY_PHASE1":3804,"PHASE1":3806,"PHASE2":3837,"PHASE3":3839,"PHASE4":3841,"NA":3843},{"trials":3805,"activeCount":96},[],{"trials":3807,"activeCount":96},[3808,3817,3827],{"nctId":3809,"briefTitle":3810,"status":114,"phases":3811,"primaryCompletion":3812,"completion":3812,"start":3813,"enrollment":3814,"conditions":3815,"interventions":3816},"NCT03330314","Molar Potency Study of HM12460A in Healthy Subjects",[86],"2018-02-08","2017-10-24",38,[3222],[3802],{"nctId":3818,"briefTitle":3819,"status":2694,"phases":3820,"primaryCompletion":3821,"completion":3822,"start":3823,"enrollment":3824,"conditions":3825,"interventions":3826},"NCT03332836","Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus",[86],"2019-01-30","2020-09-30","2017-10-25",21,[34],[3802],{"nctId":3828,"briefTitle":3829,"status":114,"phases":3830,"primaryCompletion":3831,"completion":3831,"start":3832,"enrollment":3833,"conditions":3834,"interventions":3836},"NCT01724814","A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A",[86],"2014-07-01","2012-12-20",86,[15,3835,34],"Type 1 Diabetes Mellitus",[3802],{"trials":3838,"activeCount":96},[],{"trials":3840,"activeCount":96},[],{"trials":3842,"activeCount":96},[],{"trials":3844,"activeCount":96},[],{"intervention":535,"totalTrials":263,"cells":3846},{"EARLY_PHASE1":3847,"PHASE1":3849,"PHASE2":3863,"PHASE3":3865,"PHASE4":3867,"NA":3869},{"trials":3848,"activeCount":96},[],{"trials":3850,"activeCount":96},[3851,3855,3859],{"nctId":3716,"briefTitle":3717,"status":114,"phases":3852,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":3721,"conditions":3853,"interventions":3854},[86],[15],[3724,535,536],{"nctId":3738,"briefTitle":3739,"status":114,"phases":3856,"primaryCompletion":3741,"completion":3741,"start":3742,"enrollment":3743,"conditions":3857,"interventions":3858},[86],[15],[3724,535,536],{"nctId":528,"briefTitle":529,"status":114,"phases":3860,"primaryCompletion":531,"completion":531,"start":532,"enrollment":357,"conditions":3861,"interventions":3862},[86],[15],[492,535,536],{"trials":3864,"activeCount":96},[],{"trials":3866,"activeCount":96},[],{"trials":3868,"activeCount":96},[],{"trials":3870,"activeCount":96},[],{"intervention":3735,"totalTrials":263,"cells":3872},{"EARLY_PHASE1":3873,"PHASE1":3875,"PHASE2":3899,"PHASE3":3901,"PHASE4":3903,"NA":3905},{"trials":3874,"activeCount":96},[],{"trials":3876,"activeCount":96},[3877,3886,3890],{"nctId":3878,"briefTitle":3879,"status":114,"phases":3880,"primaryCompletion":3881,"completion":3881,"start":3882,"enrollment":325,"conditions":3883,"interventions":3884},"NCT05862090","A Study to Evaluate the Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy Volunteers",[86],"2023-05-26","2023-04-05",[3222],[3885,3735],"RLD2301",{"nctId":3726,"briefTitle":3727,"status":114,"phases":3887,"primaryCompletion":3729,"completion":3729,"start":3730,"enrollment":3731,"conditions":3888,"interventions":3889},[86],[15],[3734,3735,3736,536],{"nctId":3891,"briefTitle":3892,"status":114,"phases":3893,"primaryCompletion":3894,"completion":3894,"start":3895,"enrollment":1130,"conditions":3896,"interventions":3897},"NCT04946903","A Study to Evaluate the Pharmacokinetics and Safety Between HCP1902 and Co-administration of RLD2007, RLD2008",[86],"2021-08-10","2021-06-10",[15],[3735,3736,3898],"HCP1902",{"trials":3900,"activeCount":96},[],{"trials":3902,"activeCount":96},[],{"trials":3904,"activeCount":96},[],{"trials":3906,"activeCount":96},[],{"intervention":3908,"totalTrials":263,"cells":3909},"RLD2202",{"EARLY_PHASE1":3910,"PHASE1":3912,"PHASE2":3940,"PHASE3":3942,"PHASE4":3944,"NA":3946},{"trials":3911,"activeCount":96},[],{"trials":3913,"activeCount":96},[3914,3924,3932],{"nctId":3915,"briefTitle":3916,"status":114,"phases":3917,"primaryCompletion":3918,"completion":3918,"start":3919,"enrollment":325,"conditions":3920,"interventions":3921},"NCT05548543","A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions",[86],"2022-12-22","2022-10-17",[15],[3922,3908,3923],"HCP2202","RLD2203",{"nctId":3925,"briefTitle":3926,"status":114,"phases":3927,"primaryCompletion":3928,"completion":3928,"start":3929,"enrollment":1120,"conditions":3930,"interventions":3931},"NCT05481307","A Study to Evaluate Pharmacokinetic\u002FPharmacodynamic Drug-drug Interaction and Safety\u002FTolerability Between RLD2202 and RLD2203",[86],"2022-10-25","2022-08-02",[15],[3908,3923],{"nctId":3933,"briefTitle":3934,"status":114,"phases":3935,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":325,"conditions":3938,"interventions":3939},"NCT05548387","A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers",[86],"2022-11-10","2022-09-02",[15],[3922,3908,3923],{"trials":3941,"activeCount":96},[],{"trials":3943,"activeCount":96},[],{"trials":3945,"activeCount":96},[],{"trials":3947,"activeCount":96},[],{"intervention":3923,"totalTrials":263,"cells":3949},{"EARLY_PHASE1":3950,"PHASE1":3952,"PHASE2":3966,"PHASE3":3968,"PHASE4":3970,"NA":3972},{"trials":3951,"activeCount":96},[],{"trials":3953,"activeCount":96},[3954,3958,3962],{"nctId":3915,"briefTitle":3916,"status":114,"phases":3955,"primaryCompletion":3918,"completion":3918,"start":3919,"enrollment":325,"conditions":3956,"interventions":3957},[86],[15],[3922,3908,3923],{"nctId":3925,"briefTitle":3926,"status":114,"phases":3959,"primaryCompletion":3928,"completion":3928,"start":3929,"enrollment":1120,"conditions":3960,"interventions":3961},[86],[15],[3908,3923],{"nctId":3933,"briefTitle":3934,"status":114,"phases":3963,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":325,"conditions":3964,"interventions":3965},[86],[15],[3922,3908,3923],{"trials":3967,"activeCount":96},[],{"trials":3969,"activeCount":96},[],{"trials":3971,"activeCount":96},[],{"trials":3973,"activeCount":96},[],{"intervention":3975,"totalTrials":179,"cells":3976},"HIP1601 40mg",{"EARLY_PHASE1":3977,"PHASE1":3979,"PHASE2":3999,"PHASE3":4001,"PHASE4":4003,"NA":4005},{"trials":3978,"activeCount":96},[],{"trials":3980,"activeCount":96},[3981,3990],{"nctId":3982,"briefTitle":3983,"status":114,"phases":3984,"primaryCompletion":3985,"completion":3985,"start":3986,"enrollment":3987,"conditions":3988,"interventions":3989},"NCT04204629","Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects",[86],"2020-02-20","2020-01-13",25,[1650],[3975],{"nctId":3991,"briefTitle":3992,"status":114,"phases":3993,"primaryCompletion":3994,"completion":3994,"start":3995,"enrollment":1120,"conditions":3996,"interventions":3998},"NCT03882112","Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male Subjects",[86],"2019-08-28","2019-04-17",[3997],"Heathy Volunteer",[3975],{"trials":4000,"activeCount":96},[],{"trials":4002,"activeCount":96},[],{"trials":4004,"activeCount":96},[],{"trials":4006,"activeCount":96},[],{"intervention":4008,"totalTrials":179,"cells":4009},"Rosuvastatin 10mg",{"EARLY_PHASE1":4010,"PHASE1":4012,"PHASE2":4031,"PHASE3":4033,"PHASE4":4035,"NA":4037},{"trials":4011,"activeCount":96},[],{"trials":4013,"activeCount":96},[4014,4023],{"nctId":4015,"briefTitle":4016,"status":114,"phases":4017,"primaryCompletion":3219,"completion":106,"start":4018,"enrollment":158,"conditions":4019,"interventions":4020},"NCT02011633","Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg",[86],"2013-10",[21],[4021,4022,4008],"HCP1201 500\u002F10mg","Metformin SR 500mg",{"nctId":4024,"briefTitle":4025,"status":114,"phases":4026,"primaryCompletion":106,"completion":137,"start":106,"enrollment":9,"conditions":4027,"interventions":4028},"NCT02026817","Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mg",[86],[21],[4029,4030,4008],"HCP1201 750\u002F10mg","Metformin SR 750mg",{"trials":4032,"activeCount":96},[],{"trials":4034,"activeCount":96},[],{"trials":4036,"activeCount":96},[],{"trials":4038,"activeCount":96},[],{"intervention":4040,"totalTrials":179,"cells":4041},"HM30181AK tablet + Irinotecan",{"EARLY_PHASE1":4042,"PHASE1":4044,"PHASE2":4061,"PHASE3":4063,"PHASE4":4065,"NA":4067},{"trials":4043,"activeCount":96},[],{"trials":4045,"activeCount":96},[4046,4053],{"nctId":4047,"briefTitle":4048,"status":114,"phases":4049,"primaryCompletion":117,"completion":1698,"start":4050,"enrollment":8,"conditions":4051,"interventions":4052},"NCT00986843","Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)",[86],"2008-06",[3267],[4040],{"nctId":4054,"briefTitle":4055,"status":114,"phases":4056,"primaryCompletion":1296,"completion":737,"start":4057,"enrollment":4058,"conditions":4059,"interventions":4060},"NCT00979563","Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies",[86],"2008-07",15,[3267],[4040],{"trials":4062,"activeCount":96},[],{"trials":4064,"activeCount":96},[],{"trials":4066,"activeCount":96},[],{"trials":4068,"activeCount":96},[],{"intervention":4070,"totalTrials":179,"cells":4071},"HIP1403",{"EARLY_PHASE1":4072,"PHASE1":4074,"PHASE2":4089,"PHASE3":4091,"PHASE4":4093,"NA":4095},{"trials":4073,"activeCount":96},[],{"trials":4075,"activeCount":96},[4076,4083],{"nctId":4077,"briefTitle":4078,"status":114,"phases":4079,"primaryCompletion":148,"completion":148,"start":148,"enrollment":1775,"conditions":4080,"interventions":4081},"NCT02473900","Evaluating the Bioequivalence of HIP1403, HGP0919",[86],[15],[4070,4082],"HGP0919",{"nctId":4084,"briefTitle":4085,"status":114,"phases":4086,"primaryCompletion":1203,"completion":1203,"start":148,"enrollment":1775,"conditions":4087,"interventions":4088},"NCT02941731","Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions",[86],[15],[4070,4082],{"trials":4090,"activeCount":96},[],{"trials":4092,"activeCount":96},[],{"trials":4094,"activeCount":96},[],{"trials":4096,"activeCount":96},[],{"intervention":4082,"totalTrials":179,"cells":4098},{"EARLY_PHASE1":4099,"PHASE1":4101,"PHASE2":4111,"PHASE3":4113,"PHASE4":4115,"NA":4117},{"trials":4100,"activeCount":96},[],{"trials":4102,"activeCount":96},[4103,4107],{"nctId":4077,"briefTitle":4078,"status":114,"phases":4104,"primaryCompletion":148,"completion":148,"start":148,"enrollment":1775,"conditions":4105,"interventions":4106},[86],[15],[4070,4082],{"nctId":4084,"briefTitle":4085,"status":114,"phases":4108,"primaryCompletion":1203,"completion":1203,"start":148,"enrollment":1775,"conditions":4109,"interventions":4110},[86],[15],[4070,4082],{"trials":4112,"activeCount":96},[],{"trials":4114,"activeCount":96},[],{"trials":4116,"activeCount":96},[],{"trials":4118,"activeCount":96},[],{"intervention":1188,"totalTrials":179,"cells":4120},{"EARLY_PHASE1":4121,"PHASE1":4123,"PHASE2":4133,"PHASE3":4135,"PHASE4":4137,"NA":4139},{"trials":4122,"activeCount":96},[],{"trials":4124,"activeCount":96},[4125,4129],{"nctId":1180,"briefTitle":1181,"status":114,"phases":4126,"primaryCompletion":1183,"completion":1183,"start":1184,"enrollment":9,"conditions":4127,"interventions":4128},[86],[26,1186],[1188,1123,1173],{"nctId":1200,"briefTitle":1201,"status":114,"phases":4130,"primaryCompletion":1152,"completion":1203,"start":1204,"enrollment":1205,"conditions":4131,"interventions":4132},[86],[26,1186],[1188,1123,1173],{"trials":4134,"activeCount":96},[],{"trials":4136,"activeCount":96},[],{"trials":4138,"activeCount":96},[],{"trials":4140,"activeCount":96},[],{"intervention":3724,"totalTrials":179,"cells":4142},{"EARLY_PHASE1":4143,"PHASE1":4145,"PHASE2":4155,"PHASE3":4157,"PHASE4":4159,"NA":4161},{"trials":4144,"activeCount":96},[],{"trials":4146,"activeCount":96},[4147,4151],{"nctId":3716,"briefTitle":3717,"status":114,"phases":4148,"primaryCompletion":3719,"completion":3719,"start":3720,"enrollment":3721,"conditions":4149,"interventions":4150},[86],[15],[3724,535,536],{"nctId":3738,"briefTitle":3739,"status":114,"phases":4152,"primaryCompletion":3741,"completion":3741,"start":3742,"enrollment":3743,"conditions":4153,"interventions":4154},[86],[15],[3724,535,536],{"trials":4156,"activeCount":96},[],{"trials":4158,"activeCount":96},[],{"trials":4160,"activeCount":96},[],{"trials":4162,"activeCount":96},[],{"intervention":1134,"totalTrials":179,"cells":4164},{"EARLY_PHASE1":4165,"PHASE1":4167,"PHASE2":4177,"PHASE3":4179,"PHASE4":4181,"NA":4183},{"trials":4166,"activeCount":96},[],{"trials":4168,"activeCount":96},[4169,4173],{"nctId":1126,"briefTitle":1127,"status":114,"phases":4170,"primaryCompletion":104,"completion":104,"start":1129,"enrollment":1130,"conditions":4171,"interventions":4172},[86],[1132],[518,519,1134],{"nctId":1915,"briefTitle":1916,"status":114,"phases":4174,"primaryCompletion":1183,"completion":1183,"start":1152,"enrollment":1918,"conditions":4175,"interventions":4176},[86],[15],[1921,1134,1908],{"trials":4178,"activeCount":96},[],{"trials":4180,"activeCount":96},[],{"trials":4182,"activeCount":96},[],{"trials":4184,"activeCount":96},[],{"intervention":4186,"totalTrials":179,"cells":4187},"HM15912",{"EARLY_PHASE1":4188,"PHASE1":4190,"PHASE2":4210,"PHASE3":4212,"PHASE4":4214,"NA":4216},{"trials":4189,"activeCount":96},[],{"trials":4191,"activeCount":96},[4192,4201],{"nctId":4193,"briefTitle":4194,"status":114,"phases":4195,"primaryCompletion":4196,"completion":4197,"start":4198,"enrollment":325,"conditions":4199,"interventions":4200},"NCT04076293","Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects",[86],"2020-11-10","2021-05-03","2019-10-08",[327],[4186],{"nctId":4202,"briefTitle":4203,"status":114,"phases":4204,"primaryCompletion":4205,"completion":4205,"start":4206,"enrollment":335,"conditions":4207,"interventions":4209},"NCT05711381","Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function",[86],"2023-08-15","2022-12-02",[4208],"Renal Impairment",[4186],{"trials":4211,"activeCount":96},[],{"trials":4213,"activeCount":96},[],{"trials":4215,"activeCount":96},[],{"trials":4217,"activeCount":96},[],{"intervention":3736,"totalTrials":179,"cells":4219},{"EARLY_PHASE1":4220,"PHASE1":4222,"PHASE2":4232,"PHASE3":4234,"PHASE4":4236,"NA":4238},{"trials":4221,"activeCount":96},[],{"trials":4223,"activeCount":96},[4224,4228],{"nctId":3726,"briefTitle":3727,"status":114,"phases":4225,"primaryCompletion":3729,"completion":3729,"start":3730,"enrollment":3731,"conditions":4226,"interventions":4227},[86],[15],[3734,3735,3736,536],{"nctId":3891,"briefTitle":3892,"status":114,"phases":4229,"primaryCompletion":3894,"completion":3894,"start":3895,"enrollment":1130,"conditions":4230,"interventions":4231},[86],[15],[3735,3736,3898],{"trials":4233,"activeCount":96},[],{"trials":4235,"activeCount":96},[],{"trials":4237,"activeCount":96},[],{"trials":4239,"activeCount":96},[],{"intervention":3922,"totalTrials":179,"cells":4241},{"EARLY_PHASE1":4242,"PHASE1":4244,"PHASE2":4254,"PHASE3":4256,"PHASE4":4258,"NA":4260},{"trials":4243,"activeCount":96},[],{"trials":4245,"activeCount":96},[4246,4250],{"nctId":3915,"briefTitle":3916,"status":114,"phases":4247,"primaryCompletion":3918,"completion":3918,"start":3919,"enrollment":325,"conditions":4248,"interventions":4249},[86],[15],[3922,3908,3923],{"nctId":3933,"briefTitle":3934,"status":114,"phases":4251,"primaryCompletion":3936,"completion":3936,"start":3937,"enrollment":325,"conditions":4252,"interventions":4253},[86],[15],[3922,3908,3923],{"trials":4255,"activeCount":96},[],{"trials":4257,"activeCount":96},[],{"trials":4259,"activeCount":96},[],{"trials":4261,"activeCount":96},[],{"intervention":4030,"totalTrials":179,"cells":4263},{"EARLY_PHASE1":4264,"PHASE1":4266,"PHASE2":4281,"PHASE3":4283,"PHASE4":4285,"NA":4287},{"trials":4265,"activeCount":96},[],{"trials":4267,"activeCount":96},[4268,4277],{"nctId":4269,"briefTitle":4270,"status":114,"phases":4271,"primaryCompletion":4272,"completion":4272,"start":156,"enrollment":158,"conditions":4273,"interventions":4274},"NCT01929512","Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg",[86],"2013-08",[21],[4275,4030,4276],"HCP1201 750\u002F20mg","Rosuvastatin 20mg",{"nctId":4024,"briefTitle":4025,"status":114,"phases":4278,"primaryCompletion":106,"completion":137,"start":106,"enrollment":9,"conditions":4279,"interventions":4280},[86],[21],[4029,4030,4008],{"trials":4282,"activeCount":96},[],{"trials":4284,"activeCount":96},[],{"trials":4286,"activeCount":96},[],{"trials":4288,"activeCount":96},[],{"intervention":4276,"totalTrials":179,"cells":4290},{"EARLY_PHASE1":4291,"PHASE1":4293,"PHASE2":4307,"PHASE3":4309,"PHASE4":4311,"NA":4313},{"trials":4292,"activeCount":96},[],{"trials":4294,"activeCount":96},[4295,4299],{"nctId":4269,"briefTitle":4270,"status":114,"phases":4296,"primaryCompletion":4272,"completion":4272,"start":156,"enrollment":158,"conditions":4297,"interventions":4298},[86],[21],[4275,4030,4276],{"nctId":4300,"briefTitle":4301,"status":114,"phases":4302,"primaryCompletion":1119,"completion":502,"start":2128,"enrollment":1120,"conditions":4303,"interventions":4304},"NCT02127320","Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe",[86],[15],[4276,4305,4306],"Ezetimibe 10mg","Rosuvastatin 20mg + Ezetimibe 10mg",{"trials":4308,"activeCount":96},[],{"trials":4310,"activeCount":96},[],{"trials":4312,"activeCount":96},[],{"trials":4314,"activeCount":96},[],{"intervention":4316,"totalTrials":179,"cells":4317},"HM10760A or Placebo",{"EARLY_PHASE1":4318,"PHASE1":4320,"PHASE2":4338,"PHASE3":4340,"PHASE4":4342,"NA":4344},{"trials":4319,"activeCount":96},[],{"trials":4321,"activeCount":96},[4322,4329],{"nctId":4323,"briefTitle":4324,"status":114,"phases":4325,"primaryCompletion":744,"completion":4326,"start":3273,"enrollment":3367,"conditions":4327,"interventions":4328},"NCT01013064","A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects",[86],"2011-01",[15],[4316],{"nctId":4330,"briefTitle":4331,"status":114,"phases":4332,"primaryCompletion":744,"completion":4326,"start":4333,"enrollment":4334,"conditions":4335,"interventions":4336},"NCT01030315","A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects",[86],"2009-10",65,[15],[4337],"HM10760A or placebo",{"trials":4339,"activeCount":96},[],{"trials":4341,"activeCount":96},[],{"trials":4343,"activeCount":96},[],{"trials":4345,"activeCount":96},[],{"intervention":4347,"totalTrials":179,"cells":4348},"HM95573",{"EARLY_PHASE1":4349,"PHASE1":4351,"PHASE2":4372,"PHASE3":4374,"PHASE4":4376,"NA":4378},{"trials":4350,"activeCount":96},[],{"trials":4352,"activeCount":96},[4353,4363],{"nctId":4354,"briefTitle":4355,"status":114,"phases":4356,"primaryCompletion":4357,"completion":4358,"start":4359,"enrollment":158,"conditions":4360,"interventions":4362},"NCT02405065","Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573",[86],"2017-01-18","2018-05-16","2015-01-12",[4361],"Neoplasms",[4347],{"nctId":4364,"briefTitle":4365,"status":114,"phases":4366,"primaryCompletion":4367,"completion":4367,"start":4368,"enrollment":4334,"conditions":4369,"interventions":4371},"NCT03118817","Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers",[86],"2020-02-04","2017-05-19",[4370],"Solid Tumor",[4347],{"trials":4373,"activeCount":96},[],{"trials":4375,"activeCount":96},[],{"trials":4377,"activeCount":96},[],{"trials":4379,"activeCount":96},[],{"intervention":4381,"totalTrials":185,"cells":4382},"HGP1810",{"EARLY_PHASE1":4383,"PHASE1":4385,"PHASE2":4397,"PHASE3":4399,"PHASE4":4401,"NA":4403},{"trials":4384,"activeCount":96},[],{"trials":4386,"activeCount":96},[4387],{"nctId":4388,"briefTitle":4389,"status":114,"phases":4390,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":3367,"conditions":4393,"interventions":4395},"NCT04081857","A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects",[86],"2019-08-05","2019-06-03",[4394],"Health, Subjective",[4381,4396],"HCP1704",{"trials":4398,"activeCount":96},[],{"trials":4400,"activeCount":96},[],{"trials":4402,"activeCount":96},[],{"trials":4404,"activeCount":96},[],{"intervention":4396,"totalTrials":185,"cells":4406},{"EARLY_PHASE1":4407,"PHASE1":4409,"PHASE2":4415,"PHASE3":4417,"PHASE4":4419,"NA":4421},{"trials":4408,"activeCount":96},[],{"trials":4410,"activeCount":96},[4411],{"nctId":4388,"briefTitle":4389,"status":114,"phases":4412,"primaryCompletion":4391,"completion":4391,"start":4392,"enrollment":3367,"conditions":4413,"interventions":4414},[86],[4394],[4381,4396],{"trials":4416,"activeCount":96},[],{"trials":4418,"activeCount":96},[],{"trials":4420,"activeCount":96},[],{"trials":4422,"activeCount":96},[],{"intervention":4424,"totalTrials":185,"cells":4425},"HIP0901 \u002F Lipidilsupra",{"EARLY_PHASE1":4426,"PHASE1":4428,"PHASE2":4436,"PHASE3":4438,"PHASE4":4440,"NA":4442},{"trials":4427,"activeCount":96},[],{"trials":4429,"activeCount":96},[4430],{"nctId":4431,"briefTitle":4432,"status":114,"phases":4433,"primaryCompletion":157,"completion":759,"start":1737,"enrollment":1701,"conditions":4434,"interventions":4435},"NCT01509196","A Bioequivalence Study Comparing HIP0901 Capsule With Lipidilsupra Tablet",[86],[15],[4424],{"trials":4437,"activeCount":96},[],{"trials":4439,"activeCount":96},[],{"trials":4441,"activeCount":96},[],{"trials":4443,"activeCount":96},[],{"intervention":4445,"totalTrials":185,"cells":4446},"HCP0912 \u002F Irbesartan and Atorvastatin",{"EARLY_PHASE1":4447,"PHASE1":4449,"PHASE2":4457,"PHASE3":4459,"PHASE4":4461,"NA":4463},{"trials":4448,"activeCount":96},[],{"trials":4450,"activeCount":96},[4451],{"nctId":4452,"briefTitle":4453,"status":114,"phases":4454,"primaryCompletion":1737,"completion":157,"start":3365,"enrollment":313,"conditions":4455,"interventions":4456},"NCT01447797","A Bioequivalence Study Comparing Irbesartan\u002FAtorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin",[86],[15],[4445],{"trials":4458,"activeCount":96},[],{"trials":4460,"activeCount":96},[],{"trials":4462,"activeCount":96},[],{"trials":4464,"activeCount":96},[],{"intervention":4466,"totalTrials":185,"cells":4467},"HCP1007 \u002F omarco and crestor",{"EARLY_PHASE1":4468,"PHASE1":4470,"PHASE2":4478,"PHASE3":4480,"PHASE4":4482,"NA":4484},{"trials":4469,"activeCount":96},[],{"trials":4471,"activeCount":96},[4472],{"nctId":4473,"briefTitle":4474,"status":114,"phases":4475,"primaryCompletion":3231,"completion":1699,"start":3231,"enrollment":1701,"conditions":4476,"interventions":4477},"NCT01548157","Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule",[86],[15],[4466],{"trials":4479,"activeCount":96},[],{"trials":4481,"activeCount":96},[],{"trials":4483,"activeCount":96},[],{"trials":4485,"activeCount":96},[],{"intervention":4021,"totalTrials":185,"cells":4487},{"EARLY_PHASE1":4488,"PHASE1":4490,"PHASE2":4496,"PHASE3":4498,"PHASE4":4500,"NA":4502},{"trials":4489,"activeCount":96},[],{"trials":4491,"activeCount":96},[4492],{"nctId":4015,"briefTitle":4016,"status":114,"phases":4493,"primaryCompletion":3219,"completion":106,"start":4018,"enrollment":158,"conditions":4494,"interventions":4495},[86],[21],[4021,4022,4008],{"trials":4497,"activeCount":96},[],{"trials":4499,"activeCount":96},[],{"trials":4501,"activeCount":96},[],{"trials":4503,"activeCount":96},[],{"intervention":4022,"totalTrials":185,"cells":4505},{"EARLY_PHASE1":4506,"PHASE1":4508,"PHASE2":4514,"PHASE3":4516,"PHASE4":4518,"NA":4520},{"trials":4507,"activeCount":96},[],{"trials":4509,"activeCount":96},[4510],{"nctId":4015,"briefTitle":4016,"status":114,"phases":4511,"primaryCompletion":3219,"completion":106,"start":4018,"enrollment":158,"conditions":4512,"interventions":4513},[86],[21],[4021,4022,4008],{"trials":4515,"activeCount":96},[],{"trials":4517,"activeCount":96},[],{"trials":4519,"activeCount":96},[],{"trials":4521,"activeCount":96},[],{"intervention":4523,"totalTrials":185,"cells":4524},"Paclitaxel+HM30181",{"EARLY_PHASE1":4525,"PHASE1":4527,"PHASE2":4538,"PHASE3":4540,"PHASE4":4542,"NA":4544},{"trials":4526,"activeCount":96},[],{"trials":4528,"activeCount":96},[4529],{"nctId":4530,"briefTitle":4531,"status":114,"phases":4532,"primaryCompletion":4533,"completion":4533,"start":4534,"enrollment":3987,"conditions":4535,"interventions":4537},"NCT01491204","Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer",[86],"2008-10","2006-08",[4536],"Advanced Solid Tumors",[4523],{"trials":4539,"activeCount":96},[],{"trials":4541,"activeCount":96},[],{"trials":4543,"activeCount":96},[],{"trials":4545,"activeCount":96},[],{"intervention":4547,"totalTrials":185,"cells":4548},"amosartan",{"EARLY_PHASE1":4549,"PHASE1":4551,"PHASE2":4562,"PHASE3":4564,"PHASE4":4566,"NA":4568},{"trials":4550,"activeCount":96},[],{"trials":4552,"activeCount":96},[4553],{"nctId":4554,"briefTitle":4555,"status":102,"phases":4556,"primaryCompletion":4557,"completion":1129,"start":129,"enrollment":1205,"conditions":4558,"interventions":4559},"NCT02140489","Evaluating a Pharmacokinetic Drug Interaction Between Amlodipine\u002FLosartan and Rosuvastatin",[86],"2014-05",[15],[4547,4560,4561],"rosuvastatin","amosartan and rosuvastatin",{"trials":4563,"activeCount":96},[],{"trials":4565,"activeCount":96},[],{"trials":4567,"activeCount":96},[],{"trials":4569,"activeCount":96},[],{"intervention":4560,"totalTrials":185,"cells":4571},{"EARLY_PHASE1":4572,"PHASE1":4574,"PHASE2":4580,"PHASE3":4582,"PHASE4":4584,"NA":4586},{"trials":4573,"activeCount":96},[],{"trials":4575,"activeCount":96},[4576],{"nctId":4554,"briefTitle":4555,"status":102,"phases":4577,"primaryCompletion":4557,"completion":1129,"start":129,"enrollment":1205,"conditions":4578,"interventions":4579},[86],[15],[4547,4560,4561],{"trials":4581,"activeCount":96},[],{"trials":4583,"activeCount":96},[],{"trials":4585,"activeCount":96},[],{"trials":4587,"activeCount":96},[],{"intervention":4561,"totalTrials":185,"cells":4589},{"EARLY_PHASE1":4590,"PHASE1":4592,"PHASE2":4598,"PHASE3":4600,"PHASE4":4602,"NA":4604},{"trials":4591,"activeCount":96},[],{"trials":4593,"activeCount":96},[4594],{"nctId":4554,"briefTitle":4555,"status":102,"phases":4595,"primaryCompletion":4557,"completion":1129,"start":129,"enrollment":1205,"conditions":4596,"interventions":4597},[86],[15],[4547,4560,4561],{"trials":4599,"activeCount":96},[],{"trials":4601,"activeCount":96},[],{"trials":4603,"activeCount":96},[],{"trials":4605,"activeCount":96},[],{"intervention":4607,"totalTrials":185,"cells":4608},"HGP1607",{"EARLY_PHASE1":4609,"PHASE1":4611,"PHASE2":4625,"PHASE3":4627,"PHASE4":4629,"NA":4631},{"trials":4610,"activeCount":96},[],{"trials":4612,"activeCount":96},[4613],{"nctId":4614,"briefTitle":4615,"status":114,"phases":4616,"primaryCompletion":4617,"completion":4618,"start":4619,"enrollment":1205,"conditions":4620,"interventions":4622},"NCT03089112","Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501",[86],"2017-05-28","2017-06-16","2017-03-31",[4621],"Healthy Male Volunteers",[4607,4623,4624],"HGP1501","HGP1607+HGP1501",{"trials":4626,"activeCount":96},[],{"trials":4628,"activeCount":96},[],{"trials":4630,"activeCount":96},[],{"trials":4632,"activeCount":96},[],{"intervention":4623,"totalTrials":185,"cells":4634},{"EARLY_PHASE1":4635,"PHASE1":4637,"PHASE2":4643,"PHASE3":4645,"PHASE4":4647,"NA":4649},{"trials":4636,"activeCount":96},[],{"trials":4638,"activeCount":96},[4639],{"nctId":4614,"briefTitle":4615,"status":114,"phases":4640,"primaryCompletion":4617,"completion":4618,"start":4619,"enrollment":1205,"conditions":4641,"interventions":4642},[86],[4621],[4607,4623,4624],{"trials":4644,"activeCount":96},[],{"trials":4646,"activeCount":96},[],{"trials":4648,"activeCount":96},[],{"trials":4650,"activeCount":96},[],{"intervention":4624,"totalTrials":185,"cells":4652},{"EARLY_PHASE1":4653,"PHASE1":4655,"PHASE2":4661,"PHASE3":4663,"PHASE4":4665,"NA":4667},{"trials":4654,"activeCount":96},[],{"trials":4656,"activeCount":96},[4657],{"nctId":4614,"briefTitle":4615,"status":114,"phases":4658,"primaryCompletion":4617,"completion":4618,"start":4619,"enrollment":1205,"conditions":4659,"interventions":4660},[86],[4621],[4607,4623,4624],{"trials":4662,"activeCount":96},[],{"trials":4664,"activeCount":96},[],{"trials":4666,"activeCount":96},[],{"trials":4668,"activeCount":96},[],{"intervention":508,"totalTrials":185,"cells":4670},{"EARLY_PHASE1":4671,"PHASE1":4673,"PHASE2":4679,"PHASE3":4681,"PHASE4":4683,"NA":4685},{"trials":4672,"activeCount":96},[],{"trials":4674,"activeCount":96},[4675],{"nctId":499,"briefTitle":500,"status":114,"phases":4676,"primaryCompletion":105,"completion":127,"start":502,"enrollment":503,"conditions":4677,"interventions":4678},[86],[505],[507,508,492],{"trials":4680,"activeCount":96},[],{"trials":4682,"activeCount":96},[],{"trials":4684,"activeCount":96},[],{"trials":4686,"activeCount":96},[],{"intervention":3885,"totalTrials":185,"cells":4688},{"EARLY_PHASE1":4689,"PHASE1":4691,"PHASE2":4697,"PHASE3":4699,"PHASE4":4701,"NA":4703},{"trials":4690,"activeCount":96},[],{"trials":4692,"activeCount":96},[4693],{"nctId":3878,"briefTitle":3879,"status":114,"phases":4694,"primaryCompletion":3881,"completion":3881,"start":3882,"enrollment":325,"conditions":4695,"interventions":4696},[86],[3222],[3885,3735],{"trials":4698,"activeCount":96},[],{"trials":4700,"activeCount":96},[],{"trials":4702,"activeCount":96},[],{"trials":4704,"activeCount":96},[],{"intervention":4706,"totalTrials":185,"cells":4707},"HM15211 or Placebo",{"EARLY_PHASE1":4708,"PHASE1":4710,"PHASE2":4720,"PHASE3":4722,"PHASE4":4724,"NA":4726},{"trials":4709,"activeCount":96},[],{"trials":4711,"activeCount":96},[4712],{"nctId":4713,"briefTitle":4714,"status":114,"phases":4715,"primaryCompletion":4716,"completion":4716,"start":4717,"enrollment":118,"conditions":4718,"interventions":4719},"NCT03374241","A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)",[86],"2018-09-14","2018-04-04",[24],[4706],{"trials":4721,"activeCount":96},[],{"trials":4723,"activeCount":96},[],{"trials":4725,"activeCount":96},[],{"trials":4727,"activeCount":96},[],{"intervention":1198,"totalTrials":185,"cells":4729},{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4738,"PHASE3":4740,"PHASE4":4742,"NA":4744},{"trials":4731,"activeCount":96},[],{"trials":4733,"activeCount":96},[4734],{"nctId":1190,"briefTitle":1191,"status":114,"phases":4735,"primaryCompletion":1193,"completion":1194,"start":1195,"enrollment":543,"conditions":4736,"interventions":4737},[86],[15],[1173,1198],{"trials":4739,"activeCount":96},[],{"trials":4741,"activeCount":96},[],{"trials":4743,"activeCount":96},[],{"trials":4745,"activeCount":96},[],{"intervention":4747,"totalTrials":185,"cells":4748},"HIP1302",{"EARLY_PHASE1":4749,"PHASE1":4751,"PHASE2":4760,"PHASE3":4762,"PHASE4":4764,"NA":4766},{"trials":4750,"activeCount":96},[],{"trials":4752,"activeCount":96},[4753],{"nctId":4754,"briefTitle":4755,"status":114,"phases":4756,"primaryCompletion":1184,"completion":1184,"start":1152,"enrollment":3814,"conditions":4757,"interventions":4758},"NCT02545829","Evaluating the Bioequivalence of HIP1302, HGP1406",[86],[15],[4747,4759],"HGP1406",{"trials":4761,"activeCount":96},[],{"trials":4763,"activeCount":96},[],{"trials":4765,"activeCount":96},[],{"trials":4767,"activeCount":96},[],{"intervention":4759,"totalTrials":185,"cells":4769},{"EARLY_PHASE1":4770,"PHASE1":4772,"PHASE2":4778,"PHASE3":4780,"PHASE4":4782,"NA":4784},{"trials":4771,"activeCount":96},[],{"trials":4773,"activeCount":96},[4774],{"nctId":4754,"briefTitle":4755,"status":114,"phases":4775,"primaryCompletion":1184,"completion":1184,"start":1152,"enrollment":3814,"conditions":4776,"interventions":4777},[86],[15],[4747,4759],{"trials":4779,"activeCount":96},[],{"trials":4781,"activeCount":96},[],{"trials":4783,"activeCount":96},[],{"trials":4785,"activeCount":96},[],{"intervention":1124,"totalTrials":185,"cells":4787},{"EARLY_PHASE1":4788,"PHASE1":4790,"PHASE2":4796,"PHASE3":4798,"PHASE4":4800,"NA":4802},{"trials":4789,"activeCount":96},[],{"trials":4791,"activeCount":96},[4792],{"nctId":1116,"briefTitle":1117,"status":114,"phases":4793,"primaryCompletion":105,"completion":105,"start":1119,"enrollment":1120,"conditions":4794,"interventions":4795},[86],[15],[1123,518,1124],{"trials":4797,"activeCount":96},[],{"trials":4799,"activeCount":96},[],{"trials":4801,"activeCount":96},[],{"trials":4803,"activeCount":96},[],{"intervention":3783,"totalTrials":185,"cells":4805},{"EARLY_PHASE1":4806,"PHASE1":4808,"PHASE2":4814,"PHASE3":4816,"PHASE4":4818,"NA":4820},{"trials":4807,"activeCount":96},[],{"trials":4809,"activeCount":96},[4810],{"nctId":3776,"briefTitle":3777,"status":114,"phases":4811,"primaryCompletion":3779,"completion":3779,"start":127,"enrollment":3780,"conditions":4812,"interventions":4813},[86],[21],[3759,3783],{"trials":4815,"activeCount":96},[],{"trials":4817,"activeCount":96},[],{"trials":4819,"activeCount":96},[],{"trials":4821,"activeCount":96},[],{"intervention":1740,"totalTrials":185,"cells":4823},{"EARLY_PHASE1":4824,"PHASE1":4826,"PHASE2":4832,"PHASE3":4834,"PHASE4":4836,"NA":4838},{"trials":4825,"activeCount":96},[],{"trials":4827,"activeCount":96},[4828],{"nctId":1733,"briefTitle":1734,"status":114,"phases":4829,"primaryCompletion":1736,"completion":1736,"start":1737,"enrollment":1205,"conditions":4830,"interventions":4831},[86],[15],[1726,1740,1741],{"trials":4833,"activeCount":96},[],{"trials":4835,"activeCount":96},[],{"trials":4837,"activeCount":96},[],{"trials":4839,"activeCount":96},[],{"intervention":1741,"totalTrials":185,"cells":4841},{"EARLY_PHASE1":4842,"PHASE1":4844,"PHASE2":4850,"PHASE3":4852,"PHASE4":4854,"NA":4856},{"trials":4843,"activeCount":96},[],{"trials":4845,"activeCount":96},[4846],{"nctId":1733,"briefTitle":1734,"status":114,"phases":4847,"primaryCompletion":1736,"completion":1736,"start":1737,"enrollment":1205,"conditions":4848,"interventions":4849},[86],[15],[1726,1740,1741],{"trials":4851,"activeCount":96},[],{"trials":4853,"activeCount":96},[],{"trials":4855,"activeCount":96},[],{"trials":4857,"activeCount":96},[],{"intervention":4859,"totalTrials":185,"cells":4860},"HCP2201",{"EARLY_PHASE1":4861,"PHASE1":4863,"PHASE2":4875,"PHASE3":4877,"PHASE4":4879,"NA":4881},{"trials":4862,"activeCount":96},[],{"trials":4864,"activeCount":96},[4865],{"nctId":4866,"briefTitle":4867,"status":114,"phases":4868,"primaryCompletion":4869,"completion":4869,"start":4870,"enrollment":107,"conditions":4871,"interventions":4872},"NCT05737082","A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers",[86],"2023-05-14","2023-03-30",[15],[4859,4873,4874],"RLD2205","RLD2206",{"trials":4876,"activeCount":96},[],{"trials":4878,"activeCount":96},[],{"trials":4880,"activeCount":96},[],{"trials":4882,"activeCount":96},[],{"intervention":4873,"totalTrials":185,"cells":4884},{"EARLY_PHASE1":4885,"PHASE1":4887,"PHASE2":4893,"PHASE3":4895,"PHASE4":4897,"NA":4899},{"trials":4886,"activeCount":96},[],{"trials":4888,"activeCount":96},[4889],{"nctId":4866,"briefTitle":4867,"status":114,"phases":4890,"primaryCompletion":4869,"completion":4869,"start":4870,"enrollment":107,"conditions":4891,"interventions":4892},[86],[15],[4859,4873,4874],{"trials":4894,"activeCount":96},[],{"trials":4896,"activeCount":96},[],{"trials":4898,"activeCount":96},[],{"trials":4900,"activeCount":96},[],{"intervention":4874,"totalTrials":185,"cells":4902},{"EARLY_PHASE1":4903,"PHASE1":4905,"PHASE2":4911,"PHASE3":4913,"PHASE4":4915,"NA":4917},{"trials":4904,"activeCount":96},[],{"trials":4906,"activeCount":96},[4907],{"nctId":4866,"briefTitle":4867,"status":114,"phases":4908,"primaryCompletion":4869,"completion":4869,"start":4870,"enrollment":107,"conditions":4909,"interventions":4910},[86],[15],[4859,4873,4874],{"trials":4912,"activeCount":96},[],{"trials":4914,"activeCount":96},[],{"trials":4916,"activeCount":96},[],{"trials":4918,"activeCount":96},[],{"intervention":4920,"totalTrials":185,"cells":4921},"HCP1104 \u002F Mulex Tab. and Airtal Tab.",{"EARLY_PHASE1":4922,"PHASE1":4924,"PHASE2":4932,"PHASE3":4934,"PHASE4":4936,"NA":4938},{"trials":4923,"activeCount":96},[],{"trials":4925,"activeCount":96},[4926],{"nctId":4927,"briefTitle":4928,"status":114,"phases":4929,"primaryCompletion":2983,"completion":137,"start":4272,"enrollment":1205,"conditions":4930,"interventions":4931},"NCT01869985","Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers",[86],[15],[4920],{"trials":4933,"activeCount":96},[],{"trials":4935,"activeCount":96},[],{"trials":4937,"activeCount":96},[],{"trials":4939,"activeCount":96},[],{"intervention":1836,"totalTrials":185,"cells":4941},{"EARLY_PHASE1":4942,"PHASE1":4944,"PHASE2":4950,"PHASE3":4952,"PHASE4":4954,"NA":4956},{"trials":4943,"activeCount":96},[],{"trials":4945,"activeCount":96},[4946],{"nctId":1830,"briefTitle":1831,"status":114,"phases":4947,"primaryCompletion":156,"completion":1833,"start":759,"enrollment":1505,"conditions":4948,"interventions":4949},[86],[1044],[1823,1836],{"trials":4951,"activeCount":96},[],{"trials":4953,"activeCount":96},[],{"trials":4955,"activeCount":96},[],{"trials":4957,"activeCount":96},[],{"intervention":3734,"totalTrials":185,"cells":4959},{"EARLY_PHASE1":4960,"PHASE1":4962,"PHASE2":4968,"PHASE3":4970,"PHASE4":4972,"NA":4974},{"trials":4961,"activeCount":96},[],{"trials":4963,"activeCount":96},[4964],{"nctId":3726,"briefTitle":3727,"status":114,"phases":4965,"primaryCompletion":3729,"completion":3729,"start":3730,"enrollment":3731,"conditions":4966,"interventions":4967},[86],[15],[3734,3735,3736,536],{"trials":4969,"activeCount":96},[],{"trials":4971,"activeCount":96},[],{"trials":4973,"activeCount":96},[],{"trials":4975,"activeCount":96},[],{"intervention":4977,"totalTrials":185,"cells":4978},"Oratecan and Capecitabine",{"EARLY_PHASE1":4979,"PHASE1":4981,"PHASE2":4991,"PHASE3":4993,"PHASE4":4995,"NA":4997},{"trials":4980,"activeCount":96},[],{"trials":4982,"activeCount":96},[4983],{"nctId":4984,"briefTitle":4985,"status":114,"phases":4986,"primaryCompletion":4987,"completion":106,"start":744,"enrollment":3824,"conditions":4988,"interventions":4990},"NCT01463982","Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies",[86],"2012-04",[4370,4989],"Advanced Cancer",[4977],{"trials":4992,"activeCount":96},[],{"trials":4994,"activeCount":96},[],{"trials":4996,"activeCount":96},[],{"trials":4998,"activeCount":96},[],{"intervention":5000,"totalTrials":185,"cells":5001},"HIP1701",{"EARLY_PHASE1":5002,"PHASE1":5004,"PHASE2":5014,"PHASE3":5016,"PHASE4":5018,"NA":5020},{"trials":5003,"activeCount":96},[],{"trials":5005,"activeCount":96},[5006],{"nctId":5007,"briefTitle":5008,"status":114,"phases":5009,"primaryCompletion":5010,"completion":5010,"start":1715,"enrollment":515,"conditions":5011,"interventions":5012},"NCT04087525","A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects",[86],"2018-11-27",[4394],[5000,5013],"HGP1809",{"trials":5015,"activeCount":96},[],{"trials":5017,"activeCount":96},[],{"trials":5019,"activeCount":96},[],{"trials":5021,"activeCount":96},[],{"intervention":5013,"totalTrials":185,"cells":5023},{"EARLY_PHASE1":5024,"PHASE1":5026,"PHASE2":5032,"PHASE3":5034,"PHASE4":5036,"NA":5038},{"trials":5025,"activeCount":96},[],{"trials":5027,"activeCount":96},[5028],{"nctId":5007,"briefTitle":5008,"status":114,"phases":5029,"primaryCompletion":5010,"completion":5010,"start":1715,"enrollment":515,"conditions":5030,"interventions":5031},[86],[4394],[5000,5013],{"trials":5033,"activeCount":96},[],{"trials":5035,"activeCount":96},[],{"trials":5037,"activeCount":96},[],{"trials":5039,"activeCount":96},[],{"intervention":5041,"totalTrials":185,"cells":5042},"HCP0605 + HGP0816",{"EARLY_PHASE1":5043,"PHASE1":5045,"PHASE2":5054,"PHASE3":5056,"PHASE4":5058,"NA":5060},{"trials":5044,"activeCount":96},[],{"trials":5046,"activeCount":96},[5047],{"nctId":5048,"briefTitle":5049,"status":114,"phases":5050,"primaryCompletion":1151,"completion":1151,"start":128,"enrollment":543,"conditions":5051,"interventions":5052},"NCT04039724","Pharmacokinetics of HCP1305 and Co-administration of HCP0605, HGP0816 in Healthy Male Volunteers",[86],[15],[5041,5053],"HCP1305",{"trials":5055,"activeCount":96},[],{"trials":5057,"activeCount":96},[],{"trials":5059,"activeCount":96},[],{"trials":5061,"activeCount":96},[],{"intervention":5053,"totalTrials":185,"cells":5063},{"EARLY_PHASE1":5064,"PHASE1":5066,"PHASE2":5072,"PHASE3":5074,"PHASE4":5076,"NA":5078},{"trials":5065,"activeCount":96},[],{"trials":5067,"activeCount":96},[5068],{"nctId":5048,"briefTitle":5049,"status":114,"phases":5069,"primaryCompletion":1151,"completion":1151,"start":128,"enrollment":543,"conditions":5070,"interventions":5071},[86],[15],[5041,5053],{"trials":5073,"activeCount":96},[],{"trials":5075,"activeCount":96},[],{"trials":5077,"activeCount":96},[],{"trials":5079,"activeCount":96},[],{"intervention":5081,"totalTrials":185,"cells":5082},"Glucophage SR tablet 750 mg, Crestor tablet 20 mg",{"EARLY_PHASE1":5083,"PHASE1":5085,"PHASE2":5094,"PHASE3":5096,"PHASE4":5098,"NA":5100},{"trials":5084,"activeCount":96},[],{"trials":5086,"activeCount":96},[5087],{"nctId":5088,"briefTitle":5089,"status":114,"phases":5090,"primaryCompletion":5091,"completion":156,"start":1084,"enrollment":9,"conditions":5092,"interventions":5093},"NCT01775579","Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium",[86],"2013-03",[21],[5081],{"trials":5095,"activeCount":96},[],{"trials":5097,"activeCount":96},[],{"trials":5099,"activeCount":96},[],{"trials":5101,"activeCount":96},[],{"intervention":5103,"totalTrials":185,"cells":5104},"HM71224 single ascending dose",{"EARLY_PHASE1":5105,"PHASE1":5107,"PHASE2":5119,"PHASE3":5121,"PHASE4":5123,"NA":5125},{"trials":5106,"activeCount":96},[],{"trials":5108,"activeCount":96},[5109],{"nctId":5110,"briefTitle":5111,"status":114,"phases":5112,"primaryCompletion":502,"completion":502,"start":1084,"enrollment":5113,"conditions":5114,"interventions":5116},"NCT01765478","Safety,PK\u002FPD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers",[86],62,[5115],"Rheumatoid Arthritis",[5103,5117,5118],"HM71224 food effect","HM71224 Multiple ascending dose",{"trials":5120,"activeCount":96},[],{"trials":5122,"activeCount":96},[],{"trials":5124,"activeCount":96},[],{"trials":5126,"activeCount":96},[],{"intervention":5117,"totalTrials":185,"cells":5128},{"EARLY_PHASE1":5129,"PHASE1":5131,"PHASE2":5137,"PHASE3":5139,"PHASE4":5141,"NA":5143},{"trials":5130,"activeCount":96},[],{"trials":5132,"activeCount":96},[5133],{"nctId":5110,"briefTitle":5111,"status":114,"phases":5134,"primaryCompletion":502,"completion":502,"start":1084,"enrollment":5113,"conditions":5135,"interventions":5136},[86],[5115],[5103,5117,5118],{"trials":5138,"activeCount":96},[],{"trials":5140,"activeCount":96},[],{"trials":5142,"activeCount":96},[],{"trials":5144,"activeCount":96},[],{"intervention":5118,"totalTrials":185,"cells":5146},{"EARLY_PHASE1":5147,"PHASE1":5149,"PHASE2":5155,"PHASE3":5157,"PHASE4":5159,"NA":5161},{"trials":5148,"activeCount":96},[],{"trials":5150,"activeCount":96},[5151],{"nctId":5110,"briefTitle":5111,"status":114,"phases":5152,"primaryCompletion":502,"completion":502,"start":1084,"enrollment":5113,"conditions":5153,"interventions":5154},[86],[5115],[5103,5117,5118],{"trials":5156,"activeCount":96},[],{"trials":5158,"activeCount":96},[],{"trials":5160,"activeCount":96},[],{"trials":5162,"activeCount":96},[],{"intervention":5164,"totalTrials":185,"cells":5165},"HCP1007",{"EARLY_PHASE1":5166,"PHASE1":5168,"PHASE2":5178,"PHASE3":5180,"PHASE4":5182,"NA":5184},{"trials":5167,"activeCount":96},[],{"trials":5169,"activeCount":96},[5170],{"nctId":5171,"briefTitle":5172,"status":114,"phases":5173,"primaryCompletion":5091,"completion":5091,"start":1750,"enrollment":5174,"conditions":5175,"interventions":5176},"NCT01929070","A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007",[86],12,[15],[5164,5177],"Omarco and Crestor",{"trials":5179,"activeCount":96},[],{"trials":5181,"activeCount":96},[],{"trials":5183,"activeCount":96},[],{"trials":5185,"activeCount":96},[],{"intervention":5177,"totalTrials":185,"cells":5187},{"EARLY_PHASE1":5188,"PHASE1":5190,"PHASE2":5196,"PHASE3":5198,"PHASE4":5200,"NA":5202},{"trials":5189,"activeCount":96},[],{"trials":5191,"activeCount":96},[5192],{"nctId":5171,"briefTitle":5172,"status":114,"phases":5193,"primaryCompletion":5091,"completion":5091,"start":1750,"enrollment":5174,"conditions":5194,"interventions":5195},[86],[15],[5164,5177],{"trials":5197,"activeCount":96},[],{"trials":5199,"activeCount":96},[],{"trials":5201,"activeCount":96},[],{"trials":5203,"activeCount":96},[],{"intervention":5205,"totalTrials":185,"cells":5206},"HCP1805",{"EARLY_PHASE1":5207,"PHASE1":5209,"PHASE2":5222,"PHASE3":5224,"PHASE4":5226,"NA":5228},{"trials":5208,"activeCount":96},[],{"trials":5210,"activeCount":96},[5211],{"nctId":5212,"briefTitle":5213,"status":114,"phases":5214,"primaryCompletion":5215,"completion":5216,"start":5217,"enrollment":5218,"conditions":5219,"interventions":5220},"NCT03826641","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects",[86],"2019-03-25","2019-04-16","2019-02-01",85,[15],[5205,5221],"HCP1801",{"trials":5223,"activeCount":96},[],{"trials":5225,"activeCount":96},[],{"trials":5227,"activeCount":96},[],{"trials":5229,"activeCount":96},[],{"intervention":5221,"totalTrials":185,"cells":5231},{"EARLY_PHASE1":5232,"PHASE1":5234,"PHASE2":5240,"PHASE3":5242,"PHASE4":5244,"NA":5246},{"trials":5233,"activeCount":96},[],{"trials":5235,"activeCount":96},[5236],{"nctId":5212,"briefTitle":5213,"status":114,"phases":5237,"primaryCompletion":5215,"completion":5216,"start":5217,"enrollment":5218,"conditions":5238,"interventions":5239},[86],[15],[5205,5221],{"trials":5241,"activeCount":96},[],{"trials":5243,"activeCount":96},[],{"trials":5245,"activeCount":96},[],{"trials":5247,"activeCount":96},[],{"intervention":4275,"totalTrials":185,"cells":5249},{"EARLY_PHASE1":5250,"PHASE1":5252,"PHASE2":5258,"PHASE3":5260,"PHASE4":5262,"NA":5264},{"trials":5251,"activeCount":96},[],{"trials":5253,"activeCount":96},[5254],{"nctId":4269,"briefTitle":4270,"status":114,"phases":5255,"primaryCompletion":4272,"completion":4272,"start":156,"enrollment":158,"conditions":5256,"interventions":5257},[86],[21],[4275,4030,4276],{"trials":5259,"activeCount":96},[],{"trials":5261,"activeCount":96},[],{"trials":5263,"activeCount":96},[],{"trials":5265,"activeCount":96},[],{"intervention":1996,"totalTrials":185,"cells":5267},{"EARLY_PHASE1":5268,"PHASE1":5270,"PHASE2":5276,"PHASE3":5278,"PHASE4":5280,"NA":5282},{"trials":5269,"activeCount":96},[],{"trials":5271,"activeCount":96},[5272],{"nctId":1989,"briefTitle":1990,"status":114,"phases":5273,"primaryCompletion":1992,"completion":1847,"start":1161,"enrollment":1993,"conditions":5274,"interventions":5275},[86],[1345],[1347,1996,1997],{"trials":5277,"activeCount":96},[],{"trials":5279,"activeCount":96},[],{"trials":5281,"activeCount":96},[],{"trials":5283,"activeCount":96},[],{"intervention":1997,"totalTrials":185,"cells":5285},{"EARLY_PHASE1":5286,"PHASE1":5288,"PHASE2":5294,"PHASE3":5296,"PHASE4":5298,"NA":5300},{"trials":5287,"activeCount":96},[],{"trials":5289,"activeCount":96},[5290],{"nctId":1989,"briefTitle":1990,"status":114,"phases":5291,"primaryCompletion":1992,"completion":1847,"start":1161,"enrollment":1993,"conditions":5292,"interventions":5293},[86],[1345],[1347,1996,1997],{"trials":5295,"activeCount":96},[],{"trials":5297,"activeCount":96},[],{"trials":5299,"activeCount":96},[],{"trials":5301,"activeCount":96},[],{"intervention":3370,"totalTrials":185,"cells":5303},{"EARLY_PHASE1":5304,"PHASE1":5306,"PHASE2":5312,"PHASE3":5314,"PHASE4":5316,"NA":5318},{"trials":5305,"activeCount":96},[],{"trials":5307,"activeCount":96},[5308],{"nctId":3362,"briefTitle":3363,"status":114,"phases":5309,"primaryCompletion":3365,"start":3366,"enrollment":3367,"conditions":5310,"interventions":5311},[86],[15],[3355,3370,3371],{"trials":5313,"activeCount":96},[],{"trials":5315,"activeCount":96},[],{"trials":5317,"activeCount":96},[],{"trials":5319,"activeCount":96},[],{"intervention":5321,"totalTrials":185,"cells":5322},"HM10460A or placebo or Neulasta",{"EARLY_PHASE1":5323,"PHASE1":5325,"PHASE2":5335,"PHASE3":5337,"PHASE4":5339,"NA":5341},{"trials":5324,"activeCount":96},[],{"trials":5326,"activeCount":96},[5327],{"nctId":5328,"briefTitle":5329,"status":114,"phases":5330,"primaryCompletion":5331,"completion":5332,"start":3273,"enrollment":761,"conditions":5333,"interventions":5334},"NCT01037543","Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects",[86],"2011-02","2011-04",[15],[5321],{"trials":5336,"activeCount":96},[],{"trials":5338,"activeCount":96},[],{"trials":5340,"activeCount":96},[],{"trials":5342,"activeCount":96},[],{"intervention":5344,"totalTrials":185,"cells":5345},"Tadalafil",{"EARLY_PHASE1":5346,"PHASE1":5348,"PHASE2":5359,"PHASE3":5361,"PHASE4":5363,"NA":5365},{"trials":5347,"activeCount":96},[],{"trials":5349,"activeCount":96},[5350],{"nctId":5351,"briefTitle":5352,"status":114,"phases":5353,"primaryCompletion":1119,"completion":1119,"start":5354,"enrollment":1205,"conditions":5355,"interventions":5356},"NCT02239484","Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin",[86],"2014-03",[26,1381],[5344,5357,5358],"Tamsulosin","Tadalafil + Tamsulosin",{"trials":5360,"activeCount":96},[],{"trials":5362,"activeCount":96},[],{"trials":5364,"activeCount":96},[],{"trials":5366,"activeCount":96},[],{"intervention":5357,"totalTrials":185,"cells":5368},{"EARLY_PHASE1":5369,"PHASE1":5371,"PHASE2":5377,"PHASE3":5379,"PHASE4":5381,"NA":5383},{"trials":5370,"activeCount":96},[],{"trials":5372,"activeCount":96},[5373],{"nctId":5351,"briefTitle":5352,"status":114,"phases":5374,"primaryCompletion":1119,"completion":1119,"start":5354,"enrollment":1205,"conditions":5375,"interventions":5376},[86],[26,1381],[5344,5357,5358],{"trials":5378,"activeCount":96},[],{"trials":5380,"activeCount":96},[],{"trials":5382,"activeCount":96},[],{"trials":5384,"activeCount":96},[],{"intervention":5358,"totalTrials":185,"cells":5386},{"EARLY_PHASE1":5387,"PHASE1":5389,"PHASE2":5395,"PHASE3":5397,"PHASE4":5399,"NA":5401},{"trials":5388,"activeCount":96},[],{"trials":5390,"activeCount":96},[5391],{"nctId":5351,"briefTitle":5352,"status":114,"phases":5392,"primaryCompletion":1119,"completion":1119,"start":5354,"enrollment":1205,"conditions":5393,"interventions":5394},[86],[26,1381],[5344,5357,5358],{"trials":5396,"activeCount":96},[],{"trials":5398,"activeCount":96},[],{"trials":5400,"activeCount":96},[],{"trials":5402,"activeCount":96},[],{"intervention":5404,"totalTrials":185,"cells":5405},"HIP1503",{"EARLY_PHASE1":5406,"PHASE1":5408,"PHASE2":5419,"PHASE3":5421,"PHASE4":5423,"NA":5425},{"trials":5407,"activeCount":96},[],{"trials":5409,"activeCount":96},[5410],{"nctId":5411,"briefTitle":5412,"status":114,"phases":5413,"primaryCompletion":1378,"completion":1378,"start":5414,"enrollment":9,"conditions":5415,"interventions":5417},"NCT02940314","Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers",[86],"2016-03",[5416],"Overactive Bladder",[5404,5418],"HGP1103",{"trials":5420,"activeCount":96},[],{"trials":5422,"activeCount":96},[],{"trials":5424,"activeCount":96},[],{"trials":5426,"activeCount":96},[],{"intervention":5418,"totalTrials":185,"cells":5428},{"EARLY_PHASE1":5429,"PHASE1":5431,"PHASE2":5437,"PHASE3":5439,"PHASE4":5441,"NA":5443},{"trials":5430,"activeCount":96},[],{"trials":5432,"activeCount":96},[5433],{"nctId":5411,"briefTitle":5412,"status":114,"phases":5434,"primaryCompletion":1378,"completion":1378,"start":5414,"enrollment":9,"conditions":5435,"interventions":5436},[86],[5416],[5404,5418],{"trials":5438,"activeCount":96},[],{"trials":5440,"activeCount":96},[],{"trials":5442,"activeCount":96},[],{"trials":5444,"activeCount":96},[],{"intervention":5446,"totalTrials":185,"cells":5447},"HM10460A 5μg\u002Fkg",{"EARLY_PHASE1":5448,"PHASE1":5450,"PHASE2":5462,"PHASE3":5464,"PHASE4":5466,"NA":5468},{"trials":5449,"activeCount":96},[],{"trials":5451,"activeCount":96},[5452],{"nctId":5453,"briefTitle":5454,"status":114,"phases":5455,"primaryCompletion":745,"completion":745,"start":4333,"enrollment":325,"conditions":5456,"interventions":5457},"NCT00998283","Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects",[86],[15],[5446,5458,5459,5460,5461],"HM10460A 15μg\u002Fkg","HM10460A 45μg\u002Fkg","HM10460A 135μg\u002Fkg","HM10460A 350μg\u002Fkg",{"trials":5463,"activeCount":96},[],{"trials":5465,"activeCount":96},[],{"trials":5467,"activeCount":96},[],{"trials":5469,"activeCount":96},[],{"intervention":5458,"totalTrials":185,"cells":5471},{"EARLY_PHASE1":5472,"PHASE1":5474,"PHASE2":5480,"PHASE3":5482,"PHASE4":5484,"NA":5486},{"trials":5473,"activeCount":96},[],{"trials":5475,"activeCount":96},[5476],{"nctId":5453,"briefTitle":5454,"status":114,"phases":5477,"primaryCompletion":745,"completion":745,"start":4333,"enrollment":325,"conditions":5478,"interventions":5479},[86],[15],[5446,5458,5459,5460,5461],{"trials":5481,"activeCount":96},[],{"trials":5483,"activeCount":96},[],{"trials":5485,"activeCount":96},[],{"trials":5487,"activeCount":96},[],{"intervention":5459,"totalTrials":185,"cells":5489},{"EARLY_PHASE1":5490,"PHASE1":5492,"PHASE2":5498,"PHASE3":5500,"PHASE4":5502,"NA":5504},{"trials":5491,"activeCount":96},[],{"trials":5493,"activeCount":96},[5494],{"nctId":5453,"briefTitle":5454,"status":114,"phases":5495,"primaryCompletion":745,"completion":745,"start":4333,"enrollment":325,"conditions":5496,"interventions":5497},[86],[15],[5446,5458,5459,5460,5461],{"trials":5499,"activeCount":96},[],{"trials":5501,"activeCount":96},[],{"trials":5503,"activeCount":96},[],{"trials":5505,"activeCount":96},[],{"intervention":5460,"totalTrials":185,"cells":5507},{"EARLY_PHASE1":5508,"PHASE1":5510,"PHASE2":5516,"PHASE3":5518,"PHASE4":5520,"NA":5522},{"trials":5509,"activeCount":96},[],{"trials":5511,"activeCount":96},[5512],{"nctId":5453,"briefTitle":5454,"status":114,"phases":5513,"primaryCompletion":745,"completion":745,"start":4333,"enrollment":325,"conditions":5514,"interventions":5515},[86],[15],[5446,5458,5459,5460,5461],{"trials":5517,"activeCount":96},[],{"trials":5519,"activeCount":96},[],{"trials":5521,"activeCount":96},[],{"trials":5523,"activeCount":96},[],{"intervention":5461,"totalTrials":185,"cells":5525},{"EARLY_PHASE1":5526,"PHASE1":5528,"PHASE2":5534,"PHASE3":5536,"PHASE4":5538,"NA":5540},{"trials":5527,"activeCount":96},[],{"trials":5529,"activeCount":96},[5530],{"nctId":5453,"briefTitle":5454,"status":114,"phases":5531,"primaryCompletion":745,"completion":745,"start":4333,"enrollment":325,"conditions":5532,"interventions":5533},[86],[15],[5446,5458,5459,5460,5461],{"trials":5535,"activeCount":96},[],{"trials":5537,"activeCount":96},[],{"trials":5539,"activeCount":96},[],{"trials":5541,"activeCount":96},[],{"intervention":5543,"totalTrials":185,"cells":5544},"HCP1201, Fasted followed by fed",{"EARLY_PHASE1":5545,"PHASE1":5547,"PHASE2":5556,"PHASE3":5558,"PHASE4":5560,"NA":5562},{"trials":5546,"activeCount":96},[],{"trials":5548,"activeCount":96},[5549],{"nctId":5550,"briefTitle":5551,"status":114,"phases":5552,"primaryCompletion":1833,"completion":1833,"start":156,"enrollment":5174,"conditions":5553,"interventions":5554},"NCT01901757","Single-dose, 2-way Crossover Open Study to Evaluate the Food Effect on the PK of HCP1201 in Healthy Volunteers",[86],[21],[5543,5555],"HCP1201, Fed followed by fasted",{"trials":5557,"activeCount":96},[],{"trials":5559,"activeCount":96},[],{"trials":5561,"activeCount":96},[],{"trials":5563,"activeCount":96},[],{"intervention":5555,"totalTrials":185,"cells":5565},{"EARLY_PHASE1":5566,"PHASE1":5568,"PHASE2":5574,"PHASE3":5576,"PHASE4":5578,"NA":5580},{"trials":5567,"activeCount":96},[],{"trials":5569,"activeCount":96},[5570],{"nctId":5550,"briefTitle":5551,"status":114,"phases":5571,"primaryCompletion":1833,"completion":1833,"start":156,"enrollment":5174,"conditions":5572,"interventions":5573},[86],[21],[5543,5555],{"trials":5575,"activeCount":96},[],{"trials":5577,"activeCount":96},[],{"trials":5579,"activeCount":96},[],{"trials":5581,"activeCount":96},[],{"intervention":5583,"totalTrials":185,"cells":5584},"HM30181AK 1mg",{"EARLY_PHASE1":5585,"PHASE1":5587,"PHASE2":5601,"PHASE3":5603,"PHASE4":5605,"NA":5607},{"trials":5586,"activeCount":96},[],{"trials":5588,"activeCount":96},[5589],{"nctId":5590,"briefTitle":5591,"status":114,"phases":5592,"primaryCompletion":784,"completion":5593,"start":5594,"enrollment":1205,"conditions":5595,"interventions":5596},"NCT00954304","Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet",[86],"2009-09","2009-06",[15],[5583,5597,5598,5599,5600],"HM30181AK 5mg","HM30181AK 15mg","HM30181AK 60mg","Loperamide 2mg",{"trials":5602,"activeCount":96},[],{"trials":5604,"activeCount":96},[],{"trials":5606,"activeCount":96},[],{"trials":5608,"activeCount":96},[],{"intervention":5597,"totalTrials":185,"cells":5610},{"EARLY_PHASE1":5611,"PHASE1":5613,"PHASE2":5619,"PHASE3":5621,"PHASE4":5623,"NA":5625},{"trials":5612,"activeCount":96},[],{"trials":5614,"activeCount":96},[5615],{"nctId":5590,"briefTitle":5591,"status":114,"phases":5616,"primaryCompletion":784,"completion":5593,"start":5594,"enrollment":1205,"conditions":5617,"interventions":5618},[86],[15],[5583,5597,5598,5599,5600],{"trials":5620,"activeCount":96},[],{"trials":5622,"activeCount":96},[],{"trials":5624,"activeCount":96},[],{"trials":5626,"activeCount":96},[],{"intervention":5598,"totalTrials":185,"cells":5628},{"EARLY_PHASE1":5629,"PHASE1":5631,"PHASE2":5637,"PHASE3":5639,"PHASE4":5641,"NA":5643},{"trials":5630,"activeCount":96},[],{"trials":5632,"activeCount":96},[5633],{"nctId":5590,"briefTitle":5591,"status":114,"phases":5634,"primaryCompletion":784,"completion":5593,"start":5594,"enrollment":1205,"conditions":5635,"interventions":5636},[86],[15],[5583,5597,5598,5599,5600],{"trials":5638,"activeCount":96},[],{"trials":5640,"activeCount":96},[],{"trials":5642,"activeCount":96},[],{"trials":5644,"activeCount":96},[],{"intervention":5599,"totalTrials":185,"cells":5646},{"EARLY_PHASE1":5647,"PHASE1":5649,"PHASE2":5655,"PHASE3":5657,"PHASE4":5659,"NA":5661},{"trials":5648,"activeCount":96},[],{"trials":5650,"activeCount":96},[5651],{"nctId":5590,"briefTitle":5591,"status":114,"phases":5652,"primaryCompletion":784,"completion":5593,"start":5594,"enrollment":1205,"conditions":5653,"interventions":5654},[86],[15],[5583,5597,5598,5599,5600],{"trials":5656,"activeCount":96},[],{"trials":5658,"activeCount":96},[],{"trials":5660,"activeCount":96},[],{"trials":5662,"activeCount":96},[],{"intervention":5600,"totalTrials":185,"cells":5664},{"EARLY_PHASE1":5665,"PHASE1":5667,"PHASE2":5673,"PHASE3":5675,"PHASE4":5677,"NA":5679},{"trials":5666,"activeCount":96},[],{"trials":5668,"activeCount":96},[5669],{"nctId":5590,"briefTitle":5591,"status":114,"phases":5670,"primaryCompletion":784,"completion":5593,"start":5594,"enrollment":1205,"conditions":5671,"interventions":5672},[86],[15],[5583,5597,5598,5599,5600],{"trials":5674,"activeCount":96},[],{"trials":5676,"activeCount":96},[],{"trials":5678,"activeCount":96},[],{"trials":5680,"activeCount":96},[],{"intervention":1327,"totalTrials":185,"cells":5682},{"EARLY_PHASE1":5683,"PHASE1":5685,"PHASE2":5691,"PHASE3":5693,"PHASE4":5695,"NA":5697},{"trials":5684,"activeCount":96},[],{"trials":5686,"activeCount":96},[5687],{"nctId":1322,"briefTitle":1323,"status":114,"phases":5688,"primaryCompletion":1152,"completion":1152,"start":1204,"enrollment":9,"conditions":5689,"interventions":5690},[86],[15],[1327,507,1328],{"trials":5692,"activeCount":96},[],{"trials":5694,"activeCount":96},[],{"trials":5696,"activeCount":96},[],{"trials":5698,"activeCount":96},[],{"intervention":1328,"totalTrials":185,"cells":5700},{"EARLY_PHASE1":5701,"PHASE1":5703,"PHASE2":5709,"PHASE3":5711,"PHASE4":5713,"NA":5715},{"trials":5702,"activeCount":96},[],{"trials":5704,"activeCount":96},[5705],{"nctId":1322,"briefTitle":1323,"status":114,"phases":5706,"primaryCompletion":1152,"completion":1152,"start":1204,"enrollment":9,"conditions":5707,"interventions":5708},[86],[15],[1327,507,1328],{"trials":5710,"activeCount":96},[],{"trials":5712,"activeCount":96},[],{"trials":5714,"activeCount":96},[],{"trials":5716,"activeCount":96},[],{"intervention":4029,"totalTrials":185,"cells":5718},{"EARLY_PHASE1":5719,"PHASE1":5721,"PHASE2":5727,"PHASE3":5729,"PHASE4":5731,"NA":5733},{"trials":5720,"activeCount":96},[],{"trials":5722,"activeCount":96},[5723],{"nctId":4024,"briefTitle":4025,"status":114,"phases":5724,"primaryCompletion":106,"completion":137,"start":106,"enrollment":9,"conditions":5725,"interventions":5726},[86],[21],[4029,4030,4008],{"trials":5728,"activeCount":96},[],{"trials":5730,"activeCount":96},[],{"trials":5732,"activeCount":96},[],{"trials":5734,"activeCount":96},[],{"intervention":5736,"totalTrials":185,"cells":5737},"HCP0911 \u002F clopidogrel, aspirin",{"EARLY_PHASE1":5738,"PHASE1":5740,"PHASE2":5749,"PHASE3":5751,"PHASE4":5753,"NA":5755},{"trials":5739,"activeCount":96},[],{"trials":5741,"activeCount":96},[5742],{"nctId":5743,"briefTitle":5744,"status":114,"phases":5745,"primaryCompletion":3365,"completion":3365,"start":5746,"enrollment":1918,"conditions":5747,"interventions":5748},"NCT01448330","A Bioequivalence Study Comparing Clopidogrel\u002FAspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin",[86],"2011-07",[15],[5736],{"trials":5750,"activeCount":96},[],{"trials":5752,"activeCount":96},[],{"trials":5754,"activeCount":96},[],{"trials":5756,"activeCount":96},[],{"intervention":5758,"totalTrials":185,"cells":5759},"HIP2001",{"EARLY_PHASE1":5760,"PHASE1":5762,"PHASE2":5776,"PHASE3":5778,"PHASE4":5780,"NA":5782},{"trials":5761,"activeCount":96},[],{"trials":5763,"activeCount":96},[5764],{"nctId":5765,"briefTitle":5766,"status":114,"phases":5767,"primaryCompletion":5768,"completion":5769,"start":5770,"enrollment":5771,"conditions":5772,"interventions":5774},"NCT04764201","The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers",[86],"2021-02-26","2021-03-08","2021-01-16",50,[5773],"Atrial Fibrillation",[5758,5775],"HGP2001",{"trials":5777,"activeCount":96},[],{"trials":5779,"activeCount":96},[],{"trials":5781,"activeCount":96},[],{"trials":5783,"activeCount":96},[],{"intervention":5775,"totalTrials":185,"cells":5785},{"EARLY_PHASE1":5786,"PHASE1":5788,"PHASE2":5794,"PHASE3":5796,"PHASE4":5798,"NA":5800},{"trials":5787,"activeCount":96},[],{"trials":5789,"activeCount":96},[5790],{"nctId":5765,"briefTitle":5766,"status":114,"phases":5791,"primaryCompletion":5768,"completion":5769,"start":5770,"enrollment":5771,"conditions":5792,"interventions":5793},[86],[5773],[5758,5775],{"trials":5795,"activeCount":96},[],{"trials":5797,"activeCount":96},[],{"trials":5799,"activeCount":96},[],{"trials":5801,"activeCount":96},[],{"intervention":5803,"totalTrials":185,"cells":5804},"HM95573, cobimetinib",{"EARLY_PHASE1":5805,"PHASE1":5807,"PHASE2":5822,"PHASE3":5824,"PHASE4":5826,"NA":5828},{"trials":5806,"activeCount":96},[],{"trials":5808,"activeCount":96},[5809],{"nctId":5810,"briefTitle":5811,"status":102,"phases":5812,"primaryCompletion":5813,"completion":5814,"start":5815,"enrollment":5816,"conditions":5817,"interventions":5820},"NCT03284502","HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors",[86],"2024-09-30","2024-12-31","2017-05-22",148,[5818,5819],"Locally Advanced Solid Tumor","Metastatic Solid Tumor",[5803,5821,5803,5821],"HM95573, cetuximab",{"trials":5823,"activeCount":96},[],{"trials":5825,"activeCount":96},[],{"trials":5827,"activeCount":96},[],{"trials":5829,"activeCount":96},[],{"intervention":5821,"totalTrials":185,"cells":5831},{"EARLY_PHASE1":5832,"PHASE1":5834,"PHASE2":5840,"PHASE3":5842,"PHASE4":5844,"NA":5846},{"trials":5833,"activeCount":96},[],{"trials":5835,"activeCount":96},[5836],{"nctId":5810,"briefTitle":5811,"status":102,"phases":5837,"primaryCompletion":5813,"completion":5814,"start":5815,"enrollment":5816,"conditions":5838,"interventions":5839},[86],[5818,5819],[5803,5821,5803,5821],{"trials":5841,"activeCount":96},[],{"trials":5843,"activeCount":96},[],{"trials":5845,"activeCount":96},[],{"trials":5847,"activeCount":96},[],{"intervention":3898,"totalTrials":185,"cells":5849},{"EARLY_PHASE1":5850,"PHASE1":5852,"PHASE2":5858,"PHASE3":5860,"PHASE4":5862,"NA":5864},{"trials":5851,"activeCount":96},[],{"trials":5853,"activeCount":96},[5854],{"nctId":3891,"briefTitle":3892,"status":114,"phases":5855,"primaryCompletion":3894,"completion":3894,"start":3895,"enrollment":1130,"conditions":5856,"interventions":5857},[86],[15],[3735,3736,3898],{"trials":5859,"activeCount":96},[],{"trials":5861,"activeCount":96},[],{"trials":5863,"activeCount":96},[],{"trials":5865,"activeCount":96},[],{"intervention":1508,"totalTrials":185,"cells":5867},{"EARLY_PHASE1":5868,"PHASE1":5870,"PHASE2":5876,"PHASE3":5878,"PHASE4":5880,"NA":5882},{"trials":5869,"activeCount":96},[],{"trials":5871,"activeCount":96},[5872],{"nctId":1500,"briefTitle":1501,"status":114,"phases":5873,"primaryCompletion":1503,"completion":1503,"start":1504,"enrollment":1505,"conditions":5874,"interventions":5875},[86],[15],[1408,1508,1509],{"trials":5877,"activeCount":96},[],{"trials":5879,"activeCount":96},[],{"trials":5881,"activeCount":96},[],{"trials":5883,"activeCount":96},[],{"intervention":1705,"totalTrials":185,"cells":5885},{"EARLY_PHASE1":5886,"PHASE1":5888,"PHASE2":5894,"PHASE3":5896,"PHASE4":5898,"NA":5900},{"trials":5887,"activeCount":96},[],{"trials":5889,"activeCount":96},[5890],{"nctId":1695,"briefTitle":1696,"status":114,"phases":5891,"primaryCompletion":1698,"completion":1699,"start":1700,"enrollment":1701,"conditions":5892,"interventions":5893},[86],[1703],[1688,1705],{"trials":5895,"activeCount":96},[],{"trials":5897,"activeCount":96},[],{"trials":5899,"activeCount":96},[],{"trials":5901,"activeCount":96},[],{"intervention":5903,"totalTrials":185,"cells":5904},"HGP1206",{"EARLY_PHASE1":5905,"PHASE1":5907,"PHASE2":5917,"PHASE3":5919,"PHASE4":5921,"NA":5923},{"trials":5906,"activeCount":96},[],{"trials":5908,"activeCount":96},[5909],{"nctId":5910,"briefTitle":5911,"status":114,"phases":5912,"primaryCompletion":2696,"completion":2696,"start":2810,"enrollment":1701,"conditions":5913,"interventions":5915},"NCT01864863","To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers",[86],[5914],"Pulmonary Arterial Hypertension",[5903,5916],"Traclear",{"trials":5918,"activeCount":96},[],{"trials":5920,"activeCount":96},[],{"trials":5922,"activeCount":96},[],{"trials":5924,"activeCount":96},[],{"intervention":5916,"totalTrials":185,"cells":5926},{"EARLY_PHASE1":5927,"PHASE1":5929,"PHASE2":5935,"PHASE3":5937,"PHASE4":5939,"NA":5941},{"trials":5928,"activeCount":96},[],{"trials":5930,"activeCount":96},[5931],{"nctId":5910,"briefTitle":5911,"status":114,"phases":5932,"primaryCompletion":2696,"completion":2696,"start":2810,"enrollment":1701,"conditions":5933,"interventions":5934},[86],[5914],[5903,5916],{"trials":5936,"activeCount":96},[],{"trials":5938,"activeCount":96},[],{"trials":5940,"activeCount":96},[],{"trials":5942,"activeCount":96},[],{"intervention":110,"totalTrials":185,"cells":5944},{"EARLY_PHASE1":5945,"PHASE1":5947,"PHASE2":5953,"PHASE3":5955,"PHASE4":5957,"NA":5959},{"trials":5946,"activeCount":96},[],{"trials":5948,"activeCount":96},[5949],{"nctId":100,"briefTitle":101,"status":102,"phases":5950,"primaryCompletion":104,"completion":105,"start":106,"enrollment":107,"conditions":5951,"interventions":5952},[86],[21],[40,110],{"trials":5954,"activeCount":96},[],{"trials":5956,"activeCount":96},[],{"trials":5958,"activeCount":96},[],{"trials":5960,"activeCount":96},[],{"intervention":5962,"totalTrials":185,"cells":5963},"HGP1812",{"EARLY_PHASE1":5964,"PHASE1":5966,"PHASE2":5977,"PHASE3":5979,"PHASE4":5981,"NA":5983},{"trials":5965,"activeCount":96},[],{"trials":5967,"activeCount":96},[5968],{"nctId":5969,"briefTitle":5970,"status":114,"phases":5971,"primaryCompletion":5215,"completion":5972,"start":5973,"enrollment":1701,"conditions":5974,"interventions":5975},"NCT04084184","A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HGP1602 in Healthy Subjects",[86],"2019-03-29","2019-03-15",[15],[5962,5976],"HGP1602",{"trials":5978,"activeCount":96},[],{"trials":5980,"activeCount":96},[],{"trials":5982,"activeCount":96},[],{"trials":5984,"activeCount":96},[],{"intervention":5976,"totalTrials":185,"cells":5986},{"EARLY_PHASE1":5987,"PHASE1":5989,"PHASE2":5995,"PHASE3":5997,"PHASE4":5999,"NA":6001},{"trials":5988,"activeCount":96},[],{"trials":5990,"activeCount":96},[5991],{"nctId":5969,"briefTitle":5970,"status":114,"phases":5992,"primaryCompletion":5215,"completion":5972,"start":5973,"enrollment":1701,"conditions":5993,"interventions":5994},[86],[15],[5962,5976],{"trials":5996,"activeCount":96},[],{"trials":5998,"activeCount":96},[],{"trials":6000,"activeCount":96},[],{"trials":6002,"activeCount":96},[],{"intervention":6004,"totalTrials":185,"cells":6005},"Olmutinib",{"EARLY_PHASE1":6006,"PHASE1":6008,"PHASE2":6018,"PHASE3":6020,"PHASE4":6022,"NA":6024},{"trials":6007,"activeCount":96},[],{"trials":6009,"activeCount":96},[6010],{"nctId":6011,"briefTitle":6012,"status":2694,"phases":6013,"primaryCompletion":6014,"completion":6014,"start":6015,"enrollment":179,"conditions":6016,"interventions":6017},"NCT04510415","Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI",[86],"2018-12-11","2018-03-29",[29],[6004],{"trials":6019,"activeCount":96},[],{"trials":6021,"activeCount":96},[],{"trials":6023,"activeCount":96},[],{"trials":6025,"activeCount":96},[],{"intervention":6027,"totalTrials":185,"cells":6028},"montelukast and levocetirizine FDC",{"EARLY_PHASE1":6029,"PHASE1":6031,"PHASE2":6042,"PHASE3":6044,"PHASE4":6046,"NA":6048},{"trials":6030,"activeCount":96},[],{"trials":6032,"activeCount":96},[6033],{"nctId":6034,"briefTitle":6035,"status":114,"phases":6036,"primaryCompletion":6037,"completion":6037,"start":6038,"enrollment":1120,"conditions":6039,"interventions":6040},"NCT03371849","PK and Safety Study of HCP1102, HGP0813 and HGP1408",[86],"2017-08-03","2017-07-19",[15],[6027,6041],"Singulair + xyzal",{"trials":6043,"activeCount":96},[],{"trials":6045,"activeCount":96},[],{"trials":6047,"activeCount":96},[],{"trials":6049,"activeCount":96},[],{"intervention":6041,"totalTrials":185,"cells":6051},{"EARLY_PHASE1":6052,"PHASE1":6054,"PHASE2":6060,"PHASE3":6062,"PHASE4":6064,"NA":6066},{"trials":6053,"activeCount":96},[],{"trials":6055,"activeCount":96},[6056],{"nctId":6034,"briefTitle":6035,"status":114,"phases":6057,"primaryCompletion":6037,"completion":6037,"start":6038,"enrollment":1120,"conditions":6058,"interventions":6059},[86],[15],[6027,6041],{"trials":6061,"activeCount":96},[],{"trials":6063,"activeCount":96},[],{"trials":6065,"activeCount":96},[],{"trials":6067,"activeCount":96},[],{"intervention":4305,"totalTrials":185,"cells":6069},{"EARLY_PHASE1":6070,"PHASE1":6072,"PHASE2":6078,"PHASE3":6080,"PHASE4":6082,"NA":6084},{"trials":6071,"activeCount":96},[],{"trials":6073,"activeCount":96},[6074],{"nctId":4300,"briefTitle":4301,"status":114,"phases":6075,"primaryCompletion":1119,"completion":502,"start":2128,"enrollment":1120,"conditions":6076,"interventions":6077},[86],[15],[4276,4305,4306],{"trials":6079,"activeCount":96},[],{"trials":6081,"activeCount":96},[],{"trials":6083,"activeCount":96},[],{"trials":6085,"activeCount":96},[],{"intervention":4306,"totalTrials":185,"cells":6087},{"EARLY_PHASE1":6088,"PHASE1":6090,"PHASE2":6096,"PHASE3":6098,"PHASE4":6100,"NA":6102},{"trials":6089,"activeCount":96},[],{"trials":6091,"activeCount":96},[6092],{"nctId":4300,"briefTitle":4301,"status":114,"phases":6093,"primaryCompletion":1119,"completion":502,"start":2128,"enrollment":1120,"conditions":6094,"interventions":6095},[86],[15],[4276,4305,4306],{"trials":6097,"activeCount":96},[],{"trials":6099,"activeCount":96},[],{"trials":6101,"activeCount":96},[],{"trials":6103,"activeCount":96},[],{"intervention":6105,"totalTrials":185,"cells":6106},"HIP0908",{"EARLY_PHASE1":6107,"PHASE1":6109,"PHASE2":6119,"PHASE3":6121,"PHASE4":6123,"NA":6125},{"trials":6108,"activeCount":96},[],{"trials":6110,"activeCount":96},[6111],{"nctId":6112,"briefTitle":6113,"status":114,"phases":6114,"primaryCompletion":157,"completion":157,"start":157,"enrollment":6115,"conditions":6116,"interventions":6117},"NCT01514903","Pharmacokinetics of Sildenafil Following Administration of an Chewable Tablet of Sildenafil Relative to Viagra® Conventional Oral Tablet in Healthy Volunteers",[86],54,[26],[6105,6118],"viagra",{"trials":6120,"activeCount":96},[],{"trials":6122,"activeCount":96},[],{"trials":6124,"activeCount":96},[],{"trials":6126,"activeCount":96},[],{"intervention":6118,"totalTrials":185,"cells":6128},{"EARLY_PHASE1":6129,"PHASE1":6131,"PHASE2":6137,"PHASE3":6139,"PHASE4":6141,"NA":6143},{"trials":6130,"activeCount":96},[],{"trials":6132,"activeCount":96},[6133],{"nctId":6112,"briefTitle":6113,"status":114,"phases":6134,"primaryCompletion":157,"completion":157,"start":157,"enrollment":6115,"conditions":6135,"interventions":6136},[86],[26],[6105,6118],{"trials":6138,"activeCount":96},[],{"trials":6140,"activeCount":96},[],{"trials":6142,"activeCount":96},[],{"trials":6144,"activeCount":96},[],{"intervention":6146,"totalTrials":185,"cells":6147},"Ambroxol and Levodropropizine",{"EARLY_PHASE1":6148,"PHASE1":6150,"PHASE2":6160,"PHASE3":6162,"PHASE4":6164,"NA":6166},{"trials":6149,"activeCount":96},[],{"trials":6151,"activeCount":96},[6152],{"nctId":6153,"briefTitle":6154,"status":114,"phases":6155,"primaryCompletion":4987,"completion":4987,"start":759,"enrollment":3824,"conditions":6156,"interventions":6157},"NCT01573663","A Drug-Drug Interaction Study of Ambroxol and Levodropropizine",[86],[15],[6146,6158,6159],"Ambroxol","Levodropropizine",{"trials":6161,"activeCount":96},[],{"trials":6163,"activeCount":96},[],{"trials":6165,"activeCount":96},[],{"trials":6167,"activeCount":96},[],{"intervention":6158,"totalTrials":185,"cells":6169},{"EARLY_PHASE1":6170,"PHASE1":6172,"PHASE2":6178,"PHASE3":6180,"PHASE4":6182,"NA":6184},{"trials":6171,"activeCount":96},[],{"trials":6173,"activeCount":96},[6174],{"nctId":6153,"briefTitle":6154,"status":114,"phases":6175,"primaryCompletion":4987,"completion":4987,"start":759,"enrollment":3824,"conditions":6176,"interventions":6177},[86],[15],[6146,6158,6159],{"trials":6179,"activeCount":96},[],{"trials":6181,"activeCount":96},[],{"trials":6183,"activeCount":96},[],{"trials":6185,"activeCount":96},[],{"intervention":6159,"totalTrials":185,"cells":6187},{"EARLY_PHASE1":6188,"PHASE1":6190,"PHASE2":6196,"PHASE3":6198,"PHASE4":6200,"NA":6202},{"trials":6189,"activeCount":96},[],{"trials":6191,"activeCount":96},[6192],{"nctId":6153,"briefTitle":6154,"status":114,"phases":6193,"primaryCompletion":4987,"completion":4987,"start":759,"enrollment":3824,"conditions":6194,"interventions":6195},[86],[15],[6146,6158,6159],{"trials":6197,"activeCount":96},[],{"trials":6199,"activeCount":96},[],{"trials":6201,"activeCount":96},[],{"trials":6203,"activeCount":96},[],{"intervention":1652,"totalTrials":185,"cells":6205},{"EARLY_PHASE1":6206,"PHASE1":6208,"PHASE2":6214,"PHASE3":6216,"PHASE4":6218,"NA":6220},{"trials":6207,"activeCount":96},[],{"trials":6209,"activeCount":96},[6210],{"nctId":1643,"briefTitle":1644,"status":114,"phases":6211,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":1648,"conditions":6212,"interventions":6213},[86],[1650],[1652,1600],{"trials":6215,"activeCount":96},[],{"trials":6217,"activeCount":96},[],{"trials":6219,"activeCount":96},[],{"trials":6221,"activeCount":96},[],{"intervention":6223,"totalTrials":185,"cells":6224},"HIP2105",{"EARLY_PHASE1":6225,"PHASE1":6227,"PHASE2":6238,"PHASE3":6240,"PHASE4":6242,"NA":6244},{"trials":6226,"activeCount":96},[],{"trials":6228,"activeCount":96},[6229],{"nctId":6230,"briefTitle":6231,"status":114,"phases":6232,"primaryCompletion":6233,"completion":6233,"start":6234,"enrollment":3367,"conditions":6235,"interventions":6236},"NCT04975711","Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers",[86],"2021-11-03","2021-07-12",[1650],[6223,6237],"RLD2104",{"trials":6239,"activeCount":96},[],{"trials":6241,"activeCount":96},[],{"trials":6243,"activeCount":96},[],{"trials":6245,"activeCount":96},[],{"intervention":6237,"totalTrials":185,"cells":6247},{"EARLY_PHASE1":6248,"PHASE1":6250,"PHASE2":6256,"PHASE3":6258,"PHASE4":6260,"NA":6262},{"trials":6249,"activeCount":96},[],{"trials":6251,"activeCount":96},[6252],{"nctId":6230,"briefTitle":6231,"status":114,"phases":6253,"primaryCompletion":6233,"completion":6233,"start":6234,"enrollment":3367,"conditions":6254,"interventions":6255},[86],[1650],[6223,6237],{"trials":6257,"activeCount":96},[],{"trials":6259,"activeCount":96},[],{"trials":6261,"activeCount":96},[],{"trials":6263,"activeCount":96},[],{"intervention":6265,"totalTrials":185,"cells":6266},"single arm, single group",{"EARLY_PHASE1":6267,"PHASE1":6269,"PHASE2":6271,"PHASE3":6273,"PHASE4":6275,"NA":6277},{"trials":6268,"activeCount":96},[],{"trials":6270,"activeCount":96},[],{"trials":6272,"activeCount":96},[],{"trials":6274,"activeCount":96},[],{"trials":6276,"activeCount":96},[],{"trials":6278,"activeCount":96},[6279],{"nctId":6280,"briefTitle":6281,"status":114,"phases":6282,"primaryCompletion":6283,"completion":6283,"start":6284,"enrollment":6285,"conditions":6286,"interventions":6288},"NCT05555238","An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia",[],"2022-01-27","2020-01-16",1716,[6287],"Dyslipidemia",[6265],{"intervention":6290,"totalTrials":185,"cells":6291},"Amosartan Plus Tab.",{"EARLY_PHASE1":6292,"PHASE1":6294,"PHASE2":6296,"PHASE3":6298,"PHASE4":6300,"NA":6302},{"trials":6293,"activeCount":96},[],{"trials":6295,"activeCount":96},[],{"trials":6297,"activeCount":96},[],{"trials":6299,"activeCount":96},[],{"trials":6301,"activeCount":96},[],{"trials":6303,"activeCount":96},[6304],{"nctId":6305,"briefTitle":6306,"status":114,"phases":6307,"primaryCompletion":6308,"completion":6308,"start":6309,"enrollment":6310,"conditions":6311,"interventions":6313},"NCT05462535","An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet",[],"2021-07-15","2018-02-26",4785,[6312],"Hypertension,Essential",[6290],{"intervention":6315,"totalTrials":185,"cells":6316},"Esomezol Cap",{"EARLY_PHASE1":6317,"PHASE1":6319,"PHASE2":6321,"PHASE3":6323,"PHASE4":6325,"NA":6327},{"trials":6318,"activeCount":96},[],{"trials":6320,"activeCount":96},[],{"trials":6322,"activeCount":96},[],{"trials":6324,"activeCount":96},[],{"trials":6326,"activeCount":96},[],{"trials":6328,"activeCount":96},[6329],{"nctId":6330,"briefTitle":6331,"status":114,"phases":6332,"primaryCompletion":6333,"completion":6333,"start":6334,"enrollment":6335,"conditions":6336,"interventions":6338},"NCT05487560","An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding",[],"2022-06-22","2019-04-18",4133,[6337],"Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months",[6315],{"intervention":6340,"totalTrials":185,"cells":6341},"Hanmi Tams®",{"EARLY_PHASE1":6342,"PHASE1":6344,"PHASE2":6346,"PHASE3":6348,"PHASE4":6350,"NA":6352},{"trials":6343,"activeCount":96},[],{"trials":6345,"activeCount":96},[],{"trials":6347,"activeCount":96},[],{"trials":6349,"activeCount":96},[],{"trials":6351,"activeCount":96},[],{"trials":6353,"activeCount":96},[6354],{"nctId":6355,"briefTitle":6356,"status":114,"phases":6357,"primaryCompletion":1876,"completion":1876,"start":6358,"enrollment":6359,"conditions":6360,"interventions":6362},"NCT05422677","An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia",[],"2019-07-15",4698,[6361,1381],"BPH",[6340],{"intervention":6364,"totalTrials":185,"cells":6365},"Amosartan Q",{"EARLY_PHASE1":6366,"PHASE1":6368,"PHASE2":6370,"PHASE3":6372,"PHASE4":6374,"NA":6376},{"trials":6367,"activeCount":96},[],{"trials":6369,"activeCount":96},[],{"trials":6371,"activeCount":96},[],{"trials":6373,"activeCount":96},[],{"trials":6375,"activeCount":96},[],{"trials":6377,"activeCount":96},[6378],{"nctId":6379,"briefTitle":6380,"status":114,"phases":6381,"primaryCompletion":6382,"completion":6382,"start":6383,"enrollment":6384,"conditions":6385,"interventions":6386},"NCT05450575","An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet",[],"2021-07-20","2018-04-17",5400,[18,6287],[6364]]